![Unadjusted estimates of ART coverage and proportion with ART-induced HIV RNA suppression by EuroSIDA country and region in two different time periods. **Each bubble represents a country. The area of the bubble is proportional to the number of people under follow-up in each country. The two dotted lines indicate \>90% ART coverage (x-axis) and \>90% ART-induced HIV RNA suppression (y-axis). **Eastern Europe:** Belarus, Estonia, Georgia\*, Latvia, Lithuania, Russia, Ukraine. **East Central Europe:** Bosnia-Herzegovina\*, Croatia\*, Czech Republic, Hungary, Poland, Romania, Serbia, Slovakia†, Slovenia\*. **Western Europe:** Austria, Belgium, France, Germany, Luxembourg, Switzerland. **Southern Europe:** Argentina, Greece, Israel, Italy, Portugal, Spain. **Northern Europe:** Denmark, Finland, Iceland\*, Ireland, Netherlands, Norway, Sweden, UK. \*included only in 2014/15 cohort; †included only in 2004/05 cohort**.](JIAS-19-21487007-g001){#F0001_21487007}

###### 

Baseline patients characteristics based on randomization arm (interim 96-week population n = 254)

                                                                                    ATV/r + 3TC (DT arm) n = 126   ATV/r+2NRTIs (TT arm) n=128   p
  --------------------------------------------------------------------------------- ------------------------------ ----------------------------- -------
  Age, years[a](#TF0001_21487008){ref-type="table-fn"}                              43.4 (35.7--49.2)              44.2 (36.2--51.0)             0.963
  Male gender                                                                       107 (84.9)                     96 (75.0)                     0.069
  IDU (risk factor)                                                                 8 (6.3)                        11 (8.6)                      0.659
  HCV co-infection                                                                  12 (9.5)                       14 (10.9)                     0.836
  Previous AIDS events                                                              17 (13.5)                      11 (8.6)                      0.961
  Years from HIV diagnosis[a](#TF0001_21487008){ref-type="table-fn"}                4.2 (2.1--8.6)                 4.9 (2.5--10.4)               0.102
  Years from first cART initiation[a](#TF0001_21487008){ref-type="table-fn"}        2.7 (1.7--4.8)                 2.7 (1.6--6.5)                0.207
  Therapeutic line[a](#TF0001_21487008){ref-type="table-fn"}                        2 (1--3)                       2 (1--3)                      0.628
  Months from last regimen initiation[a](#TF0001_21487008){ref-type="table-fn"}     27.6 (17.9--52.5)              28.7 (16.1--52.0)             0.352
  TDF-containing backbone                                                           100 (79.4)                     109 (85.2)                    0.296
  CD4 nadir, cells/µL[a](#TF0001_21487008){ref-type="table-fn"}                     277 (132--359)                 257 (144--349)                0.848
  CD4, cells/µL[a](#TF0001_21487008){ref-type="table-fn"}                           621 (466--777)                 614 (485--784)                0.806
  Months with viral load \<50 copies/mL[a](#TF0001_21487008){ref-type="table-fn"}   23.4 (12.6--46.7)              21.0 (12.5--44.9)             0.403

Values are expressed as n (%) except for median (interquartile range, IQR). 3TC, lamivudine; ATV/r, atazanavir/ritonavir; HCV, hepatitis C virus; NRTI, nucleos(t)ide reverse transcriptase inhibitors; TDF, tenofovir.

###### 

Changes in proteinuria at week 48

                                                        PV/FTC/TAF   RPV/FTC/TDF   p
  ----------------------------------------------------- ------------ ------------- ---------
  **Urine protein: creatinine ratio**                                              
   Median baseline value (mg/g)                         53.2         50.0          0.69
   Median % changes at week 48                          −18.8        +7.3          \<0.001
  **Urine albumin: creatinine ratio**                                              
   Median baseline value (mg/g)                         5.5          5.4           0.98
   Median % changes at week 48                          −7.8         +16.8         \<0.001
  **Urine retinol binding protein: creatinine ratio**                              
   Median baseline value (µg/g)                         101.2        111.1         0.12
   Median % changes at week 48                          −18.0        +21.5         \<0.001
  **Urine beta-2-microglobulin: creatinine ratio**                                 
   Median baseline value (µg/g)                         111.6        116.1         0.72
   Median % changes at week 48                          −29.0        +12.0         \<0.001

###### 

Changes in renal, bone and lipid parameters from baseline to week 96

  Parameters[a](#TF0001_21487012){ref-type="table-fn"}[b](#TF0002_21487012){ref-type="table-fn"}   FTC/TAF (N=333)   FTC/TDF (N=330)
  ------------------------------------------------------------------------------------------------ ----------------- -----------------
  eGFR, mL/min (Cockcroft Gault)                                                                   10.0              4.0
  Urine protein: creatinine ratio, %                                                               −26.0             2.7
  Urine albumin: creatinine ratio, %                                                               3.4               27.0
  Urine beta-2-microglobulin: creatinine ratio, %                                                  −29.7             46.8
  Urine retinol binding protein: creatinine ratio, %                                               −4.1              42.6
  Lumbar spine BMD, %                                                                              2.153             −0.167
  Hip BMD, %                                                                                       1.853             −0.331
  Total cholesterol, mg/dL                                                                         14                1
  LDL cholesterol, mg/dL                                                                           14                4
  HDL cholesterol, mg/dL                                                                           1                 −1
  Triglycerides, mg/dL                                                                             11                2
  Total cholesterol: HDL ratio                                                                     0.1               0.1

Mean is used to summarize BMD; otherwise, median is used

p-values were \<0.05 for all, except total cholesterol to HDL ratio (p = 0.26).

###### 

Prevalence of comorbidities, their treatments and risk factors in 2004 and 2014

                                                           2004; N = 2,138   2014; N = 2,138   p
  -------------------------------------------------------- ----------------- ----------------- ----------
  Patients with CD4 count ≥500 cells/mL, %                 43.6              72.0              \<0.0001
  Patients with HIV RNA \>50 copies/mL, %                  50.9              91.5              \<0.0001
  Prevalent CKD (diagnose or 2 consecutive eGFR \<60), %   3.6               18.3              \<0.0001
  DAD CKD high risk score, %                               29.9              50.7              \<0.0001
  Prevalent fractures (anywhere), %                        0.7               7.0               \<0.0001
  10-year FRAX high risk score group, %                    0.3               2.9               \<0.0001
  Prevalent CVD events (ever), %                           3.6               14.0              \<0.0001
  DAD CVD very high risk score group, %                    5.3               19.9              \<0.0001
  Framingham high risk score group, %                      11.6              26.2              \<0.0001
  Patients on clopidogrel, %                               0.8               4.1               \<0.0001
  Patients on aspirin, %                                   0.9               8.0               \<0.0001
  Prevalent hypertension, %                                18.8              56.3              \<0.0001
  On blood-lowering treatment, %                           6.0               22.7              \<0.0001
  Prevalent diabetes, %                                    8.4               18.5              \<0.0001
  On antidiabetics, %                                      2.4               5.8               \<0.0001
  Prevalent dyslipidaemia, %                               14.3              54.5              \<0.0001
  On treatment with statins, %                             9.2               24                \<0.0001

CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, glomerular filtration; DAD, Data Collection on Adverse Events of Anti-HIV Drugs; FRAX, WHO Fracture Risk Assessment tool.

###### 

Incidence rate ratios (IRR) (95% CI) of any lipoatrophy (LA), any lipohypertrophy (LH) or both lipodystrophy (LD) for non-AIDS comorbidities, AIDS events or death

  Outcomes                                       Any LA (n=207)      Any LH (n=109)      Any LD (n=227)
  ---------------------------------------------- ------------------- ------------------- -------------------
  Any non-AIDS comorbidity (n=379)               1.05 (0.81--1.36)   1.25 (0.93--1.68)   1.06 (0.82--1.38)
  Hypertension (n=70)                            1.77 (1.10--2.86)   2.41 (1.49--3.90)   2.00 (1.22--3.28)
  Non-AIDS neoplasia (n=65)                      1.19 (0.73--1.93)   1.21 (0.70--2.11)   1.04 (0.64--1.70)
  Cardiovascular events (n=56)                   1.30 (0.77--2.19)   1.38 (0.78--2.47)   1.53 (0.89--2.61)
  Diabetes mellitus (n=42)                       2.27 (1.19--4.31)   2.51 (1.35--4.65)   2.51 (1.28--4.90)
  Bone fractures (n=39)                          0.53 (0.27--1.03)   0.61 (0.26--1.46)   0.58 (0.31--1.11)
  Chronic kidney disease (n=38)                  1.09 (0.58--2.05)   1.05 (0.50--2.22)   1.06 (0.56--2.00)
  Chronic obstructive pulmonary disease (n=34)   0.58 (0.29--1.17)   1.06 (0.48--2.34)   0.57 (0.29--1.15)
  Hepatic decompensation (n=18)                  0.31 (0.10--0.93)   --                  0.27 (0.09--0.82)
  Neurocognitive impairment (n=17)               0.58 (0.22--1.58)   0.73 (0.21--2.52)   0.51 (0.19--1.38)
  AIDS events (n=104)                            0.53 (0.33--0.86)   0.68 (0.37--1.24)   0.53 (0.33--0.85)
  Death (n=71)                                   0.41 (0.25--0.70)   0.48 (0.25--0.92)   0.43 (0.26--0.71)

![Differences (with 95% CI) in the median global Z-score across cohorts (≥50 PLWH, \<50 PLWH and HIV-negative controls).](JIAS-19-21487021-g001){#F0002_21487021}

![Figure adjusted incidence rate ratios (aIRR) for NHL and HL.](JIAS-19-21487025-g003){#F0003_21487025}

###### 

Gender differences in FTC/TDF for PrEP utilization by race

           Black   White   Hispanic   Asian
  -------- ------- ------- ---------- -------
  Female   17%     65%     15%        3%
  Male     9%      76%     11%        3%

###### 

Proportion of subjects with HIV-1 RNA \<40 copies/mL at week 48 by prognostic and demographic factors (observed failure approach)

  Virologic response by subgroup                                                               
  ------------------------------------------------------------------ ----- ------ ----- ------ --------------------
  All subjects                                                       501   94.2   251   93.6   0.6 (−2.8--4.7)
  Baseline plasma HIV RNA (copies/mL)                                                          
   ≤100,000 copies/mL                                                358   97.2   177   97.7   −0.5 (−3.2--3.1)
   \>100,000 copies/mL                                               143   86.7   74    83.8   2.9 (−6.5--14.1)
  Baseline plasma HIV RNA (copies/mL)                                                          
   ≤500,000 copies/mL                                                479   95.2   237   95.8   −0.6 (−3.6--3.1)
   \>500,000 copies/mL                                               22    72.7   14    57.1   15.6 (−15.6--45.9)
  Baseline CD4 cell counts (cells/mm3)                                                         
   ≤200 cells/mm3                                                    67    85.1   33    87.9   −2.8 (−16.0--14.0)
   \>200 cells/mm3                                                   434   95.6   218   94.5   1.1 (−2.2--5.3)
  Hepatitis co-infection[b](#TF0002_21487039){ref-type="table-fn"}                             
   Hepatitis B or C positive                                         13    100    7     85.7   14.3 (−11.7--52.2)
   Hepatitis B and C negative                                        488   94.1   244   93.9   0.2 (−3.3--4.3)
  Gender                                                                                       
   Male                                                              415   94.7   220   93.6   1.1 (−2.6--5.5)
   Female                                                            86    91.9   31    93.5   −1.7 (−11.1--13.3)
  Viral subtype                                                                                
   Clade B                                                           313   94.6   175   93.7   0.9 (−3.3--5.9)
   Non-clade B                                                       187   93.6   74    93.2   0.3 (−5.7--8.9)
  Geographic region                                                                            
   Africa                                                            41    95.1   12    100    −4.9 (−16.3--20.0)
   Asia/Pacific                                                      84    94.0   43    93.0   1.0 (−7.7--13.3)
   Europe                                                            190   96.3   108   94.4   1.9 (−2.9--8.2)
   Latin America                                                     73    94.5   26    100    −5.5 (−13.3--7.7)
   North America                                                     113   90.3   62    88.7   1.6 (−7.5--12.7)

95% CIs by Miettinen and Nurminen\'s method;

Hepatitis B surface antigen and/or HCV RNA by PCR.

N=number in subgroup.

###### 

Response rates (HIV-1 RNA \<50 copies/mL) at week 96 by subgroup (observed)

                                                                              BMS-663068 pooled[a](#TF0001_21487040){ref-type="table-fn"} (N=136) No. of responders (%)                                     ATV/r (N=30) No. of responders (%)
  --------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- --------------------------------- ------------------------------------
  **Subgroups**                                                                                                                                                           **Subgroups**                     
  **Age**                                                                                                                                                                 **Age**                           
  \<40 years (n=65)                                                           60 (92.3)                                                                                   \<40 years (n=14)                 12 (85.7)
  ≥40 years (n=71)                                                            62 (87.3)                                                                                   ≥40 years (n=16)                  15 (93.8)
  **Gender**                                                                                                                                                              **Gender**                        
  Male (n=78)                                                                 69 (88.5)                                                                                   Male (n=17)                       16 (94.1)
  Female (n=58)                                                               53 (91.4)                                                                                   Female (n=13)                     11 (84.6)
  **Race**                                                                                                                                                                **Race**                          
  Black (n=40)                                                                37 (92.5)                                                                                   Black (n=8)                       7 (87.5)
  White (n=54)                                                                49 (90.7)                                                                                   White (n=12)                      11 (91.7)
  Other (n=42)                                                                36 (85.7)                                                                                   Other (n=10)                      9 (90.0)
  **Baseline viral load**                                                                                                                                                 **Baseline viral load**           
  \<100,000 copies/mL (n=84)                                                  73 (86.9)                                                                                   \<100,000 copies/mL (n=20)        19 (95.0)
  ≥100,000 copies/mL (n=52)                                                   49 (94.2)                                                                                   ≥100,000 copies/mL (n=10)         8 (80.0)
  **Baseline CD4+ T-cell counts**[b](#TF0002_21487040){ref-type="table-fn"}                                                                                               **Baseline CD4+ T-cell counts**   
  \<200 cells/mm^3^ (n=42)                                                    37 (88.1)                                                                                   \<200 cells/mm^3^ (n=13)          12 (92.3)
  ≥200 cells/mm^3^ (n=93)                                                     85 (91.4)                                                                                   ≥200 cells/mm^3^ (n=17)           15 (88.2)

Pooled data are presented because BMS-663068 1200 mg QD was selected as the open-label continuation dose after week 48

One subject did not have a baseline CD4 value.

###### 

Mean increases in CD4+ T-cell count from baseline to week 96 by subgroup (observed)[a](#TF0003_21487040){ref-type="table-fn"}

                                    BMS-663068 pooled[b](#TF0004_21487040){ref-type="table-fn"} (N=134) cells/mm^3^                                     ATV/r (N=31) cells/mm^3^
  --------------------------------- --------------------------------------------------------------------------------- --------------------------------- --------------------------
  **Subgroups**                                                                                                       **Subgroups**                     
  **Age**                                                                                                             **Age**                           
  \<40 years (n=64)                 215.5                                                                             \<40 years (n=15)                 244.0
  ≥40 years (n=69)                  221.8                                                                             ≥40 years (n=16)                  255.8
  **Gender**                                                                                                          **Gender**                        
  Male (n=75)                       210.1                                                                             Male (n=18)                       151.9
  Female (n=58)                     230.0                                                                             Female (n=13)                     386.0
  **Race**                                                                                                            **Race**                          
  Black (n=38)                      213.9                                                                             Black (n=8)                       415.4
  White (n=54)                      231.0                                                                             White (n=13)                      259.8
  Other (n=41)                      207.2                                                                             Other (n=10)                      105.2
  **Baseline viral load**                                                                                             **Baseline viral load**           
  \<100,000 copies/mL (n=81)        184.2                                                                             \<100,000 copies/mL (n=21)        208.0
  ≥100,000 copies/mL (n=52)         272.6                                                                             ≥100,000 copies/mL (n=10)         338.4
  **Baseline CD4+ T-cell counts**                                                                                     **Baseline CD4+ T-cell counts**   
  \<200 cells/mm^3^ (n=42)          202.5                                                                             \<200 cells/mm^3^ (n=13)          216.4
  ≥200 cells/mm^3^ (n=91)           226.2                                                                             ≥200 cells/mm^3^ (n=18)           274.4

One subject did not have a baseline CD4 value

Pooled data are presented because BMS-663068 1200 mg QD was selected as the open-label continuation dose after week 48.

###### 

Week 96 pooled safety results

  Parameter, n (%)                                                           BMS-663068[a](#TF0001_21487041){ref-type="table-fn"}+TDF (300 mg QD)+RAL (400 mg BID) N=200   ATV/r (300/100 mg QD)+TDF (300 mg QD)+RAL (400 mg BID) N=51
  -------------------------------------------------------------------------- --------------------------------------------------------------------------------------------- -------------------------------------------------------------
  Subjects with ≥1 AE (grade 1--4)                                           181 (91)                                                                                      50 (98)
  Related grade 1--4 AEs                                                     64 (32)                                                                                       28 (55)
  Related grade 2--4 AEs                                                     17 (8.5)                                                                                      19 (37)
  SAEs                                                                       24 (12)                                                                                       7 (14)
  AEs leading to discontinuation[b](#TF0002_21487041){ref-type="table-fn"}   5 (2.5)                                                                                       5 (10)
  Deaths[b](#TF0002_21487041){ref-type="table-fn"}                           1 (0.5)                                                                                       0

Pooled data are presented because BMS-663068 1200 mg QD was selected as the open-label continuation dose after week 48;

None were related to BMS-663068.

###### 

Frequencies of abortion and the moment of HIV diagnosis

                               No abortion   Abortion
  ---------------------------- ------------- ------------
  HIV+ previous to pregnancy   38 (64.4%)    21 (35.6%)
  HIV+ during pregnancy        45 (88.2%)    6 (11.8%)

###### 

Maternal baseline characteristics

  Maternal baseline characteristics                             Group I HIV-positive babies (n = 26)   Group II HIV-negative babies (n = 96)   p value
  ------------------------------------------------------------- -------------------------------------- --------------------------------------- ---------
  Median age, years                                             25.8                                   26.5                                    
  Intravenous drug users                                        3 (11.5%)                              0                                       \<0.001
  Smoking                                                       16 (61.5%)                             57 (59.3%)                              \>0.05
  Marital status, no. (%)                                                                                                                      
  Single                                                        16 (61.5%)                             62 (64.5%)                              
  Gravida including current pregnancy, no. (%)                                                                                                 
  1                                                             8 (30.7%)                              43 (44.7%)                              
  2                                                             12 (46.2%)                             38 (39.5%)                              
  3                                                             4 (15.4%)                              8 (8.4%)                                
  4 and more                                                    2 (7.7%)                               7 (7.4%)                                
  Gestational age at study enrolment                                                                                                           
  26--28 weeks                                                  4 (15.4%)                              0%                                      
  29--31 weeks                                                  16 (61.5%)                             10 (10.4%)                              \<0.001
  32--34 weeks                                                  4 (15.4%)                              14 (14.6%)                              
  35--37 weeks                                                  2 (7.7%)                               72 (75%)                                \<0.001
  Sexually transmitted diseases                                                                                                                
  Trichomoniasis                                                10 (38.4%)                             16 (16.6%)                              \<0.01
  Chlamydiosis                                                  8 (30.7%)                              20 (20.8%)                              
  Syphilis                                                      4 (15.4%)                              0%                                      \<0.001
  Herpes simplex                                                6 (23.1%)                              6 (9.1%)                                \<0.01
  Viral load \>10,000 copies/mL                                 6 (23.1%)                              20 (20.8%)                              
  \<1000 copies/mL                                              4 (15.4%)                              52 (54.1%)                              \<0.001
  Unknown                                                       16 (61.5%)                             4 (4.1%)                                \<0.001
  CD4 cell count \>500 cells/µL                                 4 (15.4%)                              68 (70.8%)                              \<0.001
  200--499 cells/µL                                             2 (7.7%)                               12 (12.5%)                              
  \<200 cells/µL                                                4 (15.4%)                              12 (12.5%)                              
  Unknown                                                       16 (61.5%)                             4 (4.2%)                                \<0.001
  The length of time of rupture of membranes (ROM) \<12 hours   8 (30.7%)                              67 (69.7%)                              \<0.01
  \>12 hours                                                    18 (69.3%)                             29 (30.3%)                              \<0.01
  Mode of delivery                                                                                                                             
  Vaginal                                                       20 (76.9%)                             44 (45.8%)                              \<0.05
  Elective caesarean section                                    0%                                     36 (37.5%)                              
  Emergency caesarean section                                   6 (23.1%)                              16 (16.7%)                              
  Triple-combined HAART                                         14 (53.8%)                             92 (95.8%)                              
  Untreated                                                     12 (46.2%)                             4 (4.2%)                                \<0.001

###### 

Since you\'ve started PrEP how do you think the number of times you have had condomless sex has changed?

  Length on PrEP       Decreased   No change   Increased   Total
  -------------------- ----------- ----------- ----------- -----------------------------------------------
  4 months or more     3           22          18          43
  Less than 4 months   2           41          12          55
  Total                5           63          30          98[\*](#TF0001_21487054){ref-type="table-fn"}

Two respondents did not indicate length on PrEP.

![Temporal trends of the proportion on ART of those diagnosed and the proportion with suppressed HIV-RNA of those on ART in Tyrol.](JIAS-19-21487060-g001){#F0001_21487060}

![Number of new HIV infections in Tyrol over time.](JIAS-19-21487060-g002){#F0002_21487060}

![HR for time to viral suppression after starting cART.](JIAS-19-21487062-g001){#F0003_21487062}

###### 

Characteristics of the included patients

                                              ATV/r (N = 939)   DRV (N = 931)    RAL (N = 202)    p
  ------------------------------------------- ----------------- ---------------- ---------------- ---------
  **Male gender, n (%)**                      717 (76.4%)       764 (82.1%)      165 (81.7%)      0.007
  **Age, years, median (IQR)**                39 (32--47)       40 (32--49)      43 (35--51)      0.002
  **Italians, n (%)**                         716 (76.2%)       749 (80.4%)      173 (85.6%)      0.004
  **Mode of HIV transmission, n (%)**                                                             
  Heterosexual                                430 (45.8%)       388 (41.7%)      89 (44.1%)       \<0.001
  IVDU                                        113 (12.0%)       57 (6.1%)        8 (4.0%)         
  Homosexual                                  339 (36.1%)       396 (42.5%)      89 (44.1%)       
  Other/unknown                               57 (6.1%)         90 (9.7%)        16 (7.9%)        
  **AIDS, n (%)**                             81 (8.6%)         148 (15.9%)      21 (10.4%)       \<0.001
  **HCV co-infection, n (%)**                                                                     
  Positive                                    120 (12.7%)       74 (7.9%)        11 (5.4%)        \<0.001
  Negative                                    723 (77.0%)       737 (79.2%)      161 (79.7%)      
  Not known                                   96 (10.2%)        120 (12.9%)      30 (14.8%)       
  **HBV co-infection, n (%)**                                                                     
  Positive                                    40 (4.3%)         33 (3.5%)        13 (6.4%)        0.224
  Negative                                    760 (80.9%)       745 (80.0%)      152 (75.2%)      
  Not known                                   139 (14.8%)       153 (16.4%)      37 (18.3%)       
  **CD4 cell/mm**^**3**^**, n (%)**                                                               
  0--200                                      98 (10.4%)        11 (1.2%)        13 (6.4%)        \<0.001
  201--350                                    350 (37.3%)       264 (28.4%)      32 (15.8%)       
  351--500                                    348 (37.1%)       386 (41.5%)      51 (25.2%)       
  501 +                                       143 (15.2%)       270 (29.0%)      106 (52.5%)      
  Missing                                     54 (5.7%)         81 (8.7%)        17 (8.4%)        
  **CD4 cell/mm**^**3**^**, median (IQR)**    302 (168--413)    250 (87--393)    351 (206--504)   \<0.001
  **HIV RNA copies/mL, n (%)**                                                                    
  50--20,000                                  235 (25.0%)       176 (18.9%)      54 (26.7%)       \<0.001
  20,000--100,000                             272 (29.0%)       225 (24.2%)      60 (29.7%)       
  100,000--250,000                            145 (15.4%)       164 (17.6%)      29 (14.4%)       
  250,000 +                                   187 (19.9%)       230 (24.7%)      35 (17.3%)       
  Missing                                     100 (10.6%)       136 (14.6%)      24 (11.9%)       
  **HIV RNA log10 copies/mL, median (IQR)**   4.8 (4.2--5.3)    5.0 (4.4--5.5)   4.7 (4.1--5.3)   \<0.001
  **Year of cART start**                                                                          
  2008--2009                                  98 (10.4%)        11 (1.2%)        13 (6.4%)        \<0.001
  2010--2011                                  350 (37.3%)       264 (28.7%)      32 (15.8%)       
  2012--2013                                  348 (37.1%)       386 (41.5%)      51 (25.2%)       
  2014--2015                                  143 (15.2%)       270 (29.0%)      106 (52.5%)      
  **NRTIs combination**                                                                           
  FTC + TDF                                   808 (86.1%)       803 (86.2%)      173 (85.6%)      0.973
  ABC + 3TC                                   131 (13.9%)       128 (13.8%)      29 (14.4%)       

###### 

Relative hazards of reaching various outcomes from fitting a Cox regression model

  Outcomes                                         Unadjusted HR (95% CI)   p       Adjusted HR (95% CI)   p
  ------------------------------------------------ ------------------------ ------- ---------------------- ---------
  **TF (VF \>200 copies/mL or discontinuation)**                                                           
  ATV/r                                            1.00                             1.00                   
  DRV/r                                            0.99 (0.87--1.12)        0.821   0.92 (0.80--1.05)      0.222
  RAL                                              1.01 (0.80--1.28)        0.930   0.84 (0.66--1.08)      0.175
  **VF \>50 copies/mL**                                                                                    
  ATV/r                                            1.00                             1.00                   
  DRV/r                                            0.92 (0.74--1.13)        0.431   0.88 (0.70--1.10)      0.270
  RAL                                              0.51 (0.30--0.86)        0.011   0.54 (0.32--0.93)      0.026
  **All-cause discontinuation**                                                                            
  ATV/r                                            1.00                             1.00                   
  DRV/r                                            1.00 (0.88--1.15)        0.935   0.93 (0.81--1.07)      0.296
  RAL                                              1.08 (0.85--1.38)        0.509   0.88 (0.69--1.13)      0.321
  **Discontinuation due to toxicity**                                                                      
  ATV/r                                            1.00                             1.00                   
  DRV/r                                            0.70 (0.56--0.89)        0.003   0.65 (0.51--0.82)      \<0.001
  RAL                                              0.44 (0.26--0.76)        0.003   0.34 (0.20--0.60)      \<0.001

Models were adjusted for gender, age, nation of birth, mode of HIV transmission, hepatitis co-infection status, AIDS diagnosis, nucleoside pair started, baseline CD4 count and viral load and year of starting cART.

###### 

Suppressive ART strategies in Pitié-Salpêtrière Hospital in 2015

  Median (%) IQR                       1-drug regimen                2-drug regimen                 3-drug regimen     
  ------------------------------------ ------------------ ---------- ------------------ ----------- ------------------ ------------
                                       n = 140 (4%)                  n = 710 (19%)                  n = 2898 (77%)     
  **M/F (%)**                          69% / 21%                     68% / 32%                      69% / 31%          
  **Age**                              52 \[46--59\]                 53 \[48--61\]                  49 \[42--56\]      
                                                                                                                       
  **ART regimen**                                                    INSTI+ NNRTI       283 (40%)                      
                                                                     RAL/NNRTI          193 (27%)                      
                                                                     DTG/NNRTI          90 (13%)                       
                                       DRV/r              97 (69%)   2 NRTI             94 (13%)    2NRTI + NNRTI      1240 (43%)
                                       DTG                24 (17%)   NRTI + PI/r        77 (11%)    2NRTI + INI        831 (29%)
                                       ATV/r              10 (7%)    INSTI + PI/r       66 (9%)     2NRTI + PI/r       630 (22%)
                                       LPV/r              9 (6%)     NRTI + INI         60 (8%)     2NRTI + PI         72 (2.5%)
                                                                     NRTI + PI/r        49 (7%)                        
                                                                     Other              81 (11%)    Other              125 (4.4%)
                                                                                                                       
  **ART duration (3 years)**           16.8 \[9--20\]                18 \[8--21\]                   10.7 \[5--18\]     
  **Current regimen duration (mos)**   23 \[10--54\]                 15 \[7--39\]                   28.2 \[12--61\]    
  **CD4/mm**^**3**^**(IQR)**           663 \[525--824\]              627 \[474--828\]               611 \[449--805\]   
  **CD4 nadir/mm**^**3**^**(IQR)**     227 \[159--319\]              196 \[93--319\]                225 \[109--341\]   
  **First line ART**                   3 (2.1%)                      53 (7.5%)                      384 (13.3%)        
  **Switch ART**                       137 (98%)                     657 (93%)                      2514 (87%)         

n = 3748 patients.

###### 

Summary of median durability of ARV regimen by regimen composition and year of initiation in treatment-naïve HIV patients initiating care at an academically affiliated HIV clinic

  ARV regimen composition                           Treatment share N (%)   Median durability, months (95% CI)
  ------------------------------------------------- ----------------------- -----------------------------------------------------------------------------------------------
  Efavirenz/emtricitabine/tenofovir                 193 (33)                59 (47--63)
  Elvitegravir/cobicistat/emtricitabine/tenofovir   115 (20)                [\*](#TF0001_21487068){ref-type="table-fn"} (34--[\*](#TF0001_21487068){ref-type="table-fn"})
  Rilpivirine/emtricitabine/tenofovir               55 (9)                  48 (26--[\*](#TF0001_21487068){ref-type="table-fn"})
  Raltegravir/emtricitabine/tenofovir               42 (7)                  50 (28--66)
  Atazanavir/ritonavir/emtricitabine/tenofovir      31 (5)                  27 (19--76)
  Darunavir/ritonavir/emtricitabine/tenofovir       27 (5)                  44 (36--[\*](#TF0001_21487068){ref-type="table-fn"})
  Dolutegravir/emtricitabine/tenofovir              13 (2)                  7 (3--[\*](#TF0001_21487068){ref-type="table-fn"})
  Dolutegravir/abacavir/lamivudine                  7 (1)                   26 ( [\*](#TF0001_21487068){ref-type="table-fn"})
  Other                                             106 (18)                32 (26--36)
  Year of ARV regimen initiation                    Treatment share N (%)   Median durability, months (95% CI)
  2007--2009                                        177 (30)                57 (45--66)
  2010--2012                                        200 (34)                41 (34--49)
  2013--2015                                        212 (36)                38 (32--[\*](#TF0001_21487068){ref-type="table-fn"})

not estimable.

###### 

Statistical analysis summary

  Panel   Test                                                  Reference                                      N/N                                               C~max~              AUC~last~           AUC~inf~
  ------- ----------------------------------------------------- ---------------------------------------------- ------------------------------------------------- ------------------- ------------------- -------------------
  1       Dispersible tablet, fed                               Edurant^®^, fed                                15/16[a](#TF0001_21487073){ref-type="table-fn"}   1.28 (1.14--1.43)   1.21 (1.10--1.34)   1.33 (1.15--1.53)
  2       Dispersible tablet, fasted                            Dispersible tablet, fed                        16/16[b](#TF0002_21487073){ref-type="table-fn"}   0.66 (0.56--0.77)   0.72 (0.63--0.82)   0.69 (0.57--0.83)
          Dispersible tablet, fed (dispersed in orange juice)   Dispersible tablet, fed (dispersed in water)   16/16[c](#TF0003_21487073){ref-type="table-fn"}   1.11 (0.96--1.30)   1.14 (1.00--1.30)   1.12 (0.94--1.35)

N/N: 11/9 for AUC~inf~

N/N: 11/11 for AUC~inf~

N/N: 12/11 for AUC~inf~.

Data was presented as test/reference least square mean ratio (90% CI). N/N: number of participants in the test/reference; one volunteer discounted before trial completion. C~max~=maximum plasma concentration; AUC~last~=area under the plasma concentration-time curve (AUC, calculated by linear = linear trapezoidal summation) from time of administration up to the last timepoint with a measurable concentration post-dose; AUC~inf~=AUC from time of administration to infinity.

###### 

Proportion of subjects with HIV-1 RNA \<50 copies/mL (snapshot)

                                   Subgroup (n)           DTG/ABC/3TC, N = 248 (%)   ATV/r + TDF/FTC, N = 247 (%)
  -------------------------------- ---------------------- -------------------------- ------------------------------
  Overall                                                 82                         71
  Age (years)                      \<50 (424)             80                         71
                                   ≥50 (71)               92                         74
  CD4 + cell count (cells/mm3)     ≤350 (253)             85                         72
                                   \>350 (242)            78                         71
                                   ≤200 (113)             81                         69
                                   \>200 (382)            82                         72
  Baseline HIV-1 RNA (copies/mL)   ≤100,000 (360)         83                         74
                                   \>100,000 (135)        80                         64
  HIV-1 subtype                    B (206)                80                         69
                                   Non-B (271)            84                         73
  Geographic region                Western Europe (131)   83                         71
                                   US and Canada (153)    77                         70
                                   Other (211)            85                         72

###### 

Baseline parameters

                                                                              Females (n = 63)   Males (n = 125)                  
  --------------------------------------------------------------------------- ------------------ ----------------- -------------- ---------------
  Age (years: mean±SD)                                                        41±9               45±11             51±11          37±11
  Range (years)                                                               34--46             35--55            41--58         30--46
  Race (n Caucasian/non-Caucasian)                                            18/31              4/10              85/4           24/12
  (% Caucasian/non-Caucasian)                                                 36.7/63.3          28.6/71.4         94.4/5.6       68.6/31.4
  CD4/µl (mean±SD)                                                            562±290            386±149           600±251        449±188
  CD4% (mean±SD)                                                              27.6±10.8          21.4±7.9          28.5±9         22±7
  CD4/CD8 ratio (mean±SD)                                                     0.66±0.4           0.37±0.19         0.71±0.40      0.42±0.22
  Patients with viral load \<50 copies/mL (n/%)                               32/65.3            (0/0)             74/82.2        (0/0)
  Patients with viral load \>50 copies/mL (n/%)                               17/34.7            (14/100)          16/17.7        (35/100)
  Viral load (copies/mL; mean±SD)[a](#TF0001_21487077){ref-type="table-fn"}   --                 15,082±14699      --             29,501±22,597
  Viral load range (copies/mL)[b](#TF0002_21487077){ref-type="table-fn"}      723--755,348       874--49,500       806--235,000   379--73,032

In treatment-naïve patients

in treatment-experienced patients with viral-load \>50 copies/mL and treatment-naïve patients.

###### 

Baseline characteristics

                                             All patients (n = 557)                 Male patients (n = 420)               Female patients (n = 137)
  ------------------------------------------ -------------------------------------- ------------------------------------- --------------------------------------
  Age (years)                                40.8 (+/ − 11.4)                       41.5 (+/ − 11.2)                      38.3 (+/ − 11.5)
  Migration background                       30.2% (including 15% African origin)   19.3% (including 7% African origin)   63.5% (including 39% African origin)
  CDC stage                                                                                                               
  A                                          61.8%                                  58.9%                                 69.6%
  B                                          19.5%                                  20.7%                                 16.3%
  C                                          18.6%                                  20.3%                                 14.1%
  CD4 count                                  292 (+/ − 207)                         290 (+/ − 213)                        298 (+/ − 184)
  HIV RNA                                    67.600                                 73.700                                41.450
  ART components apart from NRTI backbone:                                                                                
  Protease inhibitor                         55.7%                                  53.3%                                 62.8%
  NNRTI                                      27.3%                                  28.6%                                 23.4%
  Integrase inhibitor                        20.5%                                  22.1%                                 15.3%

![CD4 count (cells/uL) at baseline, month 2, 4 and 6 of treatment with HAART and at June 2016.](JIAS-19-21487082-g001){#F0004_21487082}

![Viral load (copies/mL) at baseline, month 2, 4 and 6 of treatment with HAART and at June 2016.](JIAS-19-21487082-g002){#F0005_21487082}

###### 

Week 96 Results

                                                                                                                                                                                                                      E/C/F/TAF   E/C/F/TAF   E/C/F/TDF   E/C/F/TDF
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------- ----------- ----------- -----------
  Proportion with HIV-1 RNA \<50 copies/mL[a](#TF0001_21487085){ref-type="table-fn"},[b](#TF0002_21487085){ref-type="table-fn"}                                                                                       97%         85%         93%         84%
  Mean change from baseline in CD4 cell count, cells/µL                                                                                                                                                               +287        +279        +250        +268
  Discontinuations                                                                                                                                                                                                    1%          1%          2%          2%
  Discontinuations due to renal adverse events, n                                                                                                                                                                     0           0           0           6
  Median change from baseline in eGFR, mL/min                                                                                                                                                                         −7          −1          −9          −7
  Median % change from baseline in proteinuria                                                                                                                                                                                                            
   Urine protein: creatinine ratio (UPCR)[b](#TF0002_21487085){ref-type="table-fn"},[d](#TF0004_21487085){ref-type="table-fn"}                                                                                        0%          −10%        34%         15%
   Urine albumin: creatinine ratio (UACR)[d](#TF0004_21487085){ref-type="table-fn"}                                                                                                                                   \<1%        −6%         18%         3%
   Urine retinol binding protein: creatinine ratio (RBPCR)[c](#TF0003_21487085){ref-type="table-fn"},[d](#TF0004_21487085){ref-type="table-fn"}                                                                       12%         14%         72%         74%
   Urine beta-2-microglobulin: creatinine ratio (B2MCR)[c](#TF0003_21487085){ref-type="table-fn"},[d](#TF0004_21487085){ref-type="table-fn"}                                                                          −38%        −32%        22%         35%
  Mean % change from baseline in spine BMD[c](#TF0003_21487085){ref-type="table-fn"},[d](#TF0004_21487085){ref-type="table-fn"}                                                                                       −0.3%       −1.1%       −3.2%       −2.7%
  Mean % change from baseline in hip BMD[a](#TF0001_21487085){ref-type="table-fn"},[b](#TF0002_21487085){ref-type="table-fn"},[c](#TF0003_21487085){ref-type="table-fn"},[d](#TF0004_21487085){ref-type="table-fn"}   −1.5%       −0.6%       −4.6%       −3.1%

p\<0.05 for differences between Asian versus non-Asian in the

TAF group or

TDF group; p \< 0.05 for differences between TAF versus TDF in the

Asian group or

non-Asian group.

###### 

Baseline characteristics of the ART-naïve PROTEKT study population initiated on LPV/r + new agent±other antivirals

  Baseline characteristics                    
  ------------------------------------------- ----------------
  Total, n                                    90
  Gender, n (%)                               
   Male                                       82 (91.1%)
   Female                                     8 (8.9%)
  Median age, years (IQR)                     40 (31--47)
  Ethnicity^a^, n (%)                         
   Caucasian                                  72 (82.8%)
   African                                    10 (11.5%)
   Asian                                      2 (2.3%)
   Other                                      3 (3.4%)
  Median HIV RNA level, log copies/mL (IQR)   5.3 (4.7--6.0)
  HIV RNA \>100,000 copies/mL, n (%)          61 (67.8%)
  Median CD4 cell count, cells/µL (IQR)       302 (162--450)
  CD4 cell count \<200/µL, n (%)              29 (32.2%)
  Median rel. CD4 cell count,% (IQR)          15 (10--22)
  Patients with comorbidities                 
  Renal disease/impairment, n (%)             6 (6.7%)
  Liver disease, n (%)                        1 (1.1%)
  Chronic hepatitis B, n (%)                  1 (1.1%)
  Chronic hepatitis C, n (%)                  6 (6.7%)
  CDC B/C                                     33 (36.7%)

![Time to regimens modification during the first 24 weeks after starting antiretroviral treatment according to the regimen (TA backbone vs. non-TA backbone).](JIAS-19-21487087-g001){#F0006_21487087}

###### 

Odds ratios of starting DTG versus control from fitting a logistic regression

                                Odds ratios of starting dolutegravir versus control                                   
  ----------------------------- ----------------------------------------------------- --------- --------------------- ---------
  Viral load, log10 copies/mL                                                                                         
   \>100,000 vs. ≤100,000       1.39 (0.98--1.97)                                     0.061     2.17 (0.96--4.93)     0.063
  HDL cholesterol, mg/dL                                                                                              
   Per 100 higher               2.22 (0.52--9.49)                                     0.283     8.02 (1.13--56.88)    0.037
  Site geographical location                                                                                          
   North                        1.00                                                                                  
   Centre                       0.66 (0.44--0.99)                                     0.043     0.34 (0.12--0.99)     0.048
   South                        1.05 (0.62--1.76)                                     0.866     1.18 (0.52--2.71)     0.693
  NRTI pair                                                                                                           
   ABC/3TC vs. TDF/FTC          5.83 (4.03--8.43)                                     \<0.001   14.30 (6.81--30.04)   \<0.001
  Period of initiation                                                                                                
   January--December 2014       1.00                                                            1.00                  
   January--June 2015           13.57 (6.94--26,55)                                   \<0.001   15.49 (5.83--41.20)   \<0.001
   July 2015--March 2016        24.87 (12.62--49.04)                                  \<0.001   19.92 (6.63--59.84)   \<0.001

Besides factors shown in the table, also adjusted for gender, nationality, age, education, employment, mode of HIV transmission, time from HIV first diagnosis, AIDS diagnosis, HCV status, HBV status, baseline CD4 count, baseline CD8 count, diagnosis of diabetes dyslipidaemia and psychological disorders, and eGFR.

Treatment Strategies -- Target Populations: Primary Infection

![Median and IQR CD4 at ART start during the four study periods.](JIAS-19-21487090-g001){#F0007_21487090}

![Evolution of the ART chosen as the third drug as starting scheme among periods.](JIAS-19-21487090-g002){#F0008_21487090}

###### 

Epidemiological characteristics of the PHI cohort

                                                          Global          1997--2001       2002--2006       2007--2011       2012--2015      p
  ------------------------------------------------------- --------------- ---------------- ---------------- ---------------- --------------- ---------
  Men, n (%)                                              314 (93.2%)     23 (76.7%)       49 (87.5%)       145 (97.3%)      97 (95.1%)      \<0.001
  Age (years)                                             33.7            33.3             33.2             34.6             34.4            0.164
  Transmission, n (%) -- MSM                              291 (86.9%)     19 (63.3%)       42 (75%)         138 (93.9%)      92 (90.2%)      \<0.001
  Transmission, n (%) -- IDU                              17 (5.1%)       7 (23.3%)        5 (8.9%)         4 (2.7%)         1 (1%)          --
  Origin -- Spain                                         213 (63.4%)     23 (76.7%)       36 (65.5%)       93 (62.4%)       61 (59.8%)      0.391
  Origin -- immigrants                                    123 (36.6%)     7 (23.3%)        19 (34.5%)       56 (37.6%)       41 (40.2%)      --
  Drugs use, n (%) -- IV                                  10 (3.1%)       5 (17.2%)        2 (3.8%)         3 (2.1%)         0 (0%)          \<0.001
  Drugs use, n (%) -- inhaled                             79 (24.5%)      1 (3.4%)         13 (25%)         38 (27%)         27 (26.7%)      --
  Drugs use, n (%) -- oral                                16 (5%)         0 (0%)           2 (3.8%)         6 (4.3%)         8 (7.9%)        --
  Follow-up (months), median (IQR)                        81 (54--118)    200 (178--217)   134 (120--157)   78 (65--91)      40 (27--48)     --
  Time from infection to diagnosis (days), median (IQR)   40 (28--79)     31 (29--77)      42 (29--64)      40 (26--86)      39 (27--74)     \<0.001
  Fiebig I-III, n (%)                                     64 (19%)        9 (30%)          14 (25%)         30 (20.1%)       11 (10.8%)      0.004
  HCV+ at diagnosis, n (%)                                19 (4.9%)       7 (23.3%)        4 (7.1%)         3 (2.1%)         3 (2.1%)        \<0.001
  VDRL+ at diagnosis, n (%)                               40 (12.8%)      5 (17.2%)        6 (10.9%)        16 (11.2%)       13 (15.3%)      0.684
  Time from infection to ART (days), median (IQR)         204 (84--523)   99 (63--156)     109 (51--1140)   336 (155--646)   122 (80--239)   \<0.001
  Time from diagnosis to ART (days), median (IQR)         133 (41--472)   56 (22--74)      62 (19--1052)    284 (103--622)   79 (36--172)    \<0.001

###### 

Comparison between cases and controls

  Variable                                                    Cases N = 14        Controls N = 42       p
  ----------------------------------------------------------- ------------------- --------------------- --------
  PHI symptoms                                                14 (100%)           35 (83.3%)            --
  Fever                                                       14 (100%)           29 (69.0%)            --
  Headache                                                    12 (85.7%)          11 (26.2%)            \<0.01
  Need of hospitalization                                     14 (100%)           8 (19.0%)             --
  Days of hospitalization (n = 20), median (IQR)              6.0 (2.75--7.75)    7.0 (5.25--8.0)       0.496
  Tropism R5 (n = 22)                                         6 (85.7%)           8 (53.3%)             0.229
  Subtype B (n = 38)                                          10 (100%)           26 (92.9%)            --
  Days diagnosis -- ART (n= 53), median (IQR)                 11.5 (5.0--40.8)    140.0 (38.2--284.0)   0.041
  NNRTI-based ART                                             4 (28.6%)           10 (23.8%)            0.732
  Integrase inhibitor-based ART                               2 (14.3%)           9 (21.4%)             0.500
  Protease inhibitor-based ART                                8 (57.1%)           19 (45.2%)            0.448
  Transmitted drug resistance                                 1 (7.14%)           5 (12.2%)             0.621
  Log10 VL diagnosis, median (IQR)                            5.99 (5.29--6.59)   5.24 (4.62--5.86)     0.019
  Log10 VL ART starting (n = 53), median (IQR)                5.50 (4.80--6.19)   4.96 (4.37--5.50)     0.028
  Patients with VL \<50 copies/mL at 6 months ART (n = 47)    11 (92%)            23 (66%)              0.133
  Patients with VL \<50 copies/mL at 12 months ART (n = 46)   11 (92%)            30 (88%)              0.520
  CD4 cells/mm3 diagnosis (n = 55), median (IQR)              328 (253--443)      468 (316--568)        0.184
  CD4 cells/mm3 ART starting (n = 51), median (IQR)           368 (263--441)      404 (273--580)        0.190
  CD4 cells/mm3 6 months ART (n = 48), median (IQR)           581 (493--787)      634 (440--791)        0.569
  CD4 cells/mm3 12 months ART (n = 46), median (IQR)          804 (642--889)      630 (555--864)        0.117
  CD4/CD8 ratio diagnosis (n = 55), median (IQR)              0.33 (0.22--0.44)   0.53 (0.36--0.80)     0.039
  CD4/CD8 ratio ART starting (n = 51), median (IQR)           0.30 (0.24--0.45)   0.49 (0.36--0.67)     0.060
  CD4/CD8 ratio 6 months ART (n = 48), median (IQR)           0.82 (0.65--0.89)   0.76 (0.53--0.99)     0.738
  CD4/CD8 ratio 12 months ART (n = 46), median (IQR)          1.00 (0.82--1.04)   0.88 (0.76--1.40)     0.780

NNRTI, non-nucleoside reverse-transcriptase inhibitors; VL, viral load. p-value was not calculated in those variables with 100% or 0%.

![Proportion of patients reaching HIV RNA 40 copies/mL at various time points.](JIAS-19-21487093-g001){#F0009_21487093}

###### 

Baseline characteristics in TE experienced patients

                                                                                                                                                                  Previous ART                
  ----------------------------------------------------------------------------------------------------------------------------------- --------------------------- --------------------------- ---------------------------
  N (%)                                                                                                                               63 (54.8)                   41 (35.7)                   11 (9.6)
  Male gender, n (%)                                                                                                                  60 (95.2)                   36 (87.8)                   10 (90.9)
  White race, n (%)                                                                                                                   59 (93.7)                   36 (87.8)                   11 (100.0)
  Median age, years (IQR)[a](#TF0001_21487095){ref-type="table-fn"}                                                                   41 (34--52)                 46 (35--54)                 56 (48--64)
  Age \<50 years, n (%)[a](#TF0001_21487095){ref-type="table-fn"}                                                                     44 (69.8)                   24 (58.5)                   3 (27.3)
  Median CD4 count, cells/µL (IQR)                                                                                                    648 (480--886)              671 (519--892)              678 (609--915)
  HIV RNA level \<50 cp/mL, n (%)                                                                                                     57 (91.9)                   37 (90.2)                   10 (90.9)
  Reasons for switch to E/C/F/TAF, n (%) (multiple responses allowed)                                                                                                                         
  Simplification of ART                                                                                                               13 (20.6)                   22 (53.7)                   4 (36.4)
  Patients preference                                                                                                                 25 (39.7)                   18 (43.9)                   2 (18.2)
  Side effects of current ART                                                                                                         22 (34.9)                   21 (51.2)                   6 (54.5)
  Other                                                                                                                               8 (12.7)                    3 (7.3)                     2 (18.2)
  Median serum creatinine, mg/dL (IQR) (range)                                                                                        1.0 (0.9--1.1) (0.6--2.4)   1.0 (0.9--1.2) (0.5--1.7)   1.1 (0.8--1.2) (0.7--1.5)
  Median eGFR (MDRD), mL/min/1.73m2 (IQR) (range)                                                                                     87 (76--100) (34--145)      84 (69--92) (45--219)       79 (66--107) (50--123)
  eGFR (MDRD) \< 60 mL/min/1.73m2, n (%)                                                                                              4 (6.6)                     4 (10.0)                    1 (9.1)
  Median CrCl (Cockroft-Gault), mL/min (IQR) (range)                                                                                  102 (84--122) (38--162)     92 (74--114) (46--179)      99 (62--118) (53--235)
  CrCl (Cockroft-Gault) \< 60 mL/min, n (%)                                                                                           4 (7.0)                     5 (12.8)                    1 (10.0)
  Mean SF-36 score mental component (±SD)[b](#TF0002_21487095){ref-type="table-fn"}                                                   45.4 (12.0)                 41.5 (13.9)                 44.7 (15.2)
  Mean SF-36 score -- physical component (±SD)[a](#TF0001_21487095){ref-type="table-fn"},[b](#TF0002_21487095){ref-type="table-fn"}   56.0 (6.9)                  51.3 (11.9)                 47.0 (11.8)
  Mean HIV SI[c](#TF0003_21487095){ref-type="table-fn"} (±SD)                                                                         14.0 (13.7)                 18.3 (15.1)                 18.7 (12.9)
  Mean HIV TS score (±SD)                                                                                                             50.7 (10.5)                 49.0 (9.8)                  51.9 (5.5)

IQR, interquartile range; SD, standard deviation.

p \< 0.05 (for 3-group comparison)

norm-based scoring, higher scores indicate higher HRQOL

range 0--80, higher scores indicate more bothering symptoms; range 0--60, higher scores indicate greater satisfaction.

![(a) FI change in the follow-up period; (b) logistic regression model to identify predictors of a frail to fit health status transition.](JIAS-19-21487096-g001){#F0010_21487096}

###### 

Study population, stratified below and above 50 years of age

                                 Total                \<50 years            \>50 years               p
  ------------------------------ -------------------- --------------------- ------------------------ -------
  Number of patients (%)         406                  262 (64.53%)          144 (35.47%)             
  Age (SD)                       47.91 (7.8)          43.55 (4.58)          55.85 (5.96)             
  Females (%)                    146 (35.96%)         103 (39.31%)          43 (29.86%)              0.073
  BMI (SD)                       23.84 (3.59)         23.41 (3.29)          24.63 (3.97)             0.001
  Pack-years (IQR)               15.81 (0.5--26.12)   12.75 (0--22.44)      17.05 (2.88--33)         0.003
  CD4 nadir (cells/µL) (IQR)     200 (100--300)       204 (104--300)        189.5 (80--292.25)       0.162
  Current CD4 (cells/µL) (IQR)   596 (440--800)       620 (447--812.5)      575.5 (431.75--756.25)   0.265
  CD4/CD8 (SD)                   0.8 (0.43)           0.82 (0.43)           0.77 (0.44)              0.089
  ART exposure (months) (IQR)    34.5 (12--60)        39.5 (15.25--64.75)   21 (9--49.5)             0.003
  CVD (%)                        19 (4.68%)           7 (2.67%)             12 (8.33%)               0.001
  Hypertension (%)               139 (34.24%)         68 (25.95%)           71 (49.31%)              0.001
  Osteoporosis (%)               83 (20.44%)          38 (14.5%)            45 (31.25%)              0.001
  Diabetes (%)                   48 (11.82%)          15 (5.73%)            33 (22.92%)              0.001
  CKD (%)                        42 (10.34%)          12 (4.58%)            30 (20.83%)              0.001
  Cancers (%)                    32 (7.88%)           13 (4.96%)            19 (13.19%)              0.001
  Multimorbidity (%)             32 (7.88%)           4 (1.53%)             28 (19.44%)              0.001
  Frailty index (SD)             0.34 (0.1)           0.33 (0.1)            0.37 (0.09)              0.001

###### 

Switch and VL outcomes of individuals starting PI/r-based dual therapy regimens

  Second ARV       N starting ARV (%)   48 weeks (n = 239)                               96 weeks (n = 226)                 
  ---------------- -------------------- -------------------- ------------- ------------- -------------------- ------------- -------------
                                        p = 0.0013           p = 0.005     p = 0.02      p = 0.60             p = 0.004     p = 0.03
  CCR5 inhibitor   81                   62/69 (90%)          58/69 (84%)   57/69 (83%)   56/62 (90%)          45/62 (73%)   43/62 (69%)
  INSTI            21                   7/13 (54%)           6/13 (46%)    6/13 (46%)    6/7 (86%)            2/7 (29%)     2/7 (29%)
  NNRTI            103                  89/94 (95%)          84/94 (89%)   80/94 (85%)   77/82 (94%)          71/82 (87%)   65/82 (79%)
  NRTI             50                   30/34 (88%)          29/34 (85%)   29/34 (85%)   30/33 (91%)          27/33 (82%)   25/33 (76%)

Among all with available VL measurement, ignoring ART changes

numerator is number with VL \<50 copies/mL who remain on PIDAT strategy, denominator is those under follow-up with available VL measurement at 48/96 weeks

numerator is number with VL \<50 copies/mL who remain on original specific PIDAT regimen, denominator is those under follow-up with available VL measurement at 48/96 weeks.

###### 

Overview of questionnaire items and correlation with adherence levels

                                                                                     "Good adherence" (n = 162)   "Unstable adherence" (n = 36)   "Poor adherence" (n = 17)   p-value (Fisher\'s exact test)
  ---------------------------------------------------------------------------------- ---------------------------- ------------------------------- --------------------------- --------------------------------
  The ART intake reminds me of my disease                                            n = 7 (4.3%)                 n = 4 (11%)                     n = 5 (29%)                 \<0.01
  I want to go out/I think my medication does not go well with alcohol/party drugs   n = 3 (1.9%)                 n = 5 (14%)                     n = 4 (24%)                 \<0.01
  I\'m afraid that others see me taking the ART medication                           n = 4 (2.5%)                 n = 4 (11%)                     n = 2 (12%)                 0.019
  I think that the ART dose is too high                                              n = 3 (1.9%)                 n = 4 (11%)                     n = 1 (5.9%)                0.037
  Sometimes the copayment fee to my ART is too much for me/other financial reasons   n = 2 (1.2%)                 n = 3 (8.3%)                    n = 1 (5.9%)                0.037

###### 

Socio-demographic characteristics dichotomised into four separate cohorts to present our study population (n = 345)

                 Socio-demographic characteristics   Group 1   Group 2   Group 3   Group 4
  -------------- ----------------------------------- --------- --------- --------- ---------
  Ethnicity      Caucasian                           34        1         9         1
                 First Nations                       10        2         8         --
                 Other                               15        --        9         --
  Risk factors   Men who have sex with men           136       4         40        3
                 People who inject drugs             74        5         32        5
                 Cocaine                             49        2         14        1
                 Amphetamines                        34        4         7         2
                 Opioids                             33        3         14        --
                 Benzodiazepines                     14        1         7         --
                 Homeless                            41        3         20        --
                 Not homeless                        42        3         20        2
                 Employed                            45        1         15        1
                 Unemployed                          30        4         12        2
                 Alcohol                             67        3         31        1
                 No alcohol                          49        3         14        1
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###### 

Index regimens

  --------------------------------------------------------------------- ----------------- -------
  Single-tablet regimens (STRs)                                         n = 4156          61.3%
  elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate   EVG/COB/FTC/TDF   31.9%
  rilpivirine/emtricitabine/tenofovir disoproxil fumarate               RPV/FTC/TDF       23.0%
  abacavir/lamivudine/dolutegravir                                      ABC/3TC/DTG       6.4%
  Multi-tablet regimens (MTRs)                                          n = 2622          38.7%
  emtricitabine/tenofovir disoproxil fumarate + dolutegravir            FTC/TDF + DTG     3.8%
  emtricitabine/tenofovir disoproxil fumarate + darunavir/ritonavir     FTC/TDF + DRV/r   16.8%
  emtricitabine/tenofovir disoproxil fumarate + atazanavir/ritonavir    FTC/TDF + ATV/r   12.0%
  abacavir/lamivudine + dolutegravir                                    ABC/3TC + DTG     1.9%
  abacavir/lamivudine + darunavir/ritonavir                             ABC/3TC + DRV/r   1.4%
  abacavir/lamivudine + atazanavir/ritonavir                            ABC/3TC + ATV/r   2.8%
  --------------------------------------------------------------------- ----------------- -------

![Differentiating factors influencing HCPs' choices of ARVs.](JIAS-19-21487113-g001){#F0013_21487113}

###### 

Stratified viral load distribution between different ARV combinations

  Antiretroviral combination                                 N patients   N VL tests   %VL undetectable   %VL detectable \<20   %VL 20--50   %VL \<50   %VL 50--200   %VL \>200
  ---------------------------------------------------------- ------------ ------------ ------------------ --------------------- ------------ ---------- ------------- -----------
  DRV/cobicistat[a](#TF0001_21487123){ref-type="table-fn"}   181          196          62.8               20.4                  8.7          91.9       6.1           2
  DRV/r or LPV/r[b](#TF0002_21487123){ref-type="table-fn"}   185          1003         --                 --                    --           84.1       10.7          5.2
  Monotherapy[c](#TF0003_21487123){ref-type="table-fn"}      49           105          55.7               29.2                  8.5          93.4       2.8           3.8
  Dual therapy[c](#TF0003_21487123){ref-type="table-fn"}     79           167          56.9               25.1                  8.4          90.8       4.2           5.4
  Triple therapy[c](#TF0003_21487123){ref-type="table-fn"}   93           193          51.6               22.9                  7.8          82.3       6.2           11.5

VL, HIV plasma viral load (copies/mL).

Current analysis (monotherapy with DRV/c between July 2015 and May 2016)

historical data of our patients on monotherapy (2005--2013)

comparative study of our patients (between March 2014 and April 2015).

![Lipids and creatinine mean changes.](JIAS-19-21487125-g001){#F0014_21487125}

###### 

Population characteristics

                                                  Overall population (N = 1461)   EFV/FTC/TDF (N = 998)   RPV/FTC/TDF (N = 463)   p
  ----------------------------------------------- ------------------------------- ----------------------- ----------------------- ---------
  Male gender                                     1083 (74)                       762 (77)                321 (69)                0.003
  Risk factor                                                                                                                     
  Heterosexual                                    513 (35)                        347 (35)                166 (36)                \<0.001
  Homosexual/bisexual                             443 (30)                        310 (31)                133 (29)                
  IDU                                             167 (11)                        97 (8)                  70 (15)                 
  Other                                           232 (16)                        186 (19)                46 (10)                 
  HCV +                                           215 (15)                        127 (15)                88 (26)                 \<0.001
  Prior AIDS events                               336 (23)                        239 (26)                97 (22)                 0.144
  Age (years), median (IQR)                       44 (37--50)                     44 (37--49)             46 (38--52)             0.014
  Time from HIV diagnosis (years), median (IQR)   6.9 (2.6--12.9)                 6.0 (2.4--11.4)         8.9 (3.8--16.5)         \<0.001
  Time of ARV (years), median (IQR)               4.6 (1.2--9.9)                  3.9 (1--8.9)            6.0 (2.2--13.0)         \<0.001
  Baseline CD4+(cells/µL), median (IQR)           573 (424--773)                  546 (400--717)          662 (480--905)          \<0.001
  Nadir CD4+(cells/µL), median (IQR)              224 (102--328)                  213 (98--315)           248 (119--391)          \<0.001

###### 

Baseline characteristics of the studied population

  Characteristic                                    Baseline
  ------------------------------------------------- -------------------
                                                    (n = 61)
  Age (years)                                       52.1 (47.0--58.4)
  Years since first HIV-positive test               16.1 (10.2--23.6)
  Years of ARV exposure                             14.3 (9.0--19.0)
  CDC stage                                         
  A1                                                7 (11%)
  A2                                                12 (20%)
  A3                                                6 (10%)
  B2                                                13 (21%)
  B3                                                3 (5%)
  C2                                                1 (2%)
  C3                                                12 (20%)
  Unknown                                           7 (11%)
  Male gender                                       37 (61%)
  Risk factor                                       
  Man who has sex with man                          12 (20%)
  Heterosexual                                      24 (39%)
  Intravenous drug user                             17 (28%)
  Other/unknown                                     8 (13%)
  White race                                        58 (95%)
  European origin                                   58 (95%)
  HCV-Ab positivity                                 17 (28%)
  Genotype 1a                                       6
  Genotype 1b                                       5
  Genotype 3                                        2
  Genotype 4                                        2
  Unknown genotype                                  2
  Type of ART regimen                               
  PI/r monotherapy                                  2 (3%)
  Dual therapy                                      16 (26%)
  Three or more drugs                               43 (71%)
  Type of ART regimen according to the drug class   
  PI-based                                          55 (90%)
  INSTI-based                                       3 (5%)
  NNRTI-based                                       3 (5%)
  Reasons for switch to ATV + DTG regimen           
  Cardiovascular disease                            2 (3%)
  Concern of cardiovascular disease                 7 (12%)
  Dyslipidemia                                      8 (13%)
  Comorbidity                                       4 (7%)
  Immunologic failure -- CD4 drop                   1 (1.5%)
  Non-compliance                                    1 (1.5%)
  Simplified treatment available                    15 (25%)
  Toxicity -- GI tract/abdomen                      5 (8%)
  Toxicity -- liver                                 3 (5%)
  Toxicity -- kidney                                8 (13%)
  Toxicity -- not specified                         2 (3%)
  Treatment failure                                 1 (1.5%)
  Side effects                                      1 (1.5%)
  Other                                             3 (5%)

###### 

Laboratory parameters at baseline and at last visit

  Characteristic                    Baseline (n = 61)   Last visit (n = 58)   Change from baseline    p
  --------------------------------- ------------------- --------------------- ----------------------- -------
  CD4+ (cells/µL)                   733 (578--946)      690 (513--872)        −6 (−150; + 83)         0.395
  CD8+ (cells/µL)                   850 (583--1159)     840 (560--1169)       −40 (−165; + 117)       0.977
  CD4+ and CD8+ ratio               0.90 (0.62--1.23)   0.90 (0.63--1.20)     +0.07 (−0.10; + 0.15)   0.988
  White blood cells (109/L)         6.7 (5.5--8.4)      6.2 (5.5--7.4)        −0.2 (−0.8; + 0.6)      0.290
  ALT (U/L)                         26 (20--42)         29 (21--37)           +1 (−5; + 7)            0.829
  AST (U/L)                         26 (22--35)         25 (20--32)           0 (−4; + 4)             0.535
  Gamma GT (U/L)                    27 (18--49)         21 (17--39)           −1 (−7; + 3)            0.262
  Total bilirubin (mg/dL)           2.03 (1.08--3.00)   1.58 (0.99--2.28)     −0.72 (−1.58; −0.01)    0.168
  Direct bilirubin (mg/dL)          0.72 (0.40--0.97)   0.57 (0.36--0.72)     −0.07 (−0.19; + 0.08)   0.136
  Indirect bilirubin (mg/dL)        1.21 (0.64--2.00)   0.81 (0.50--1.58)     −0.50 (−1.16; −0.42)    0.544
  FIB-4                             1.18 (0.91--1.61)   1.23 (0.87--1.68)     −0.04 (−0.13; + 0.10)   0.866
  Creatinine (mg/dL)                0.90 (0.80--1.04)   0.96 (0.81--1.16)     0.08 (0; + 0.15)        0.240
  EGFR (mL/min/1.73 m^2^)           89 (76--100)        83 (66--96)           −5 (−13;0)              0.300
  Total cholesterol (mg/dL)         194 (156--219)      184 (165--216)        2 (−21; + 15)           0.790
  LDL cholesterol (mg/dL)           119 (90--149)       108 (85--131)         +3 (−7; + 13)           0.363
  HDL cholesterol (mg/dL)           46 (39--57)         50 (42--65)           +7 (−4; + 12)           0.091
  Total and HDL cholesterol ratio   3.93 (3.08--5.29)   3.58 (2.88--4.44)     −0.25 (−0.85; + 0.29)   0.116
  Triglycerides (mg/dL)             139 (86--193)       108 (84--145)         −13 (−70; + 18)         0.049
  Glucose (mg/dL)                   92 (84--98)         91 (84--106)          0 (−9; + 5)             0.814
  Haemoglobin (109/L)               14.8 (13.9--15.9)   14.7 (13.9--15.7)     −0.2 (−0.6; + 0.4)      0.616
  Platelets (109/L)                 223 (174--272)      230 (180--276)        0 (−19; + 12)           0.828

Mann--Whitney tests were used to evaluate differences between BL and follow-up; results are reported as median (IQR) or frequencies (%).

![Virologic failure (VF) and treatment failure (TF) of dual therapy in 116 naïve patients, 39 treatment-experienced patients without suppressed plasma HIV RNA and 86 patients with suppressed plasma HIV RNA.](JIAS-19-21487130-g001){#F0015_21487130}

###### 

Characteristics of patients (total patients = 55)

  ------------------------------------------------ ----------------
  Total N of patients = 55                         
  Sex, n (%)                                       
   Females                                         20 (36.4%)
   Males                                           35 (63.6%)
  Age, years, median (range)                       
   Total                                           49 (28--74)
   Males                                           50.5 (28--74)
   Females                                         47 (32--70)
  Risk factor, n (%)                               
   Heterosexual                                    28 (50.9%)
   MSM                                             11 (20%)
   TD                                              16 (29.1%)
  CDC stage, n (%)                                 
   C3                                              14 (25.4%)
   Other                                           41 (74.5%)
  HAART exposure, years, median (range)            9 (1--20)
  Length of HIV infection, years, median (range)   12.5 (1--8)
  Previous HAART regimens                          
   PI (%)                                          24 (43.6%)
   NN (%)                                          5 (9.1%)
   Naive                                           26 (47.3%)
   HCV co-infection, n (%)                         15 (27.3%)
  Comorbidities                                    
   Total                                           39/55 (70.96%)
   Smoking                                         32/39 (82.1%)
   Diabetes                                        3 (7.7%)
   Hypertension                                    5 (12.8%)
   Dyslipidaemia                                   5 (12.8%)
  ------------------------------------------------ ----------------

###### 

Costs and saving of dual therapy compared to conventional treatment in our cohort (Foggia, Italy)

  cART regimens     Monthly costs (Ospedali Riuniti Foggia, Italy)   Monthly saving per patient (compared with dual ATV/r + 3TC therapy)   Monthly saving (compared with dual ATV/r + 3TC therapy)   Saving per year (compared with dual ATV/r + 3TC therapy)
  ----------------- ------------------------------------------------ --------------------------------------------------------------------- --------------------------------------------------------- ----------------------------------------------------------
  ATV/r + TDF/FTC   €724.5                                           n = 45 patients: €16848.0                                             n = 45 patients: €16,848.0                                n = 45 patients: €202,176.0
  ATV/r + ABC/3TC   €687.6                                           €337.5                                                                n = 10 patients: €3375.0                                  n = 10 patients: €40,500.0
  ATV/r + 3TC       €350.1                                           --                                                                    --                                                        n = 55 patients: €242,676.0

###### 

Changes in measures of renal and bone safety by third agent

  -------------------------------------------------------------------------------- ----------------------- ----------------------- --------------------------- ---------------------------
                                                                                   **Boosted PI**          **Boosted PI**          **Unboosted third agent**   **Unboosted third agent**
                                                                                                                                                               
                                                                                   **FTC/TAF (n = 155)**   **FTC/TDF (n = 151)**   **FTC/TAF (n = 178)**       **FTC/TDF (n = 179)**
  eGFR                                                                                                                                                         
   Median baseline (mL/min)                                                        102.2                   104.5                   98.3                        97.2
   Median changes at week 48[\*](#TF0001_21487132){ref-type="table-fn"} (mL/min)   +7.7                    +3.3                    +9.3                        +2.8
  Urine protein: creatinine ratio                                                                                                                              
   Median baseline value (mg/g)                                                    57.8                    66.7                    60.6                        59.6
   Median % changes at week 48[\*](#TF0001_21487132){ref-type="table-fn"}          −11.1                   +12.8                   −16.9                       +2.1
  Urine albumin: creatinine ratio                                                                                                                              
   Median baseline value (mg/g)                                                    6.3                     6.4                     5.8                         6.1
   Median % changes at week 48[\*](#TF0001_21487132){ref-type="table-fn"}          --1.8                   +21.2                   −11.6                       +4.4
  Urine beta-2-microglobulin: creatinine ratio                                                                                                                 
   Median baseline value (µg/g)                                                    140.3                   186.5                   131.9                       134.2
   Median % changes at week 48[\*](#TF0001_21487132){ref-type="table-fn"}          −39.3                   +36.4                   −40.2                       +14.0
  Urine retinol binding protein: creatinine ratio                                                                                                              
   Median baseline value (µg/g)                                                    112.4                   117.5                   100.9                       106.8
   Median % changes at week 48[\*](#TF0001_21487132){ref-type="table-fn"}          −13.5                   +24.8                   −17.3                       +11.8
  Spine BMD                                                                                                                                                    
   Mean baseline value (g/m^2^)                                                    1.08                    1.07                    1.09                        1.08
   Mean % changes at week 48[\*](#TF0001_21487132){ref-type="table-fn"}            +1.48                   −0.40                   +1.45                       −0.13
  Hip BMD                                                                                                                                                      
   Mean baseline (g/m^2^)                                                          0.98                    0.97                    0.98                        0.98
   Mean % changes at week 48[\*](#TF0001_21487132){ref-type="table-fn"}            +1.10                   −0.08                   +1.00                       −0.22
  -------------------------------------------------------------------------------- ----------------------- ----------------------- --------------------------- ---------------------------

p-values for all between-group differences (FTC/TAF vs. FTC/TDF) were \<0.05.

###### 

Changes in DTG PK parameters following switch from an EFV-based regimen expressed as geometric mean ratio (GMR; 90% CI) determined from simulations using the final model parameters (n = 100)

            GMR (95% CI; DTG as reference)                                           
  --------- -------------------------------- ------------------- ------------------- -------------------
  AUC0-24   0.73 (0.69--0.76)                0.61 (0.58--0.64)   0.87 (0.83--0.91)   0.88 (0.84--0.92)
  Cmax      0.84 (0.80--0.88)                0.78 (0.74--0.82)   0.92 (0.88--0.96)   0.92 (0.88--0.97)
  C24       0.57 (0.53--0.61)                0.40 (0.37--0.42)   0.79 (0.74--0.84)   0.81 (0.76--0.86)

###### 

Patients' characteristics

  Characteristic                                                           GSS = 1 or 1.5 (n = 27)   GSS = 2 (n = 61)   GSS = 3 (n = 121)
  ------------------------------------------------------------------------ ------------------------- ------------------ -------------------
  Male sex, n (%)                                                          21 (78)                   35 (57)            86 (71)
  Age, median years (IQR)                                                  51 (46--55)               53 (42--59)        51 (41--58)
  Time since HIV diagnosis, median years (IQR)                             21 (16--24)               20 (8--21)         13 (6--21)
  Duration of prior ART, median years (IQR)                                17 (10--20)               18 (5--19)         11 (5--20)
  Number of previous ART lines, median (IQR)                               8 (5--10)                 6 (2--7)           4 (2--7)
  Duration of HIV-1 RNA \<50 copies/mL before switch, median years (IQR)   3 (2--7)                  4 (2--5)           3 (1--5)
  Baseline CD4 cell count, median cells/mm^3^ (IQR)                        670 (435--863)            645 (535--865)     570 (400--750)
  Nadir CD4 cell count, median cells/mm^3^ (IQR)                           183 (63--209)             236 (204--386)     221 (85--325)
  Associated antiretroviral drugs, n (%)                                                                                
  ABC/3TC                                                                  19 (70)                   4 (7)              75 (62)
  TDF/FTC                                                                  1 (4)                     4 (7)              29 (24)
  3TC                                                                      0 (0)                     7 (11)             0 (0)
  RPV                                                                      3 (11)                    26 (43)            0 (0)
  DRV/r                                                                    0 (0)                     5 (8)              0 (0)
  ATV/r                                                                    1 (4)                     6 (10)             0 (0)
  RPV + NRTI                                                               0 (0)                     3 (5)              10 (8)
  Other ARV drugs                                                          3 (11)                    6 (10)             7 (6)
  Number of NRTI drug resistance mutations, median (IQR)                   2 (1--5)                  2 (0--3)           0 (0--0)
  Number of M184V, n (%)                                                   27 (100)                  32 (52)            10 (8)
  Number of NNRTI drug resistance mutations, median (IQR)                  1 (0--2)                  0 (0--2)           0 (0--1)
  Number of major PI drug resistance mutations, median (IQR)               0 (0--2)                  0 (0--0)           0 (0--0)
  Time since last genotypic resistance test, median years (IQR)            9 (4--12)                 9 (5--14)          5 (3--12)

###### 

Results

  Time       Mutation             %VL \<50   CD4 X (SD)
  ---------- -------------------- ---------- ------------
  Baseline   Resistant (n = 30)   100        483 (199)
             Sensitive (n = 29)   100        628 (253)
  12 weeks   Resistant (n = 30)   90         489 (262)
             Sensitive (n = 25)   96         666 (286)
  24 weeks   Resistant (n = 28)   96         491 (263)
             Sensitive (n = 27)   89         636 (294)
  48 weeks   Resistant (n = 26)   88         502 (224)
             Sensitive (n = 24)   96         675 (269)

###### 

Immune phenotypes and HIV reservoir in a cohort of HIV-infected patients switching to Stribild

                                  Week 0                Week 12              Week 24             p                                             Week 0              Week 12             Week 24             p
  ------------------------------- --------------------- -------------------- ------------------- ------- ------------------------------------- ------------------- ------------------- ------------------- --------
  T-cell activation                                                                                      T-cell proliferation                                                                              
  HLA-DR + CD38 + CD4+, % (IQR)   2.28 (1.44--3.78)     1.46 (1--3.18)       1.26 (0.8--2.63)    0.016   Ki67 + CD4+, % (IQR)                  2.12 (1.59--3.74)   2.44 (1.84--4.65)   3.34 (0.87--5.21)   0.846
  HLA-DR + CD38 + CD8+, % (IQR)   5.32 (3.23--11.36)    4.54 (2.35--6.63)    4.64 (2.98--6.85)   0.048   Ki67 + CD8+, % (IQR)                  1.83 (1.22--2.22)   1.91 (1.17--2.98)   1.81 (0.77--4.65)   0.747
  HLA-DR + CD4+, % (IQR)          9.4 (7.47--17.22)     9 (6.22--14.62)      8.15 (5.3--11.9)    0.006   SEB stimulation responses                                                                         
  CD38 + CD8+, % (IQR)            24.02 (15.3--34.05)   16.73 (11.7--31.2)   14.9 (11.2--22.8)   0.018   CD4 + IFNg+, % (IQR)                  0.18 (0--1.46)      0.34 (0--0.87)      0.46 (0.07--0.86)   0.497
  T-cell exhaustion                                                                                      CD4 + IFNg + IL-2+, % (IQR)           0.21 (0.02--0.64)   0.14 (0.01--0.79)   0.03 (0--0.07)      0.024
  PD-1 + CD4+, % (IQR)            3.84 (2.25--5.35)     2.84 (1.47--6.01)    2.79 (2.04--3.68)   0.289   CD4 + IL-2+, % (IQR)                  1.55 (0.50--3.22)   0.26 (0--2.03)      0.2 (0--0.47)       0.0001
  PD-1 + CD8+, % (IQR)            4.15 (1.48--6.36)     3.16 (1.6--5.76)     3.29 (1.62--3.64)   0.339   CD8 + IFNg+, % (IQR)                  2.01 (0.48--4.39)   2.79 (0.95--3.98)   1.15 (0--3.45)      0.024
  T-cell homeostasis                                                                                     CD8 + IFNg + IL-2+, % (IQR)           0.13 (0.04--0.26)   0.09 (0.01--0.45)   0 (0--0.05)         0.003
  CD127 + CD4+, % (IQR)           26.2 (20.5--35.9)     21.4 (10.2--33.1)    28.6 (20.1--34.5)   0.129                                                                                                     
  CD127 + CD8+, % (IQR)           18.6 (15.6--25.3)     21.8 (11.3--27.1)    23.3 (17.9--27.9)   0.072   HIV stimulation responses                                                                         
  NAIVE + CD4+, % (IQR)           5.43 (2.3--7.28)      4.52 (1.49--6.49)    1.72 (0.53--6.92)   0.256   CD4 + IFNg+, % (IQR)                  0 (0--0.06)         0 (0--0.06)         0.03 (0--0.09)      0.001
  CM + CD4+, % (IQR)              3.26 (2.25--6.40)     3.21 (2.09--5.08)    2.09 (0.32--6.65)   0.030   CD4 + IFNg + IL-2+, % (IQR)           0 (0--0.001)        0 (0--0.02)         0 (0--0.06)         0.062
  EM + CD4+, % (IQR)              53.5 (44.2--67.7)     53.5 (41--63)        54.7 (45.2--61.1)   0.482   CD4 + IL-2+, % (IQR)                  0 (0--0.11)         0 (0--0)            0 (0--0.03)         0.089
  TD + CD4+, % (IQR)              32.2 (15.4--40)       34.75 (24.4--44.4)   39.6 (24.3--49.2)   0.405   CD8 + IFNg+, % (IQR)                  0 (0--0.39)         0 (0--0.26)         0 (0--0.04)         0.828
  NAIVE + CD8+, % (IQR)           32.2 (15.4--40)       13.2 (3.03--21.4)    7.98 (4.54--18.9)   0.657   CD8 + IFNg + IL-2+, % (IQR)           0 (0--0.1)          0 (0--0)            0 (0--0.01)         0.267
  CM + CD8+, % (IQR)              0.84 (0.31--3.01)     2.01 (0.64--4.41)    1.47 (0.54--2.64)   0.482                                                                                                     
  EM + CD8+, % (IQR)              33.2 (22.3--43.8)     33.4 (25.6--47.2)    37.1 (27.5--43.5)   0.857   HIV reservoir                                                                                     
  TD + CD8+, % (IQR)              52.6 (34.7--60.3)     46.2 (29.4--61.0)    47.4 (35.3--58.6)   0.962   tot HIV DNA, copies/10\*4 CD4 (IQR)   3 (2--13)           5 (3--12)           4 (2--7)            0.223

CM, central memory CCR7 + CD45RA-; EM, effector memory CCR7-CD45RA-; IQR, interquartile range; SEB, Staphylococcal enterotoxin B; TD, terminally differentiated CCR7-CD45RA+.

Note: Data are presented as median (IQR). Statistical analyses: Friedman test with Dunn\'s multiple comparison test.

###### 

Characteristics and differences of patients switching to STR and LDR

                                                            LDR                 STR                 p
  --------------------------------------------------------- ------------------- ------------------- ---------
  N                                                         317                 525                 
  Male gender, n (%)                                        246 (77.6)          418 (79.6)          0.487
  Age, years, median (IQR)                                  46 (39--52)         43 (36--50)         \<0.001
  Years from HIV test and first visit, median (IQR)         5.8 (2.8--15.3)     4.8 (2.4--9.8)      0.002
  Mode of HIV transmission, n (%)                                                                   
   Heterosexual                                             119 (37.5)          201 (38.3)          0.064
   IVDU                                                     51 (16.1)           54 (10.3)           0.114
   MSM                                                      134 (42.3)          238 (45.3)          0.391
   Other/unknown                                            13 (4.1)            32 (6.1)            0.341
  HCV co-infection, n (%)                                                                           
   Positive                                                 61 (19.2)           74 (14.1)           0.106
   Negative                                                 240 (75.7)          429 (81.7)          0.486
   Not known                                                16 (5.1)            22 (4.2)            0.609
  HBV co-infection, n (%)                                                                           
   Positive                                                 10 (3.1)            17 (3.2)            0.970
   Negative                                                 282 (89.0)          469 (89.3)          0.909
   Not known                                                25 (7.9)            39 (7.4)            0.894
  Number of regimens at switch, n (%)                                                               
   1                                                        139 (43.8)          315 (60.0)          \<0.001
   2                                                        71 (22.4)           100 (19.1)          0.797
   3 or more                                                107 (33.7)          110 (20.9)          \<0.001
  Months of undetectable HIV RNA pre-switch, median (IQR)   25.4 (12--52)       23.2 (8--54)        0.130
  Overall years of cART, median (IQR)                       3 (2--8)            3 (1--6)            0.145
  Laboratory data at switch, median (IQR)                                                           
   Haemoglobin, mg/dL                                       14.6 (13.5--15.5)   14.8 (13.8--15.6)   0.026
   White blood cells/mm^3^                                  6300 (5100--7680)   5990 (5000--7300)   0.088
   Triglicerides, mg/dL                                     133 (94--198)       121 (85--169)       0.004
   Cholesterol, mg/dL                                       193 (165--221)      188 (161--217)      0.255
   Creatinine, mg/dL                                        0.95 (0.80--1.13)   0.89 (0.78--1.00)   \<0.001
   ALT, mg/dL                                               23 (16--33)         28 (20--40)         \<0.001
   CD4, cells/mm^3^                                         598 (464--807)      606 (463--805)      0.734
  Type of pre-switch regimen, n (%)                                                                 
   NRTI/NNRTI                                               44 (13.9)           197 (37.5)          \<0.001
   NRTI/PI/r                                                265 (83.6)          296 (56.4)          \<0.001
   NRTI/INSTI                                               8 (2.5)             32 (6.1)            0.019
  Reason for switching, n (%)                                                                       
   Toxicity                                                 106 (33.4)          104 (19.8)          \<0.001
   Adherence/patient\'s decision                            8 (2.5)             15 (2.9)            0.831
   Neither failure nor toxicity                             191 (60.2)          384 (73.1)          0.005
   Other/unknown                                            12 (3.8)            22 (4.2)            0.896

###### 

Rate ratio of DAC from fitting a Poisson regression

                                               RR     95% CI low   95% CI high   p
  -------------------------------------------- ------ ------------ ------------- ---------
  Age (per 10 years older)                     1.12   1.12         0.98          0.105
  Years from first HIV test and visit (each)   0.97   0.94         0.99          0.007
  Mode of HIV transmission                                                       
   Heterosexual                                1.00                              
   IVDU                                        0.77   0.46         1.29          0.321
   MSM                                         0.71   0.53         0.96          0.026
   Other/unknown                               0.81   0.45         1.45          0.468
  HCV co-infection                                                               
   Negative                                    1.00                              
   Positive                                    1.99   1.27         3.13          0.003
   Unknown                                     0.81   0.56         1.87          0.947
  Number of regimens at switch                                                   
   1                                           1.00                              
   2                                           0.59   0.41         0.85          0.005
   3 or more                                   0.81   0.64         1.29          0.586
  Laboratory tests                                                               
   Triglycerides (per 10 mg/dL)                1.00   0.99         1.01          0.823
   Creatinine (per 10 mg/dL)                   1.30   1.01         1.67          0.041
   ALT (per 10 UI/mL more)                     1.01   0.99         1.03          0.168
  Type of pre-switch regimen                                                     
   NRTI/NNRTI                                  1.00                              
   NRTI/PI/r                                   1.60   1.14         2.23          0.006
   NRTI/INSTI                                  2.09   0.98         4.45          0.055
  Reason for switching                                                           
   Toxicity                                    1.00                              
   Adherence/patient\'s decision               1.11   0.50         2.47          0.801
   Neither failure nor toxicity                0.65   0.48         0.87          0.005
   Other/unknown                               1.81   0.99         3.31          0.053
  STR versus LDR                               0.53   0.39         0.71          \<0.001

![Serum creatinine levels before and after switch to DRV/c.](JIAS-19-21487141-g001){#F0016_21487141}

![Lipid profile before and after switch to DRV/c.](JIAS-19-21487141-g002){#F0017_21487141}

###### 

Patient characteristics

                         Patients (n = 135) (lost 15, 10%)
  ---------------------- -----------------------------------
  Male gender, n (%)     107 (71.3)
  Age, year, mean ± SD   51.1±9.5
  ART regimen, n (%)     
   Triple therapy        73 (54.1)
   Dual therapy          43 (31.8)
   Monotherapy           19 (14.1)
  Risk group, n (%)      
   HSH                   56 (41.5)
   HTX                   31 (22.9)
   IDU                   45 (33.4)
   Transfusional         3 (2.2)
  TDF, n (%)             31 (23)

###### 

Serum creatinine levels and lipid profile before and after switch to DRV/c

                      DRV/r        DRV/c        p
  ------------------- ------------ ------------ ------
  Creatinine (all)    0.93±0.05    1.01±0.05    1
   On TDF             0.89±0.02    0.98±0.03    1
   Not TDF            0.94±0.06    1.02±0.07    1
  Total cholesterol   195.4±3.8    196.7±3.9    0.6
  LDL cholesterol     109.2±3.2    115.7±3.4    0.9
  HDL cholesterol     51.1±1.3     50.5±1.25    0.3
  Triglycerides       177.1±11.6   162.8±13.9   0.03

Reference
=========

1\. Kakuda TN, Opsomer M, Timmers M, Iterbeke K, Van De Casteele T, Hillewaert V, et al. Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers. J Clin Pharmacol. 2014;54:949--57. doi: <http://dxdoi.org/10.1002/jcph.290>

2\. Temesgen Z. Cobicistat, a pharmacoenhancer for HIV treatments. Drugs Today (Barc). 2013;49:233--7. doi: <http://dxdoi.org/10.1358/dot.2013.49.4.1947288>

###### 

Adherence, health-related QoL and patient-reported symptoms at different time points, based on randomization arm

                                          Arm S (MVC + DRV/RTV)   Arm S (MVC + DRV/RTV)                Arm S (MVC + DRV/RTV)   Arm C (continuation of previous three-drug ART)   Arm C (continuation of previous three-drug ART)   Arm C (continuation of previous three-drug ART)   Between-arm comparisons   Between-arm comparisons
  --------------------------------------- ----------------------- ------------------------------------ ----------------------- ------------------------------------------------- ------------------------------------------------- ------------------------------------------------- ------------------------- -------------------------
                                          Baseline (n = 34)       Week 48 (n = 34)                     p                       Baseline (n = 27)                                 Week 48 (n = 27)                                  p                                                 p (baseline values)       p (week 48 values)
  Self-reported adherence (VAS 0--100%)   87.35% (16.57)          87.35% (11.36)                       1.00                    88.88% (13.95)                                    89.63% (14.00)                                    0.80                                              0.70                      0.48
                                          Baseline (n = 30)       Week 48 (n = 30)                                             Baseline (n = 22)                                 Week 48 (n = 22)                                                                                                              
  Patient-reported symptoms score         1.39 (0.31)             1.44 (0.38)                          0.21                    1.41 (0.31)                                       1.36 (0.27)                                       0.35                                              0.80                      0.42
  Mental health (VAS 0--100%)             62.07% (25.54)          63.33% (22.48)                       0.55                    57.95% (22.34)                                    56.82% (25.79)                                    0.83                                              0.55                      0.33
  Physical health (VAS 0--100%)           65.18% (20.79)          58.33% (20.05)                       0.26                    63.64% (16.67)                                    53.64% (26.60)                                    0.04                                              0.78                      0.47
                                          At failure (n = 9)      During treatment success (n = 129)                           At failure (n = 12)                               During treatment success (n = 108)                                                                                            
                                                                                                                                                                                                                                                                                                               
  Self-reported adherence (VAS 0--100%)   73.32% (20.00)          88.21% (12.52)                       0.001                   80.83% (17.82)                                    89.23% (13.74)                                    0.05                                                                        

###### 

Characteristics of study population at baseline

  Variables                                                                     Overall n=240       Elvitegravir n=67   Dolutegravir n=173   p
  ----------------------------------------------------------------------------- ------------------- ------------------- -------------------- ---------
  Age[a](#TF0001_21487145){ref-type="table-fn"}                                 51 (4--56)          50 (40--54)         51 (46--57)          0.082
  Male sex                                                                      178 (74.2)          54 (80.6)           124 (71.7)           0.157
  Risk factor for HIV                                                                                                                        
   Heterosexual                                                                 98 (40.8)           26 (38.8)           72 (41.6)            0.074
   MSM                                                                          67 (27.9)           25 (37.3)           42 (24.3)            
   IDU                                                                          59 (24.6)           15 (22.4)           44 (25.4)            
   Other/unknown                                                                16 (6.7)            1 (1.5)             15 (8.7)             
   Italian nationality                                                          227 (94.6)          65 (97.0)           162 (93.6)           0.582
   CDC stage C                                                                  69 (28.7)           12 (17.9)           57 (32.9)            0.021
   Anti-HCV                                                                     61 (25.4)           18 (26.9)           43 (24.9)            0.748
   HBsAg                                                                        18 (7.5)            6 (9.0)             12 (6.9)             0.594
   Time from HIV diagnosis[a](#TF0001_21487145){ref-type="table-fn"}            14 (5--23)          12 (4--21)          15 (6--23)           0.273
   Time on ARV therapy[a](#TF0001_21487145){ref-type="table-fn"}                10 (4--18)          12 (3--17)          10 (4--18)           0.293
   Nadir CD4 count[a](#TF0001_21487145){ref-type="table-fn"}                    213 (68--326)       308 (202--413)      175 (43--286)        \<0.001
   Zenith HIV RNA[a](#TF0001_21487145){ref-type="table-fn"} (log10 copies/mL)   5.06 (4.66--5.45)   5.06 (4.52--5.26)   5.06 (4.71--5.50)    0.322
   Baseline CD4 count[a](#TF0001_21487145){ref-type="table-fn"}                 586 (445--869)      662 (494--908)      568 (421--817)       0.082
   Previous virologic failure                                                   104 (43.7)          30 (46.2)           74 (42.8)            0.640
   Years of virologic suppression[a](#TF0001_21487145){ref-type="table-fn"}     4 (1--8)            1 (0--5)            5 (1--9)             \<0.001
  Therapies before switch                                                                                                                    
   2 NRTI+INI                                                                   57 (23.8)           14 (20.9)           43 (24.9)            0.518
   2 NRTI+NNRTI                                                                 56 (23.3)           18 (26.9)           38 (22.0)            0.421
   2 NRTI+PI                                                                    92 (38.3)           27 (40.3)           65 (37.6)            0.697
   Mono/dual therapy                                                            24 (10.0)           3 (4.5)             21 (12.1)            0.076
   Other                                                                        12 (5.0)            6 (9.0)             6 (3.5)              0.075
  Reasons for previous treatment discontinuation                                                                                             
   Toxicity                                                                     54 (22.5)           8 (11.9)            46 (26.6)            \<0.001
   Simplification                                                               90 (37.5)           45 (67.2)           45 (26.0)            
   DDI                                                                          54 (22.5)           0                   54 (21.2)            
   Other                                                                        42 (17.5)           14 (20.9)           28 (16.2)            

DDI, drug-drug interactions; IDU, intravenous drug users; INI, integrase inhibitor; MSM, men who have sex with men; (N)NRTI, (non-) nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.

Values within brackets are expressed in percentage except for median values (interquartile range).

![Treatment survival at the last observation according to the PI/r included in the previous regimen (atazanavir (ATV)/r, lopinavir (LPV)/r, fosamprenavir (FPV)/r and darunavir (DRV)/r\[s1\]).](JIAS-19-21487146-g001){#F0018_21487146}

![Main results of the study.](JIAS-19-21487148-g001){#F0019_21487148}

###### 

Main results of the study

               2NA+II   2NA+PI   2NA+NN   Other treatment   No treatment
  ------------ -------- -------- -------- ----------------- --------------
  1996--2005   0        1623     1511     1214              2858
  2006--2010   81       2240     3394     1033              1043
  2011--2013   325      1552     2921     1324              466
  2014--2015   3018     1575     2470     1965              230

II, integrase strand transfer inhibitor; NA, nucleoside/tide analogue; NN, non-nucleoside analogue; PI, protease inhibitor.

###### 

Estimates of PLHIV, PLHIV diagnosed and undiagnosed, undiagnosed fraction, new infections and time to diagnosis, global and by transmission categories (2014)

                              Global                    Heterosexual              MSM                 IVDU
  --------------------------- ------------------------- ------------------------- ------------------- -------------------------
  PLHIV                       44,176 (43,175--45,154)   22,109 (21,416--23,236)   7930 (7532--8440)   13,353 (13,119--13,900)
  PLHIV diagnosed             39,877 (39,476--40,295)   19,239 (18,987--19,574)   7071 (6896--7288)   13,193 (13,008--13,513)
  PLHIV undiagnosed           4298 (3508--5274)         2870 (2200--3783)         859 (570--1292)     161 (95--665)
  Undiagnosed fraction (%)    9.7 (8.0--11.8)           13 (10.3--16.3)           10.8 (7.4--15.5)    1.2 (0.7--4.8)
  New infections              528 (36--1088)            414 (47--953)             106 (58--414)       5 (0--281)
  Time to diagnosis (years)   4.1 (3.7--4.4)            4.5 (4.0--5.1)            2.8 (2.2--3.4)      3.4 (1.7--5.8)

###### 

Overview of selected study parameters at baseline and week 24 with delta and p-value

  Parameter                                         Week 0 (n = 31)   Week 24 (n = 30)    Delta (week 24-0)    p
  ------------------------------------------------- ----------------- ------------------- -------------------- -------
  HIV RNA \<50 copies/mL (patients), ITT snapshot   31 (100%)         29 (94%)            2 (6%)               0.500
  CD4 absolute (/µL)                                752 (581--970)    747 (573--913)      21.5 (−98--85)       0.959
  ALT (U/L)                                         33 (26--44)       32 (26--42)         1.5 (−9--13)         0.758
  AST (U/L)                                         21 (19--26)       23 (19--29)         0.5 (−5--5)          0.910
  gGT (U/L)                                         36 (28--64)       30 (23--51)         −4.5 (−22--1)        0.014
  HDL cholesterol (mg/dL)                           56 (45--68)       51.5 (43--62)       −2.5 (−8--3)         0.174
  LDL cholesterol (mg/dL)                           115 (92--142)     122 (95--138)       0.5 (−9--26)         0.300
  Total cholesterol (mg/dL)                         182 (160--214)    194 (178--221)      4 (--28--33)         0.524
  Triglycerides (mg/dL)                             146 (96--187)     130 (98--196)       3 (−38--45)          0.681
  Serum creatinine (mg/dL)                          1.1 (1--1.4)      1.15 (1.03--1.43)   0.02 (−0.06--0.15)   0.225
  eGFR (mL/min)                                     95 (81--114)      109.05 (83--120)    6 (--4--14)          0.077

###### 

Summary of PDVF and safety results by HCV infection status for LATTE and LATTE-2 subjects[\*](#TF0001_21487157){ref-type="table-fn"} exposed to cabotegravir

  Hepatitis C infection status, ITT-E (N = 490)   Number of subjects with protocol defined virological failure, n (%)   Number of subjects with grade 2 or higher transaminitis, maximum post baseline emergent ALT or AST, n (%)   Number of subjects with drug-related adverse events leading to withdrawal, n (%)   Number of subjects who met protocol defined liver stopping criteria, n (%)
  ----------------------------------------------- --------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- ----------------------------------------------------------------------------
  HCV co-infection (N = 22)                       1/22 (4.5%)                                                           3/22 (14%)                                                                                                  2/22 (9%)                                                                          1/22 (4.5%)
  Acute HCV infection (N = 10)                    0/10                                                                  10/10 (100%)                                                                                                0/10                                                                               10/10 (100%)[‡](#TF0003_21487157){ref-type="table-fn"}
  Non-infected (N = 458)                          12/458 (2.6%)[†](#TF0002_21487157){ref-type="table-fn"}               45/458 (9.8%)                                                                                               11/458 (2.4%)                                                                      3/458 (\<1%)[§](#TF0004_21487157){ref-type="table-fn"}

LATTE (N = 181) used week 144 data cut and LATTE-2 (N = 309) used week 48 data cut

Nine subjects were ineligible to enter the maintenance period (HIV-1 RNA =50 copies/mL just prior) and did not meet the confirmed PDVF criteria at time of withdrawal

Five subjects with acute HCV infection met protocol defined liver stopping criteria but were permitted by protocol to continue on CAB LA

One additional subject who met liver stopping criteria based on local laboratory tests is not counted in the numerator.

![The proportion of patients who initiated different third agents.](JIAS-19-21487158-g001){#F0020_21487158}

![Antiretroviral regimen-associated differences in the frequency of HIV-1 viral load \<50 copies/mL.](JIAS-19-21487159-g001){#F0021_21487159}

![Time to treatment modification by drugs.](JIAS-19-21487160-g001){#F0022_21487160}

![Time to treatment modification by drugs.](JIAS-19-21487160-g002){#F0023_21487160}

###### 

Factors associated with treatment modification: multivariable Cox regression

                 Drug-naïve patients   Multivariable Cox regression                     First use of drug in pre-treated patients   Multivariable Cox regression   
  -------------- --------------------- ------------------------------ ----------------- ------------------------------------------- ------------------------------ ----------------
  Drugs                                                                                                                                                            
  Dolutegravir   14/235                0.98                           \[0.43--2.23\]    90/928                                      0.60                           \[0.43--0.84\]
  Elvitegravir   8/89                  0.89                           \[0.35--2.26\]    38/191                                      1.09                           \[0.73--1.65\]
  Raltegravir    36/83                 5.71                           \[2.79--11.71\]   63/154                                      2.07                           \[1.43--2.98\]
  Darunavir      60/152                4.50                           \[2.29--8.86\]    77/224                                      1.63                           \[1.15--2.30\]
  Other          53/124                5.29                           \[2.68--10.44\]                                                                              
  Rilpivirine    10/104                1.00                           \[1.00--1.00\]    62/293                                      1.00                           \[1.00--1.00\]

###### 

Main characteristics of 378 patients who started antiretroviral therapy within one month after inclusion into care in the period 2005 to 2014

                                                                                  ART initiation at first physician-patient visit   ART initiation within 30 days after the first visit   Total               
  ------------------------------------------------------------------------------- ------------------------------------------------- ----------------------------------------------------- ------------------- --------------------------------------------------
  Variables                                                                       N=123                                             N=255                                                 N=378               p
  Age, years                                                                      39.2 (31.8--48.0)                                 36.4 (30.3--43.6)                                     38.2 (31.4--46.8)   0.043
  Male gender                                                                     115 (93.5)                                        225 (88.2)                                            340 (89.9)          0.111
  Residence outside Zagreb                                                        81 (65.9)                                         156 (61.2)                                            237 (62.7)          0.378
  Mode of transmission                                                                                                                                                                                        
  Men who have sex with men (MSM)                                                 98 (79.7)                                         173 (67.8)                                            271 (71.7)          0.017[\*](#TF0001_21487163){ref-type="table-fn"}
  Male to female or female to male                                                22 (17.9)                                         64 (25.1)                                             86 (22.8)           
  Persons who inject drugs                                                        1 (0.8)                                           7 (2.7)                                               8 (2.1)             
  Unknown                                                                         2 (1.6)                                           11 (4.3)                                              13 (3.4)            
  Integrated into care within 30 days[†](#TF0002_21487163){ref-type="table-fn"}   97 (78.9)                                         233 (91.4)                                            330 (87.3)          \<0.001
  Period                                                                                                                                                                                                      0.194
  2005--2009                                                                      37 (30.1)                                         94 (36.9)                                             131 (34.7)          
  2010--2014                                                                      86 (69.9)                                         161 (63.1)                                            247 (65.3)          
  Had clinical AIDS                                                               34 (27.6)                                         117 (45.9)                                            151 (39.9)          \<0.001
  CD4 cell count per mm3                                                          93 (30--255)                                      125 (47--260)                                         102 (33--255)       0.193
  Categories of CD4 cell count, per mm3                                                                                                                                                                       0.006
  \<100                                                                           54 (43.9)                                         133 (52.2)                                            187 (49.5)          
  100--350                                                                        59 (48.0)                                         82 (32.2)                                             141 (37.3)          
  \>350                                                                           10 (8.1)                                          40 (15.7)                                             50 (13.2)           
  Log HIV1 RNA, copies/mL                                                         5.5 (4.9--5.9)                                    5.2 (4.8--5.8)                                        5.4 (4.9--5.9)      0.051
  HIV RNA \>200,000 copies/mL                                                     54 (43.9)                                         148 (58.0)                                            202 (53.4)          0.010
  Initial ART type                                                                                                                                                                                            
  2NRT + NNRT                                                                     69 (56.1)                                         170 (66.7)                                            239 (63.2)          0.018[‡](#TF0003_21487163){ref-type="table-fn"}
  2NRT + PI                                                                       50 (40.7)                                         71 (27.8)                                             121 (32.0)          
  2NRT + II                                                                       3 (2.4)                                           7 (2.7)                                               10 (2.6)            
  Other                                                                           1 (0.8)                                           7 (2.7)                                               8 (2.1)             
  Had hepatitis C antibody                                                        3 (2.4)                                           8 (3.1)                                               11 (2.9)            0.761
  Had hepatitis B surface antigen                                                 5 (4.1)                                           13 (5.1)                                              18 (4.8)            0.659
  Causes of failure                                                                                                                                                                                           0.966
  Virological failure[§](#TF0004_21487163){ref-type="table-fn"}                   14 (11.4)                                         25 (9.8)                                              39 (10.3)           
  Died                                                                            4 (3.3)                                           8 (3.1)                                               12 (3.2)            
  Lost to follow-up                                                               1 (0.8)                                           2 (0.8)                                               3 (0.8)             
  Stopped ART                                                                     0 (0.0)                                           2 (0.8)                                               2 (0.5)             

Values on the table are frequencies or medians with Q1--Q3.

MSM versus non-MSM

time from HIV test to first CD4 count measurement

comparison of NNRT versus PI

at 12 months.

![Kaplan-Meier estimates of proportion of patients with HIV RNA \< 50 copies/ml according to time of initiation antiretroviral therapy.](JIAS-19-21487163-g001){#F0024_21487163}

###### 

Patient characteristics before introduction of DTG-containing ART

                                                                 TRIUMPH (N = 398)   DOL-ART (N = 411)                    
  -------------------------------------------------------------- ------------------- ------------------- ---------------- ----------------
  Sex, male, N (%)                                               155 (95.1)          203 (86.4)          89 (89.9)        268 (85.9)
  Age, years, median (range)                                     39 (29--48)         45 (35--52)         39 (32--48)      46 (38--53)
  CDC stage C, N (%)                                             9 (5.5)             54 (23.0)           10 (10.1)        86 (27.6)
  BL HIV RNA, log copies/mL, median (IQR)                        4.4 (3.9--4.9)      1.7 (1.7--1.7)      4.7 (4.1--5.1)   1.7 (1.7--1.8)
  BL HIV-1 RNA ≥100,000 copies/mL, N (%)                         30 (18.4)           --                  29 (29.3)        --
  BL HIV-1 RNA ≥500,000 copies/mL, N (%)                         6 (3.7)                                 8 (8.1)          
  BL HIV-1 RNA 50 copies/mL, N (%)                               --                  198 (84.3)          --               224 (71.8)
  BL CD4 cell count, cells/µL, median (IQR)                      450 (282--597)      602 (434--834)      377 (245--549)   584 (422--800)
  BL CD4 cell count, 200/µL, N (%)                               22 (13.5)           8 (3.4)             18 (18.2)        23 (7.4)
  \>2 previous regimens, N (%)                                   --                  48 (20.4)           --               135 (43.3)
  Comorbidities, N (%)                                           49 (30.1)           123 (52.3)          35 (35.4)        193 (61.9)
  Depression, N (%)                                              24 (14.7)           55 (23.4)           16 (16.2)        104 (33.3)
  Hypertension, N (%)                                            12 (7.4)            27 (11.5)           6 (6.1)          58 (18.6)
  Cardiovascular diseases, N (%)                                 2 (1.2)             15 (6.4)            3 (3.0)          35 (11.2)
  Chronic HCV infection, N (%)                                   6 (3.7)             20 (8.5)            5 (5.1)          20 (6.4)
  Pulmonary disease, N (%)                                       4 (2.5)             17 (7.2)            6 (6.1)          22 (7.1)
  Dyslipidaemia (requiring treatment), N (%)                     0 (0.0)             10 (4.3)            0 (0.0)          30 (9.6)
  Diabetes mellitus, N (%)                                       4 (2.5)             13 (5.5)            4 (4.0)          13 (4.2)
  Concomitant medication, N (%)                                  30 (18.4)           81 (34.5)           24 (24.2)        113 (36.2)
  Antihypertensives, N (%)                                       13 (8.0)            35 (14.9)           6 (6.1)          60 (19.2)
  Antidepressants, N (%)                                         6 (3.7)             26 (11.1)           5 (5.1)          37 (11.9)
  Ca^2\ +^/Fe^2\ +^-containing supplements/multivitamin, N (%)   2 (1.2)             12 (5.1)            3 (3.0)          10 (3.2)
  Prophylaxis/treatment of opportunistic infection, N (%)        6 (3.7)             7 (3.0)             10 (10.1)        13 (4.2)
  Metformin, N (%)                                               0 (0.0)             4 (1.7)             1 (1.0)          5 (1.6)

![Time to treatment discontinuation (Kaplan-Meier) for all patients initiated on DRV/r QD.](JIAS-19-21487172-g001){#F0025_21487172}

###### 

Clinical characteristics of solid organ recipient and post-transplant follow-up

  Characteristics               Patient 1              Patient 2         Patient 3              Patient 4              Patient 5              Patient 6
  ----------------------------- ---------------------- ----------------- ---------------------- ---------------------- ---------------------- ----------------------
  Pre-transplant assessment                                                                                                                   
  Age                           57                     52                40                     50                     56                     45
  Gender                        M                      M                 M                      F                      F                      M
  Organ                         Kidney                 Kidney            Kidney                 Liver                  Kidney                 Kidney
  Time on dialysis (months)     40                     132               83                     N/A                    70                     54
  CD4 T-cell count (cells/µl)   500                    390               620                    300                    200                    410
  Post-transplant follow-up                                                                                                                   
  ART                           ABC, 3TC, DTG          ABC, 3TC, RAL     DRV/r, ETR, RAL        FTC, 3TC, RAL          ABC, 3TC, RPV, DTG     DRV/r, EFV, RAL
  Immunosuppressive regimen     TAC, MMF, prednisone   TAC, prednisone   TAC, LEF, prednisone   TAC, AZA, prednisone   TAC, MMF, prednisone   TAC, MMF, prednisone
  CD4 T-cell count (cells/µl)   330                    410               510                    350                    270                    540
  HIV viral load (copies/ml)    \<40                   \<40              \<40                   \<40                   \<40                   \<40
  eGFR (ml/min/1,73m^2^)        53                     28                39                     54                     98                     61
  Rejection (n)                 0                      0                 1                      0                      0                      0
  Follow-up (months)            6                      49                19                     5                      2                      6

###### 

Demographic characteristics, CDC clinical stage and concomitant liver diseases at entry

                                                             ARV-naïve (N = 117)   ARV-experienced (N = 116)
  ---------------------------------------------------------- --------------------- ---------------------------
  Age, years                                                                       
  mean±SD                                                    42.0±11.0             44.3±9.5
  Gender at birth, N (%)                                                           
   Male                                                      99 (84.6)             91 (78.4)
  Race, N (%)                                                                      
   Black                                                     5 (4.3)               3 (2.6)
   Caucasian/other                                           112 (95.7)            113 (97.4)
  CDC clinical stage C, N (%)                                38 (32.5)             41 (35.3)
  History of HBV-HCV hepatitis, N (%)                                              
   No                                                        88 (75.2)             70 (60.3)
   Not active ([b](#TF0002_21487175){ref-type="table-fn"})   9 (7.7)               14 (12.1)
    HBV                                                      6                     5
    HCV                                                      2                     5
    HBV/HCV                                                  1                     3
    Unspecified                                              0                     1
   Active ([a](#TF0001_21487175){ref-type="table-fn"})       20 (17.1)             32 (27.6)
    HBV                                                      12                    4
    HCV                                                      6                     20
    HBV/HCV                                                  2                     7
    Unspecified                                              0                     1

HCV RNA quantitation within 6 months before entry, or positive HBV and HCV serology within 6 months before entry, or reported as an active concomitant disease at entry.

HCV RNA quantitation more than 6 months before entry, or positive HBV and HCV serology more than 6 months before entry, or reported as a previous (not active) disease at entry.

CDC, Center for Disease Control and Prevention; HBV, hepatitis B virus; HCV, hepatitis C virus; SD: standard deviation.

![Time trend of serum ALT levels (geometric mean) during the study.](JIAS-19-21487175-g001){#F0026_21487175}

![Time trend of total bilirubinemia (geometric mean) during the study.](JIAS-19-21487175-g002){#F0027_21487175}

**Time to treatment discontinuation (Kaplan-Meier) for patients on DRV/r QD monotherapy**

###### 

Metabolic AEs reported during the study, N (%) of patients

                                     ARV naïve (N=117)   ARV naïve (N=117)   ARV experienced (N=116)   ARV experienced (N = 116)
  ---------------------------------- ------------------- ------------------- ------------------------- ---------------------------
  Hyperlipidaemias                   8 (6.8%)            5 (4.3%)            6 (5.2%)                  4 (3.4%)
  \- Hypercholesterolemia            2                   2                   1                         1
  \- Hypercholesterolemia            0                   0                   1 (e)                     1
  \- Hypertriglyceridemia            1                   0                   3                         2
  \- Hyperlipaemia (l)               4                   2                   1                         0
  \- Hyperlipaemia (l)               1 (a)               1                   0                         0
  Other metabolic AEs                                                                                  
  \- Diabetes mellitus reactivated   1 (a)               0                   1                         0
  \- Weight increase                 1 (a)               0                   0                         0
  \- Weight decrease                 1 (s)               0                   0                         0
  \- Lipodystrophy                   1 (e)               1                   0                         0

\(l\) hypercholesterolemia + hypertriglyceridemia; (a) AEs occurring in the same patient; (s) serious AE (caused hospitalization); (e) study discontinued because of AE. ADR, adverse drug reaction (AE possibly or probably related to DRV according to the clinician); WHO-ART, World Health Organization adverse reactions terminology.

![Time to treatment discontinuation (Kaplan-Meier) for patients on DRV/r QD monotherapy.](JIAS-19-21487181-g001){#F0028_21487181}

![Kaplan-Meier showing probability of remaining smear or culture positive over time among those with 0/1/2 drugs below the cut-off.](JIAS-19-21487183-g001){#F0029_21487183}

###### 

Immuno-virologic characteristics, mortality and survival in HIV-infected patients with CNS-OIs

                                             PML n = 62          TBM n = 41          CM n = 37           PCNSL n = 10        CMVE n = 6          Toxo n = 64         p
  ------------------------------------------ ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -------
  CD4 cell count/mm^3^, median (IQR)         39 (16--103)        65 (23--122)        21 (11--56)         40 (16--78)         23 (11--48)         29 (11--63)         0.08
  Nadir CD4 cell count/mm^3^, median (IQR)   33 (12--77)         37 (19--65)         13 (8--28)          32 (11--41)         13 (8--21)          23 (11--54)         0.06
  HIV RNA log10 copies/mL, median (IQR)      4.76 (2.85--5.39)   5.32 (4.46--5.84)   5.37 (4.61--5.76)   5.71 (5.14--5.87)   5.89 (5.58--5.92)   5.33 (4.97--5.80)   0.007
  Survival in months, median (IQR)           22.1 (3.15--5.12)   14.9 (4.0--27.6)    16.2 (2.3--44.3)    2.3 (1.2--4.1)      38 (11.8--78.9)     17.8 (2.7--43.1)    0.08
  Mortality, n (%)                           23 (37.0)           20 (48.7)           18 (48.6)           7 (70.0)            2 (33.3)            24 (37.5)           0.31
  Early mortality, n (%)                     16 (25.8)           8 (19.5)            12 (32.4)           7 (70.0)            1 (16.6)            19 (29.6)           0.05

![ROC curve.](JIAS-19-21487191-g001){#F0030_21487191}

![Mean per person per year (PPPY) individual categories cost per cohort.](JIAS-19-21487192-g001){#F0031_21487192}

![Prevalence of comorbidities and risk factors in 2006 and 2014 for all patients and ≥50 years.](JIAS-19-21487193-g001){#F0032_21487193}

![Observed (red box) and predicted distribution of disability (a) and geriatric syndromes (b) in HIV-positive patients between 2014 and 2030.](JIAS-19-21487193-g002){#F0033_21487193}

![Observed (red box) and predicted age distribution (a) and burden of frailty (b) in HIV-positive patients between 2009 and 2030.](JIAS-19-21487194-g001){#F0034_21487194}

![Predicted burden of NCDs amongst HIV-positive patients on treatment in Italy, as simulated by the model. *The bar graph shows the number of people living with HIV (PLHIV) on HIV treatment with 0, 1, 2 or ≥3 comorbidities between 2010 and 2030, while the Venn diagram represents the relative number of HIV-positive patients with the three most prevalent comorbidities and their overlap in 2030*](JIAS-19-21487195-g001){#F0035_21487195}

###### 

Baseline characteristics of the study population between 65 and 75 years of age

                    Total (n = 1111)   HIV− (n = 153)   HIV+ (n = 958)   HIV− vs. HIV +   HIV+ \<10 years (n = 211)   HIV+ 10--20 years (n = 436)   HIV+ \>20 years (n = 311)   HIV+ duration   HIV− vs. HIV+ duration
  ----------------- ------------------ ---------------- ---------------- ---------------- --------------------------- ----------------------------- --------------------------- --------------- ------------------------
  Age               69.11 (2.62)       68.95 (2.73)     69.12 (2.6)      0.47             69.32 (2.56)                69.13 (2.57)                  68.98 (2.67)                0.26            0.37
  Females           177 (15.71%)       24 (15.69%)      150 (15.66%)     1                34 (16.11%)                 67 (15.37%)                   49 (15.76%)                 0.97            0.99
  BMI               26.52 (9.83)       28.72 (3.92)     26.07 (10.63)    \<0.01           28.06 (21.1)                25.83 (4.25)                  25.06 (4.18)                \<0.01          \<0.01
  Current smokers   261 (27.19%)       28 (19.18%)      230 (28.5%)      0.02             45 (25.71%)                 96 (26.37%)                   89 (33.21%)                 0.11            0.02
  Hypertension      502 (61.9%)        102 (66.67%)     399 (61.2%)      0.24             84 (54.9%)                  192 (60.19%)                  123 (68.33%)                0.04            0.04
  T2DM              216 (27.07%)       37 (24.18%)      178 (27.86%)     0.41             32 (21.19%)                 80 (25.72%)                   66 (37.29%)                 \<0.01          \<0.01
  CVD               143 (18.17%)       33 (21.57%)      110 (17.52%)     0.29             17 (11.56%)                 50 (16.34%)                   43 (24.57%)                 \<0.01          \<0.01
  CKD               121 (16.24%)       5 (7.94%)        115 (17.01%)     0.09             25 (15.15%)                 52 (15.76%)                   38 (20.99%)                 0.24            0.09
  COPD              59 (7.63%)         17 (11.41%)      41 (6.63%)       0.07             11 (7.59%)                  13 (4.38%)                    17 (9.66%)                  0.07            0.03
  Dyslipidaemia     502 (68.67%)       37 (56.92%)      463 (70.15%)     0.04             98 (61.64%)                 230 (71.43%)                  135 (75.42%)                0.02            \<0.01
  Multimorbidity    412 (61.31%)       40 (63.49%)      370 (61.36%)     0.84             72 (51.06%)                 174 (59.79%)                  124 (72.51%)                \<0.01          \<0.01
  Polypharmacy      194 (30.27%)       23 (15.03%)      170 (34.98%)     \<0.01           28 (29.47%)                 80 (34.48%)                   62 (38.99%)                 0.3             \<0.01

###### 

Baseline characteristics of the study population above 75 years of age

                    Total (n = 1111)   HIV− (n = 153)   HIV+ (n = 958)   HIV− vs. HIV +   HIV+ \<10 years (n = 211)   HIV+ 10--20 years (n = 436)   HIV+ \>20 years (n = 311)   HIV+ duration   HIV− vs. HIV+ duration
  ----------------- ------------------ ---------------- ---------------- ---------------- --------------------------- ----------------------------- --------------------------- --------------- ------------------------
  Age               78.66 (3.43)       78.97 (3.49)     78.44 (3.37)     0.06             78.25 (3)                   78.65 (3.7)                   78.25 (3.06)                0.99            0.28
  Females           124 (22.7%)        61 (27.34%)      61 (19.18%)      0.03             11 (15.9%)                  31 (19.8%)                    19 (20.43%)                 0.74            0.13
  BMI               26.22 (4.68)       27.39 (5.12)     25.24 (4.01)     \<0.01           26.25 (4.18)                24.97 (4.03)                  24.93 (3.78)                0.11            \<0.01
  Current smokers   57 (12.18%)        18 (9%)          39 (14.72%)      0.08             5 (9.09%)                   23 (17.97%)                   11 (13.41)                  0.27            0.09
  Hypertension      328 (70.54%)       153 (69.23%)     173 (71.78%)     0.61             41 (70.69%)                 88 (73.95%)                   44 (68.75%)                 0.74            0.81
  T2DM              122 (26.87%)       49 (22.27%)      70 (30.3%)       0.07             10 (17.86%)                 37 (33.04%)                   23 (36.51%)                 0.06            0.02
  CVD               130 (29.28%)       68 (30.91%)      61 (27.48%)      0.49             17 (31.48%)                 25 (23.58%)                   19 (30.65%)                 0.46            0.54
  CKD               83 (23.92%)        11 (10.28%)      72 (30.38%)      \<0.01           15 (25.42%)                 34 (29.57%)                   23 (36.51%)                 0.40            \<0.01
  COPD              66 (15%)           45 (20.55%)      20 (9.13%)       \<0.01           4 (7.69%)                   9 (8.49%)                     7 (11.48%)                  0.75            \<0.01
  Dyslipidaemia     223 (65.01%)       50 (46.73%)      172 (73.5%)      \<0.01           28 (49.12%)                 97 (84.35%)                   47 (75.81%)                 \<0.01          \<0.01
  Multimorbidity    228 (71.03%)       70 (65.42%)      156 (73.58%)     0.17             32 (62.75%)                 77 (75.49%)                   47 (79.66%)                 0.11            0.09
  Polypharmacy      168 (41.18%)       84 (37.67%)      84 (45.65%)      0.13             23 (54.76%)                 33 (36.26%)                   28 (54.9%)                  0.04            0.02

![Predicted burden of NCDs amongst HIV-positive patients on treatment in the United States, as simulated by the model. *The bar graph shows the number of people living with HIV (PLHIV) on HIV treatment with 0, 1, 2 or* ≥*3 comorbidities between 2010 and 2030, while the Venn diagram represents the relative number of HIV-positive patients with the three most prevalent comorbidities and their overlap in 2030*.](JIAS-19-21487196-g001){#F0036_21487196}

###### 

Patient demographics, HIV markers and comorbidities in 2003 and 2013

                                                    2003 (n = 2403)     2013 (n = 4910)     p
  ------------------------------------------------- ------------------- ------------------- ---------
  Mean age, years (SD)                              41.1 (10.6)         43.8 (11.4)         \<0.001
  Age ≥50                                           18.2%               26.9%               \<0.001
  Median CD4, count/mL (IQR)                        493/mL (299--717)   610/mL (425--828)   \<0.001
  AIDS diagnosis                                    16.2%               13.0%               \<0.001
  Median time since diagnosis, years (IQR)          6.0 (2.9--9.0)      6.7 (2.8--13.1)     \<0.001
  HIV RNA \<50 copies/mL                            34.1%               72.4%               \<0.001
  Patients on ART                                   76.5%               84.4%               \<0.001
  Median time on ART, years (IQR)                   3.8 (0.5--6.4)      4.5 (1.1--11.0)     \<0.001
  Triple therapy (2 NRTI + 3rd agent)               63.5%               76.9%               \<0.001
  eGFR \<60 mL/min/1.73 m^2^                        2.4%                3.4%                0.006
  Overall cardiovascular events (ever)              1.8%                2.1%                \<0.001
  Myocardial infarction (ever)                      1.3%                1.7%                0.001
  Stroke (ever)                                     0.3%                0.4%                0.102
  Median Framingham risk score (IQR)                9.7% (4.3--17.0)    8.2% (3.9--18.1)    0.096
  Patients with high (FRS \>20%) 10-year CVD risk   18.2%               22.2%               0.002
  Dyslipidemia                                      64.9%               70.3%               \<0.001
  Patients on lipid-lowering treatment              3.5%                7.5%                \<0.001
  Median total cholesterol, mg/dL (IQR)             202 (169--239)      189 (161--220)      \<0.001
  Median HDL, mg/dL (IQR)                           46 (37--55)         43 (36--53)         \<0.001
  Median LDL, mg/dL (IQR)                           122 (97--154)       114 (91--140)       \<0.001
  Median triglycerides, mg/dL (IQR)                 144 (96--237)       123 (86--183)       \<0.001
  Hypertension                                      27.0%               27.5%               0.819
  Diabetes                                          6.2%                5.6%                0.028

Percentages calculated after exclusion of missing values. eGFR, estimated glomerular filtration rate; IQR, interquartile range; NRTI, nucleotide reverse transcriptase inhibitor; SD, standard deviation.

![Multivariate logistic regression for four not conventional ARV therapy.](JIAS-19-21487201-g001){#F0037_21487201}

![Predictors of multimorbidity and polypharmacy.](JIAS-19-21487196-g002){#F0001_21487201}

###### 

Anthropometrical and clinical characteristics of patients

  Characteristics                         CD4/CD8 ratio \<0.8 - N (%) or median (IQR)   CD4/CD8 ratio \> = 0.8 - N (%) or median (IQR)   p
  --------------------------------------- --------------------------------------------- ------------------------------------------------ ---------
  Total number of patients                1470 (49)                                     1475 (51)                                        
  Female sex                              391 (27)                                      550 (37)                                         \<0.001
  Age                                     49 (45--54)                                   50 (45--54)                                      0.900
  Smokers                                 775 (53)                                      854 (58)                                         0.004
  Packyear (if smoker)                    20.8 (10--32)                                 17.9 (9.3--30)                                   0.004
  No physical activity                    717 (51)                                      665 (48)                                         0.051
  Intense alcohol intake (\>3/week)       14 (0.9)                                      16 (1.1)                                         0.923
  BMI                                     23.8 (21--26)                                 23.3 (21--25.7)                                  0.001
  HIV duration (months)                   241 (158--299)                                239 (156--299)                                   0.427
  Risk factor for HIV                                                                                                                    \<0.001
  Intravenous drug users                  409 (28)                                      357 (24)                                         
  Men who have sex with men               453 (31)                                      407 (27.5)                                       
  Heterosexual                            431 (29)                                      557 (37.8)                                       
  Other                                   177 (12)                                      154 (10)                                         
  CDC C stage                             375 (25.5)                                    305 (20.7)                                       0.005
  Age at ARV initiation                   36 (31--43)                                   34 (31--42)                                      0.005
  ARV initiation period                                                                                                                  0.106
  \<1996                                  437 (30.4)                                    397 (27.4)                                       
  1996--2005                              637 (44)                                      696 (48)                                         
  ≥2006                                   363 (25)                                      358 (24.7)                                       
  CD4 cells nadir cells/mm^3^             163 (60--260)                                 221 (109--330)                                   \<0.001
  CD8/CD38 cells count cells/mm^3^        84 (51--152)                                  58.5 (38--94)                                    \<0.001
  LDL cholesterol mg/dL                   113 (37--57)                                  112 (92--136)                                    0.791
  HDL cholesterol mg/dL                   45 (35--57)                                   51 (41--62)                                      \<0.001
  Total cholesterol mg/dL                 188 (161--226)                                189 (165--217)                                   0.352
  Glucose                                 94 (86--103)                                  93 (87--102)                                     0.451
  GOT                                     24 (20--34)                                   22 (19--31)                                      \<0.001
  HOMA index                              2 (1.2--3)                                    1.7 (1.1--2.8)                                   \<0.001
  C reactive protein                      0.2 (0.13--0.3)                               0.2 (0.18--0.22)                                 0.262
  Cardiovascular disease                  100 (6.8)                                     63 (4.3)                                         0.003
  Hypertension                            563 (38)                                      509 (34.5)                                       0.033
  Diabetes mellitus                       231 (15.7)                                    193 (13.1)                                       0.042
  Chronic kidney disease                  148 (10.1)                                    145 (9.8)                                        0.830
  Cancer                                  39 (3.9)                                      36 (2.4)                                         0.026
  Chronic obstructive pulmonary disease   57 (3.9)                                      36 (2.44)                                        0.026
  Multimorbidity                          90 (6.1)                                      55 (3.7)                                         0.003
  Frailty (2643 patients)                 722 (54.8)                                    577 (43.5)                                       \<0.001
  IADL deficit (830 patients)             94 (25.3)                                     118 (25.7)                                       0.903
  SPPB \<9 (459 patients)                 13 (6.28)                                     15 (5.95)                                        0.884
  FALLS (665 patients)                    57 (19.6)                                     76 (20.3)                                        0.815

Comorbidities (CVD, HTN, DM and COPD), MM and frailty prevalence were significantly higher in the low CD4/CD8 ratio group. No differences were found in disability items prevalence.

![Logistic regressions for age-related health outcomes.](JIAS-19-21487202-g001){#F0038_21487202}

![Changes in the prevalence of cardivascular, renal and bone comorbidities and related risk factors between 2010 and 2014 in the VACH cohort.](JIAS-19-21487204-g001){#F0039_21487204}

###### 

Results from multivariable linear regression analysis[a](#TF0001_21487207){ref-type="table-fn"} of associations between smoking status, nadir CD4 count and receipt of PI therapy with TBS

  Variable                                             Effect on TBS   95% confidence intervals   p
  ---------------------------------------------------- --------------- -------------------------- -------
  Current smoker                                       −0.047          −0.085, −0.008             0.01
  Nadir CD4 T-cell count (per 50 cells/mm^3^ higher)   0.005           0.003, 0.011               0.04
  PI-containing ART                                    −0.045          −0.079, −0.011             0.009

Model also adjusted for LS BMD, age, gender, ethnicity and BMI.

###### 

Crude incidence of bone adverse events by treatment group (per 1000 PY)

  Outcomes                    EFV (n = 4178)   All non-EFV (n = 3059)   EVG/c (n = 234)   RPV (n = 173)   PI (n = 2651)
  --------------------------- ---------------- ------------------------ ----------------- --------------- ---------------
  Any bone outcome            28.4             37.4                     49.8              36.0            36.7
  Osteoporosis                8.7              12.0                     20.6              14.1            11.4
  Any osteoporotic fracture   9.9              18.5                     13.6              28.6            18.1
  Vertebral fracture          2.1              4.2                      6.8               7.1             3.9
  Hip fracture                3.7              3.1                      0.0               14.0            2.6
  Upper arm fracture          1.4              3.5                      0.0               0.0             3.9
  Wrist/forearm fracture      3.3              8.2                      6.8               7.1             8.3

###### 

Risk of bone adverse events by treatment group

  Outcomes                    EFV vs. non-EFV: aHR (95% CI)   EFV vs. EVG/c: aHR (95% CI)   EFV vs. RPV: aHR (95% CI)   EFV vs. PI: aHR (95% CI)
  --------------------------- ------------------------------- ----------------------------- --------------------------- --------------------------
  Any bone outcome            0.78 (0.65--0.94)               0.94 (0.70--1.25)             0.85 (0.66--1.08)           0.78 (0.65--0.94)
  Osteoporosis                0.75 (0.55--1.04)               --                            --                          0.77 (0.55--1.07)
  Any osteoporotic fracture   0.57 (0.43--0.76)               --                            --                          0.57 (0.43--0.77)
  Vertebral fracture          0.45 (0.25--0.81)               --                            --                          0.47 (0.26--0.85)
  Hip fracture                1.24 (0.69--2.21)               --                            --                          1.50 (0.80--2.83)
  Upper arm fracture          0.48 (0.23--0.98)               --                            --                          0.43 (0.21--0.88)
  Wrist/forearm fracture      0.47 (0.29--0.75)               --                            --                          0.45 (0.28--0.72)

--, Fewer than five events.

###### 

Median 10-year FRAX calculated fracture probability (A) excluding or (B) including HIV infection as a secondary cause of osteoporosis or (C) including HIV infection plus the available femoral neck T-score

  10-year FRAX-calculated fracture probability   \(A\) Median (IQR 1--3)   \(B\) Median (IQR 1--3)   \(C\) Median (IQR 1--3)   
  ---------------------------------------------- ------------------------- ------------------------- ------------------------- --------------------------------------------------------------
  Hip fracture                                   0.2% (0.1--0.7)           0.3% (0.1--1.1)           0.4% (0.1--1.42)          A vs. B, p \< 0.001, A vs. C, p \< 0.001, B vs. C, p = 0.073
  Major osteoporotic fracture                    1.9% (1.4--3.6)           2.6% (1.9--4.9)           2.5% (2.5--4.5)           A vs. B, p \< 0.001, A vs. C, p \< 0.001, B vs. C, p = 0.064
  Above intervention thresholds                  3/98 (3.1%)               8/98 (8.2%)               14/98 (14.3%)             p for trend 0.007

###### 

Risk of CVD events with ATV versus non-ATV-based regimens

  Outcome                                                     ATV crude incidence (per 1000 patient-years)   ATV vs. other PIs: HR (95% CI)                                 ATV vs. NNRTIs: HR (95% CI)   ATV vs. INSTIs: HR (95% CI)
  ----------------------------------------------------------- ---------------------------------------------- -------------------------------------------------------------- ----------------------------- --------------------------------------------------------------
  MI                                                          5.16                                           0.46 (0.26--0.81)[\*](#TF0001_21487213){ref-type="table-fn"}   0.72 (0.48--1.09)             0.71 (0.31--1.61)
  Overall stroke                                              18.31                                          0.89 (0.66--1.22)                                              1.01 (0.81--1.27)             0.71 (0.47--1.07)
  Ischemic stroke                                             17.65                                          0.90 (0.66--1.25)                                              1.03 (0.81--1.29)             0.74 (0.48--1.12)
  Haemorrhagic stroke                                         0.64                                           0.50 (0.18--1.42)                                              0.50 (0.16--1.52)             0.18 (0.02--1.36)
  MI/stroke                                                   23.04                                          0.80 (0.61--1.05)                                              0.94 (0.77--1.15)             0.69 (0.47--1.00)[\*](#TF0001_21487213){ref-type="table-fn"}
  MI/stroke/death                                             38.83                                          0.90 (0.73--1.12)                                              0.98 (0.84--1.15)             0.81 (0.60--1.10)
  All-cause death[†](#TF0002_21487213){ref-type="table-fn"}   16.02                                          1.01 (0.73--1.39)                                              0.91 (0.72--1.15)             1.11 (0.66--1.90)

*P*\<0.05.

Based on VA vital status files.

![Forest plot: outcome: overall cardiovascular events. Comparison: abacavir versus tenofovir.](JIAS-19-21487214-g001){#F0040_21487214}

![Level of awareness and use of blood pressure-lowering drugs among contacted patients with elevated blood pressure (N = 66).](JIAS-19-21487215-g001){#F0041_21487215}

![Immunologic responses to initiation of cART. **Immune activation levels measured by the frequency of CD38 + HLA-DR+ CD8 T (left panel). Levels of the exhaustion marker PD-1 in the CD8 T (right panel)**.](JIAS-19-21487218-g001){#F0042_21487218}

![Endothelial response to cART initiation. **Frequencies of CEC (right), EPC (middle) and CAC (right) are shown at baseline and the end of the study (week 24). Data uninfected volunteers represented by empty dots. Light grey dots correspond to RPV and dark grey to DRV group**.](JIAS-19-21487218-g002){#F0043_21487218}

###### 

Agreement between D:A:D and other CVD calculation tools (high, non-high risk)

            Framingham CVD   Framingham Hard CHD   Score          PROCAM         QRISK2          CUORE
  --------- ---------------- --------------------- -------------- -------------- --------------- ---------------
  D:A:D                                                                                          
  K         0.729            0.191                 0.434          0.595          0.266           0.206
  95% CI    0.475, 0.982     −0.104, 0.485         0.092, 0.775   0.278, 0.912   −0.070, 0.602   −0.137, 0.548
  p-value   \<0.001          0.047                 \<0.001        \<0.001        0.004           0.002

###### 

Frequency of abnormal findings in heart assessment, cardiotropic pathogens and CD4+ counts and HIV RNA measurements at baseline and 6 weeks after ART initiation in 17 patients starting treatment with advanced HIV disease (\<200 CD4+ cells/mm^**3**^)

  Variable                                          Basal n (%)                  6 weeks n (%)
  ------------------------------------------------- ---------------------------- ---------------------
  Myocardial inflammation                           6 (35)                       5 (29)
  Systolic dysfunction (LVEF \<60%)                 5                            3
  Diastolic dysfunction (slow relaxation pattern)   2                            3
  Systolic + diastolic dysfunction                  1                            0
  Pulmonary hypertension (TTE)                      1                            1
  Plasma PCR for HHV6                               0                            1
  Plasma PCR for HHV8                               1                            2
  Plasma PCR for parvovirus B19                     2                            0
  CD4+ cells/mm^3^                                  46 (18--81)                  208 (90.5--205)
  CD4 + /CD8+ ratio                                 0.063 (0.048--0.092)         0.25 (0.131--0.326)
  HIV RNA copies/mm^3^                              449,967 (227,367--740,959)   143 (87--502)

![Evaluation of discriminative power (D:A:D ROC = 0.691, ASCVD ROC 0.624).](JIAS-19-21487226-g001){#F0044_21487226}

![Odds ratios of lymphoma in those with a marker level of greater than the upper limit of the normal (ULN) relative to a level in the normal range, \<2 and \>2 years prior to diagnosis.](JIAS-19-21487227-g001){#F0045_21487227}

###### 

Unadjusted and adjusted HR of death in all NHL, in DLBCL and in HD from fitting three separate multivariable Cox regression hazard models

            Unadjusted HR (95% CI)   p         Adjusted[a](#TF0001_21487228){ref-type="table-fn"} HR (95% CI)   p         Adjusted[b](#TF0002_21487228){ref-type="table-fn"} HR (95% CI)   p       Adjusted[c](#TF0003_21487228){ref-type="table-fn"} HR (95% CI)   p
  --------- ------------------------ --------- ---------------------------------------------------------------- --------- ---------------------------------------------------------------- ------- ---------------------------------------------------------------- -------
  All NHL                                                                                                                                                                                                                                                           
  HIV-      1.00                               1.00                                                                       1.00                                                                     1.00                                                             
  HIV +     1.63 (1.29--2.06)        \<0.001   2.08 (1.56--2.76)                                                \<0.001   1.35 (1.03--1.78)                                                0.03    1.52 (1.09--2.12)                                                0.01
  DLBCL                                                                                                                                                                                                                                                             
  HIV-      1.00                               1.00                                                                       1.00                                                                     1.00                                                             
  HIV +     1.44 (1.09--1.91)        0.01      1.83 (1.33--2.53)                                                \<0.001   1.32 (0.96--1.81)                                                0.08    1.37 (0.95--1.99)                                                0.09
                                               Adjusted[a](#TF0001_21487228){ref-type="table-fn"} RH (95% CI)             Adjusted[d](#TF0004_21487228){ref-type="table-fn"} RH (95% CI)           Adjusted[e](#TF0005_21487228){ref-type="table-fn"} RH (95% CI)   
  HD                                                                                                                                                                                                                                                                
  HIV-      1.00                               1.00                                                                       1.00                                                                     1.00                                                             
  HIV +     2.36 (1.50--3.70)        \<0.001   2.26 (1.37--3.74)                                                0.001     2.15 (1.13--4.09)                                                0.006   2.10 (1.08--4.06)                                                0.007

Adjusted for age gender and calendar year

adjusted for rituximab and IPI

adjusted for factors in a and b

adjusted for ABVD regimen and staging

adjusted for factors in [a](#TF0001_21487228){ref-type="table-fn"} and [d](#TF0001_21487228){ref-type="table-fn"}.

![Five-year overall survival of 84 patients treated with rituximab-based immunotherapy for HIV-associated MCD: 92% (95% CI 84--99%).](JIAS-19-21487232-g001){#F0046_21487232}

![Five-year relapse-free survival for patients achieving remission from HIV-associated MCD following rituximab first-line therapy: 78% (95% CI 67--89%).](JIAS-19-21487232-g002){#F0047_21487232}

###### 

Risk factors associated with incident cancer in Pune cohort

  Factors                  Hazard rates ratio (RR)   p value   95% CI for hazard rates ratio
  ------------------------ ------------------------- --------- -------------------------------
  Age \>40 years           1.886                     0.056     0.983--3.620
  Male:female              2.515                     0.039     1.046--6.046
  Baseline hepatitis B     3.835                     0.005     1.490--8.974
  Baseline CD4 count ≤50   1.881                     0.086     0.914--3.868

###### 

Baseline characteristics

                                   N (%)
  -------------------------------- -------------------
  Total                            416
  Male                             279 (67%)
  Median age at cancer diagnosis   42 (IQR 35--50)
  Caucasian                        367 (89.2%)
  Risk behaviour                   
  \- Sexual                        239 (57.4%)
  \- Parenteral                    130 (31.2%)
  \- Unknown                       47 (11.3%)
  Chronic HBV                      17 (4%)
  Chronic HCV                      87 (20.9%)
  AIDS                             280 (67.3%)
  CD4+ nadir (cells/mL)            132 (IQR 47--224)
  Receiving ART on diagnosis       277 (69%)

###### 

Type of malignancy related to ART use and diagnosis time

                             Pre-ART (before 1996)   Early ART (1996--2006)   Late ART (after 2006)   p
  -------------------------- ----------------------- ------------------------ ----------------------- ---------
  Total malignancies         46                      148                      222                     
  Lymphoma                   3 (6.5%)                35 (23.6%)               40 (18%)                0.031
  Kaposi\'s sarcoma          18 (39.1%)              56 (37.8%)               36 (16.2%)              \<0.001
  Cervix cancer              17 (36.9%)              38 (25.6%)               30 (13.5%)              \<0.001
  Anal cancer                4 (8.7%)                4 (2.7%)                 18 (8.1%)               0.084
  Hepatocellular carcinoma   0                       2 (1.35%)                18 (8.1%)               \<0.001
  Lung carcinoma             0                       0                        13 (5.8%)               \<0.001
  Head and neck cancer       0                       0                        11 (4.9%)               \<0.001

###### 

The distribution of HPV genotypes in the studied groups

  Groups          HPV (%)   HPV concentration \>log \^3   Mixed HPV genotypes   Leading genotypes
  --------------- --------- ----------------------------- --------------------- -------------------
  HIV infection   38.7%     92%                           48.3%                 18, 16, 1, 45
  Control group   14.8%     75%                           23.3%                 16, 33, 45

###### 

Percentage change in BMI after 1 year of HAART, stratified by pre-HAART BMI status

  BMI status pre-HAART   n (cohort%)   BMI change 1 year post-HAART initiation (%)   95% CI      p
  ---------------------- ------------- --------------------------------------------- ----------- ---------
  Underweight            19 (6)        19.2                                          9.3, 31.3   \<0.001
  Normal weight          171 (56)      4.7                                           3.6, 5.8    \<0.001
  Overweight             80 (26)       3.3                                           1.5, 5.1    \<0.001
  Obese                  36 (12)       1.6                                           −1.2, 4.1   0.221

###### 

Linear mixed model results for KYN and KYN/TRP ratio and CNS toxicity from baseline to week 12

  Parameter                                 Estimate (95% CI)     t(df)        P         −2 Log Likelihood for Model
  ----------------------------------------- --------------------- ------------ --------- -----------------------------
  Model 1: CNS Toxicity and KYN                                                          
  Mean CNS Toxicity Score                   10.4 (7.0 to 13.9)    6.0 (104)    \<0.001   685.2
  KYN, µmol/L                               −1.7 (−3.1 to −0.3)   −2.4 (111)   0.019     
                                                                                         
  Model 2: CNS Toxicity and KYN/TRP Ratio                                                
  Mean CNS Toxicity Score                   10.4 (6.8 to 14.1)    5.7 (83)     \<0.001   690.4
  KYN/TRP Ratio, µmol/mmol                  −0.1 (−0.2 to −0.0)   −2.3 (89)    0.027     

###### 

Overall CNS score at week 4 (IS vs. DS) and CNS grade 3/4 side effects (S/E) at 4 and 12 weeks post-switch in IS and DS arms

                                             IS (N19)      DS (N21)      IS (N19)     DS (N21)                IS (N21)                                         DS (N19)            IS (N21)            DS (N19)
  ------------------------------------------ ------------- ------------- ------------ ------------- --------- ------------------------------------------------ ------------------- ------------------- -------------------
  Overall CNS score (0--100), median (IQR)   33 (20--53)   40 (27--53)   10 (7--20)   33 (20--43)   \<0.001   10 (7--20)                                       10 (3--23)          10 (3--17)          10 (3--23)
                                                                                                              \% of improvement:                                                                       
                                                                                                              16% (4--36)                                      13% (10--26)        17% (4--33)         16% (10--33)
                                                                                                              p \< 0.001                                       p \< 0.001          p \< 0.001          p \< 0.001
  Proportion (%) of patients with:                                                                            Proportion (%) of patients with grade 3/4 S/E:                                           
  Overall grade 3/4 toxicity                 100           95.2          26.3         95.2          \<0.001   26.3 (p \< 0.001)                                47.6 (p \< 0.001)   26.3 (p \< 0.001)   42.9 (p \< 0.001)
  Insomnia                                   47.4          61.9          21.1         42.9          0.258     21.1 (p = 0.025)                                 28.6 (p = 0.317)    15.8 (p = 0.014)    19.1 (p = 0.317)
  Abnormal dreams                            84.2          85.7          5.3          81            \<0.001   5.3 (p \< 0.001)                                 14.3 (p \< 0.001)   0 (p \< 0.001)      19.1 (p \< 0.001)
  Dizziness                                  21.1          28.6          0            28.6          0.037     0 (--)                                           0 (--)              0 (--)              0 (--)
  Depression                                 42.1          38.1          5.3          38.1          0.035     5.3 (p = 0.008)                                  4.8 (p = 0.008)     5.3 (p = 0.008)     19.1 (p = 0.046)
  Anxiety                                    36.8          52.4          10.5         19.1          0.756     10.5 (p = 0.059)                                 4.8 (p = 0.180)     5.3 (p = 0.014)     14.3 (p = 0.564)
  Confusion                                  15.8          0             0            0             --        0 (--)                                           0 (--)              5.3 (p = 0.157)     4.8 (--)
  Impaired concentration                     26.3          28.6          10.5         19.1          0.756     10.5 (p = 0.180)                                 14.3 (p = 0.564)    5.3 (p = 0.046)     9.5 (p = 0.317)
  Headache                                   0             19.1          0            19.1          0.140     0 (--)                                           0 (--)              0 (--)              4.8 (p = 0.083)
  Somnolence                                 21.1          38.1          5.3          28.6          0.128     5.3 (p = 0.180)                                  14.3 (p = 0.083)    10.5 (p = 0.317)    14.3 (p = 0.083)
  Aggressive behaviour                       10.5          23.8          5.3          19.1          0.402     5.3 (p = 0.564)                                  4.8 (p = 0.083)     5.3 (p = 0.317)     4.8 (p = 0.083)

BL, baseline; DS, delayed switch; IQR, inter-quartile range; IS, immediate switch; S/E, side effect; W4, week 4; W12, week 12.

![Psychiatric Adverse Events rates from the DTG ART-Naïve Phase III Clinical Trials.](JIAS-19-21487248-g001){#F0001_21487248}

###### 

Baseline characteristics

  Baseline characteristics                            EFV group (n = 157)   PI group (n = 157) \[DRV/r: 66; ATV/r: 63; LPV/r: 28\]   p
  --------------------------------------------------- --------------------- -------------------------------------------------------- ---------
  Age (mean±SD)                                       48.82 (±12.12)        48.74 (±11.35)                                           0.95
  Gender                                                                                                                             0.892
   Male                                               121 (77.1%)           123 (78.3%)                                              
   Female                                             36 (22.9%)            34 (21.7%)                                               
  Body mass index (mean±SD)                           24.47 (±4.27)         25.51 (±4.33)                                            0.112
  Educational level                                                                                                                  0.446
   Illiteracy                                         4 (2.5%)              4 (2.5%)                                                 
   Basic 1st cycle                                    33 (21%)              49 (31.2%)                                               
   Basic 2nd cycle                                    24 (15.3%)            19 (12.1%)                                               
   Basic 3rd cycle                                    45 (28.7%)            42 (26.8%)                                               
   Secondary                                          36 (22.9%)            28 (17.8%)                                               
   Higher education                                   15 (9.6%)             15 (9.6%)                                                
  HIV transmission categories                                                                                                        \>0.999
   Heterosexual                                       89 (56.7%)            88 (56%)                                                 
   Men who have sex with men                          33 (21%)              34 (21.7%)                                               
   Blood transfusion                                  1 (0.6%)              0 (0%)                                                   
   Injection drug use                                 34 (21.7%)            35 (22.3%)                                               
  Years of HIV infection (mean±SD)                    10.73 (±5.37)         9.95 (±6.01)                                             0.224
  Years on current cART (mean±SD)                     5.36 (±2.4)           4.27 (±2.34)                                             \<0.001
  Years on antiretroviral therapy (mean±SD)           7.98 (±4.59)          7.18 (±4.75)                                             0.098
  Years of HIV viral suppression (mean±SD)            7.21 (±4.21)          5.34 (±3.56)                                             \<0.001
  AIDS                                                                                                                               \<0.001
   History of AIDS                                    21 (13.4%)            49 (31.2%)                                               
   No history of AIDS                                 136 (86.6%)           108 (68.8%)                                              
  Nadir CD4 +                                         243.85 (±136.56)      177.24 (±150.58)                                         \<0.001
  CD4+ count at the time of study entry               690.27 (±285.89)      589.77 (±287.32)                                         0.002
  CPE, antiretroviral CSF penetration-effectiveness                                                                                  \<0.001
   CPE of 6                                           0 (0%)                47 (29.9%)                                               
   CPE of 7                                           135 (86%)             84 (53.5%)                                               
   CPE of 8                                           21 (13.4%)            23 (14.7%)                                               
   CPE of 9                                           1 (0.6%)              3 (1.9%)                                                 
  Syphilis                                                                                                                           0.019
   History of syphilis                                37 (23.6%)            57 (36.3%)                                               
   No history of syphilis                             120 (76.4%)           100 (63.7%)                                              
  Erectile dysfunction                                                                                                               0.036
   Presence of erectile dysfunction                   1 (0.6%)              8 (5.1%)                                                 
   No erectile dysfunction                            156 (99.4%)           149 (94.9%)                                              
  Antidepressant use                                                                                                                 0.1
   No antidepressant use                              141 (89.8%)           130 (82.8%)                                              
   Antidepressant use                                 16 (10.2%)            27 (17.2%)                                               
  HCV co-infection                                                                                                                   0.599
   No HCV co-infection                                112 (73.2%)           115 (76.2%)                                              
   HCV co-infection                                   41 (26.8%)            36 (23.8%)                                               
   ABC/3TC backbone                                   21 (13.4%)            25 (15.9%)                                               
   AZT/3TC backbone                                   1 (0.6%)              9 (5.7%)                                                 
   FTC/TDF backbone                                   135 (86%)             121 (77.1%)                                              
   AZT + TDF backbone                                 0 (0%)                2 (1.3%)                                                 

###### 

Patient demographics

  Demographics              Naïve          Experienced    Total
  ------------------------- -------------- -------------- ---------------
  Gender                                                  
   Male                     47/52 (90%)    81/126 (64%)   128/178 (72%)
   Female                   5/52 (10%)     45/126 (36%)   50/178 (28%)
  Ethnicity                                               
   Caucasian                46/52 (88%)    92/126 (73%)   138/178 (78%)
   African/Afro Caribbean   4/52 (8%)      32/126 (25%)   36/178 (20%)
   Asian/other              2/52 (4%)      2/126 (2%)     4/178 (2%)
  Age                                                     
   Median                   34 years       43 years       40 years
   Range                    20--64 years   18--76 years   18--76 years

###### 

Incidence of adverse events of patients in dolutegravir-containing regimens

  Adverse event                  Naïve (/52)   Experienced (/126)   Total (/178)
  ------------------------------ ------------- -------------------- --------------
  Central nervous system (CNS)   10 (19%)      25 (20%)             35 (20%)
  Gastrointestinal               6 (12%)       11 (9%)              17 (10%)
  Neurological                   7 (13%)       5 (4%)               12 (7%)
  Musculoskeletal                0 (0%)        6 (5%)               6 (3%)
  Lethargy                       1 (2%)        5 (5%)               6 (3%)
  Dermatological                 1 (2%)        3 (2%)               4 (2%)
  Urogenital                     0 (0%)        2 (2%)               2 (1%)

###### 

Correlations between CSF biomarkers and specific neurocognitive tests among HIV-positive patients

                  Stroop test       Trail Making test AB   Corsi test            Serial Repetition of Disyllabic Words   Verbal Fluency      Free and Cue Selective Reminding test
  --------------- ----------------- ---------------------- --------------------- --------------------------------------- ------------------- ---------------------------------------------------------
  CSF tau         p 0.05 rho 0.39   NS                     p \<0.01 rho --0.47   p 0.01 rho --0.35                       p 0.03 rho --0.30   NS
  CSF S100 β      NS                p 0.03 rho --0.29      p \<0.01 rho --0.37   p 0.04 rho --0.24                       NS                  Delayed: p 0.04 rho --0.40 Immediate: p 0.03 rho --0.41
  CSF neopterin   p 0.03 rho 0.36   NS                     p 0.01 rho --0.31     NS                                      p 0.05 rho --0.26   NS

NS, non-significant. Spearman correlation test was used to make statistical analysis.

![Concentration of CSF NFL (log pg/mL), CSF neopterin (log ng/mL) and plasma NFL (log pg/mL) according to unimpaired results by neuropsychological assessment and HAND classification.\
ANI, asymptomatic neurocognitive impairment; HAD, HIV-associated dementia; MND, mild neurocognitive disorders.](JIAS-19-21487254-g001){#F0002_21487254}

###### 

Pre- and post-switch eGFR slopes amongst individuals who switch from either atazanavir or lopinavir to darunavir

                                                         Mean change in eGFR per year (95% CI)                        
  ----------------------------------------------- ------ --------------------------------------- -------------------- ---------
  All switchers                                                                                                       
   Atazanavir                                     676    −0.97 (−1.35, −0.59)                    1.06 (0.69, 1.44)    \<0.001
   Lopinavir                                      1015   −0.51 (−0.90, −0.12)                    0.43 (0.14, 0.71)    \<0.001
  Rapid eGFR decline (\>5 mL/min/1.73 m2)                                                                             
   Atazanavir                                     49     −14.74 (−18.79, −10.69)                 2.55 (0.50, 4.61)    \<0.001
   Lopinavir                                      42     −12.99 (−15.68, −12.30)                 0.63 (−0.85, 2.11)   \<0.001
  eGFR \<60 mL/min/1.73 m^2^                                                                                          
   Atazanavir                                     87     −6.59 (−8.69, −4.48)                    2.68 (1.23, 4.13)    \<0.001
   Lopinavir                                      66     −2.77 (−4.08, −1.46)                    2.13 (0.28, 3.99)    \<0.001
  Received TDF prior to switch                                                                                        
   Atazanavir                                     478    −1.08 (−1.52, −0.64)                    1.47 (1.01, 1.93)    \<0.001
   Lopinavir                                      605    −0.90 (−1.09, −0.52)                    0.48 (0.13, 0.82)    \<0.001
  Did not receive TDF prior to switch                                                                                 
   Atazanavir                                     198    −0.27 (−0.93, 0.40)                     0.69 (0.04, 1.34)    0.051
   Lopinavir                                      410    0.35 (−0.87, 1.57)                      0.55 (0.05, 1.05)    0.777
  Did not discontinue TDF at the time of switch                                                                       
   Atazanavir                                     530    −0.42 (−0.86, 0.02)                     0.38 (0.07, 0.69)    0.006
   Lopinavir                                      901    −0.44 (−0.74, −0.14)                    0.52 (0.27, 0.77)    \<0.001

###### 

Logistic regression odds ratios for having one or three eGFR measurements \<60

                                                  One eGFR \<60       Three eGFRs \<60                                                                                 
  ----------------------------------------------- ------------------- ------------------ ------------------- -------- -------------------- ------- ------------------- -------
  Gender (female vs. male)                        2.77 (1.49--5.16)   0.001              4.58 (2.03--10.3)   0.0001   4.70 (1.80--12.26)   0.002   5.58 (1.84--16.9)   0.002
  Entering care in 1999--2006 (vs. before 1999)   0.60 (0.27--1.36)   0.856              0.37 (0.13--1.01)   0.875    1.31 (0.47--3.63)    0.086   0.97 (0.25--3.68)   0.100
  Entering care in 2007-2016 (vs. before 1999)    0.31 (0.12--0.78)   0.056              0.16 (0.05--0.55)   0.026    0.17 (0.2--1.30)     0.064   0.08 (0.01--0.89)   0.030
  Age at registration (per 5 years older)         1.37 (1.10--1.72)   0.005              1.69 (1.27--2.23)   0.0003   1.24 (0.90--1.72)    0.179   1.48 (1.03--2.13)   0.036
  Nadir CD4 count (per 1 cell higher)             1.00 (0.99--1.00)   0.084              1.00 (0.99--1.00)   0.196    1.00 (0.99--1.00)    0.110   --                  --
  Baseline eGFR (per 5 units higher)              0.88 (0.79--0.98)   0.019              0.85 (0.76--0.96)   0.010    0.71 (0.58--0.87)    0.001   0.73 (0.60--0.90)   0.003
  Time on ARV (per 1 year longer)                 1.11 (1.05--1.17)   0.0004             0.99 (0.91--1.08)   0.882    1.11 (1.03--1.21)    0.010   1.04 (0.93--1.17)   0.462
  Undetectable on cART (yes vs. no)               3.90 (0.90--16.9)   0.069              1.13 (0.17--7.31)   0.899    2.63 (0.34--20.3)    0.349   --                  --
  Detectable on cART (yes vs. no)                 2.34 (1.14--4.81)   0.02               1.64 (0.60--4.49)   0.338    2.29 (0.74--7.07)    0.148   --                  --

HIV risk group, baseline HIV RNA, anti-HBc total and anti-HCV status, ARV group, methadone dose, breaking abstinence tested in univariate as non-significant (p \< 0.1).

![Change in creatinine clearance over time in those with (red line) and without (blue line) kidney tubular dysfunction.](JIAS-19-21487259-g001){#F0003_21487259}

![Comparison of NPZ8 score in patients on EFV-based cART and after switch to RPV-based regimen.](JIAS-19-21487270-g001){#F0004_21487270}

###### 

Patients' characteristics

                                  Experienced                     Naive                           
  ------------------------------- ------------------------------- ------------------------------- ----------
  Males                           147 (72.8)                      65 (83.3)                       0.06
  Risk factor (IVDU)              50 (24.8)                       2 (2.6)                         \<0.0001
  CDC stage C                     52 (25.7)                       14 (18.0)                       0.05
  HCV co-infection (14 missing)   58 (30.0)                       2 (2.7)                         \<0.0001
  eGFR BL \<90.0                  99 (50.8)                       23 (30.3)                       0.002
                                  **Mean (SD) or median (IQR)**   **Mean (SD) or median (IQR)**   
  Age (years)                     45.6 (9.9)                      39.2 (12.0)                     \<0.0001
  BMI (kg/m^2^)                   24.1 (3.4)                      22.9 (2.7)                      0.0009
  CD4+ (cells/mL)                 579 (356)                       382 (278)                       \<0.0001
  HIV RNA (copies/mL)             24 (19--67)                     50,042 (8040--117,171)          \<0.0001
  ART duration (years)            8.1 (3.4--16.8)                 0                               
  Total cholesterol (mg/dL)       191.0 (45.2)                    159.5 (37.2)                    \<0.0001
  HDL cholesterol (mg/dL)         43.3 (12.8)                     40.1 (13.7)                     0.09
  Triglycerides (mg/dL)           140 (91.5--194.5)               92.5 (71--121)                  \<0.0001
  Glucose (mg/dL)                 94.2 (29.6)                     89.9 (17.2)                     0.25
  AST (IU/L)                      24.5 (20--35)                   24.0 (19.5--32.0)               0.75
  ALT (IU/L)                      28 (18--46)                     27 (16.5--37.5)                 0.27
  Creatinine (mg/dL)              0.94 (0.47)                     0.99 (1.16)                     0.61
  Alcaline phosphatase (IU/L)     119.1 (77.4)                    88.2 (42.4)                     0.005
  Phosphate (mg/dL)               3.19 (0.68)                     3.10 (0.68)                     0.46
  eGFR                            94.7 (25.3)                     106.9 (28.4)                    0.0007

###### 

Characteristics of 899 HIV patients at enrolment: 474 (52.7%) current smokers; 273 (30.4%) never smokers; 152 (16.9%) ex-smokers

                                 All HIV patients N = 899   Current smokers N = 474 (52.7%)   Ex-smokers N = 152 (16.9%)   Never smokers N = 273 (30.4)   p
  ------------------------------ -------------------------- --------------------------------- ---------------------------- ------------------------------ ----------
  Age (years)                    48.0±11                    46.9±10                           53.5±12                      46.5±12                        \<0.0001
  Men (%)                        71.2                       73.2                              80.3                         62.3                           0.002
  Body mass index (kg/m^2^)      24.8±4                     24.1±4                            26.0±4                       25.3±4                         \<0.0001
  Caucasian ethnicity (%)        87.8                       93.5                              93.4                         74.7                           \<0.0001
  CDC C3 (%)                     27.1                       26.0                              31.6                         26.6                           0.95
  CD4 lymphocytes (mm^3^)        649±327                    696±365                           631±272                      576±265                        \<0.0001
  Psychiatric comorbidity (%)    9.5                        13.5                              5.9                          4.4                            \<0.0001
  ASCVD risk (%), median (IQR)   5.5 (2.6--10.1)            6.9 (4.2--12.0)                   5.5 (2.6--10.9)              2.6 (1.1--6.1)                 

Values are mean±SD.

ASCVD, atherosclerotic cardiovascular diseases risk prediction; p, unadjusted.

![Frequency and multiplicity of HPV infection at the oral (a) and at the anal site (b).](JIAS-19-21487275-g001){#F0005_21487275}

###### 

Attributes of patients with syphilic hepatitis

  Case Number   Age   Race   Duration of HIV (years)   HIV viral load (copies/mL)   CD4 cell count (cells/µL)   ARV regimen     Syphilis stage   RPR titre   Symptoms                              ALT (IU/L)   AST (IU/L)   ALP (IU/L)   Treatment
  ------------- ----- ------ ------------------------- ---------------------------- --------------------------- --------------- ---------------- ----------- ------------------------------------- ------------ ------------ ------------ ---------------------------------------
  1             28    AA     5                         \<40                         670                         EVG/c/TDF/FTC   Secondary        1:128       Abdominal pain, pharyngitis, lesion   605          427          541          Benzathine penicillin G (2.4 MU) IM×1
  2             40    C      0                         176,995                      150                         TVD/DRV         Secondary        1:256       Fever, arthralgia, rash               64           ND           307          Benzathine penicillin G (2.4 MU) IM×3
  3             63    C      26                        \<40                         450                         TVD/RGV         Primary          1:256       Lesion, rash                          76           50           382          Benzathine penicillin G (2.4 MU) IM×1

AA, African American; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; C, Caucasian; c, cobicistat; DRV, darunavir; EVG, elvitegravir; FTC, emtricitabine; ND, not done; RGV, raltegravir; TDF, tenofovir disproxil fumarate; TVD, Truvada.

###### 

Comparison of patients with acute/early syphilis with and without syphilitic hepatitis

  Characteristic                              Syphilitic hepatitis (N = 3)   Syphilis without hepatitis (N = 32)
  ------------------------------------------- ------------------------------ -------------------------------------
  Abdominal pain                              1                              1
  Pharyngitis                                 1                              0
  Rash                                        2                              17
  Fever                                       1                              1
  Arthralgia                                  1                              6
  Skin lesion                                 2                              7
  Median RPR titre                            1:256                          1:10
  Median CD4 count (cells/µL)                 423                            754
  Median HIV viral load (copies/mL)           \<40                           \<40
  Receiving ARVs                              3                              28
  Virologic suppression (VL \<40 copies/mL)   2                              24
  Male                                        3                              30
  Mean age (range)                            44 (28--63)                    46 (25--63)
  African American                            1                              1
  Caucasian                                   2                              27
  Hispanic                                    0                              1
  Asian                                       0                              3

VL, HIV viral load.

![Life expectancy at exact ages 35 and 50 according to engagement in care rates at 1, 2, 3, 4 and 5 years on ART.](JIAS-19-21487277-g001){#F0006_21487277}

###### 

Comparison between homo/bisexual and heterosexual patients

                                         Homosexual/bisexual patients   Heterosexual patients   p
  -------------------------------------- ------------------------------ ----------------------- -------
  Age, mean (SD)                         43.3 (10.9)                    49.9 (7.8)              0.001
  Years since HIV diagnosis, mean (SD)   10.6 (8.1)                     20.3 (8.5)              0.001
  Months on ART, mean (SD)               106.8 (86.2)                   187.8 (90.2)            0.001
  Non-Spanish born, N (%)                45 (34.4)                      16 (13.9)               0.002
  Risky alcohol intake, N (%)            14 (10.9)                      18 (18.2)               0.127
  Risky drug use, N (%)                  19 (17.4)                      18 (14.1)               0.724
  Polydrug use, N (%)                    25 (19.2)                      7 (6.1)                 0.002
  Cannabis/marijuana, N (%)              22 (16.9)                      31 (27)                 0.063
  Cocaine use, N (%)                     22 (16.9)                      6 (5.2)                 0.004
  Amphetamine derivates use, N (%)       15 (11.5)                      0 (0)                   0.001
  Mephedrone use, N (%)                  6 (4.6)                        0 (0)                   0.031
  Poppers, N (%)                         16 (12.3)                      0 (0)                   0.001
  Opiates, N (%)                         1 (0.77)                       6 (5.2)                 0.053

###### 

Subjects frequencies in the EQ-5D dimensions

                       No problems (%)   Some problems (%)   Extreme problems (%)
  -------------------- ----------------- ------------------- ----------------------
  Mobility             257 (79.8)        61(18.9)            2 (0.6)
  Self-care            298 (92.5)        22 (6.8)            1 (0.3)
  Usual activities     271 (84.2)        45 (14)             4 (1.2)
  Pain/discomfort      186 (57.8)        112 (34.8)          22 (6.8)
  Anxiety/depression   127 (39.4)        158 (49.1)          35 (10.9)

![Monthly distribution of serum vitamin D levels showing seasonal changes in non-African patients not taking cholecalciferol (p \< 0.001).](JIAS-19-21487282-g001){#F0007_21487282}

###### 

Baseline demographics and disease characteristics

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                   GT1\                                                     GT4\
                                                                                   N=199                                                    N=28
  -------------------------------------------------------------------------------- -------------------------------------------------------- -----------------
  Male, n (%)                                                                      156 (78)                                                 26 (93)

  White race, n (%)                                                                172 (86)                                                 25 (89)

  Age, median (range), years                                                       50 (26--69)                                              47 (30--63)

  BMI, median (range), kg/m^2^                                                     25 (17--41)[\*](#TF0001_21487286){ref-type="table-fn"}   24 (15--38)

  HCV genotype 1a, n (%)                                                           147 (74)                                                 --

  Cirrhosis, n (%)                                                                 22 (11)                                                  0

  Treatment-experienced, n (%)                                                     64 (33)[†](#TF0002_21487286){ref-type="table-fn"}        11 (39)

  HCV RNA, median (range), log~10~ IU/mL                                           6.5 (1.8--7.6)                                           6.0 (4.7--7.0)

  CD4+ cell count, median (range), /µL[‡](#TF0003_21487286){ref-type="table-fn"}   612 (133--2351)                                          731 (262--1533)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------

BMI, body mass index.

N=198

N=193

N=197 GT1, N=27 GT4.

###### 

Safety and post-baseline laboratory abnormalities

  ----------------------------------------------------------------------------
  Event, n (%)                                        GT1\         GT4\
                                                      N=199        N=28
  --------------------------------------------------- ------------ -----------
  Any AE                                              167 (84)     24 (86)

  Serious AEs                                         9 (5)        1 (4)

  RBV dose modifications due to haemoglobin decline   25 (13)      3 (11)

  ALT grade ≥3 (\>5×ULN)                              1 (1)        0

  Total bilirubin grade ≥3 (\>3×ULN)                  26 (13)      2 (7)

  Patients on ATV-containing ART, n/N (%)             23/26 (88)   2/2 (100)

  Haemoglobin grade 2 (\<10 g/dL)                     15 (8)       0

  Haemoglobin grade 3 (\<8 g/dL)                      0            0
  ----------------------------------------------------------------------------

AE, adverse event; ALT, alanine aminotransferase; ATV, atazanavir; RBV, ribavirin; ULN, upper limit of normal.

![HCV GT distribution patterns.](JIAS-19-21487287-g001){#F0008_21487287}

###### 

Baseline characteristics of HIV-infected patients under suppressive antiretroviral therapy, with or without HCV co-infection

  Characteristics at baseline               HCVAb-negative      HCVAb-positive      p
  ----------------------------------------- ------------------- ------------------- ---------
  Male gender, n (%)                        3449 (75.4)         832 (72.7)          0.060
  Age (years), median (IQR)                 39 (33--47)         40 (36--45)         0.005
  Migrants, n (%)                           674 (14.7)          53 (4.6)            \<0.001
  IDU as mode of HIV transmission           108 (2.4%)          806 (70.4%)         \<0.001
  Time since HIV infection, sum (IQR)       1.9 (0.7--4.9)      9.0 (3.7--14.8)     \<0.001
  CD4 at baseline cell/mm^3^, n (%)         276 (152--378)      243 (120--343)      0.016
  Nadir CD4, cell/mm^3^, n (%)              463 (321--619)      442 (285--630)      \<0.001
  Calendar year of baseline, median (IQR)   2010 (2004--2012)   2004 (2001--2008)   \<0.001
  Diabetes at baseline                      176 (3.8%)          53 (4.6%)           0.226
  HDL cholesterol, mg/dL                    44 (37--53)         44 (36--55)         0.502
  NVP-based first line                      217 (4.7%)          79 (6.9%)           0.030
  PI/r-based first line                     1831 (40.0%)        267 (23.3%)         \<0.001
  ddI/d4t-containing first line             509 (11.1%)         261 (22.8%)         \<0.001

###### 

Calculated target prices and current prices for 12-week DAA treatment courses

  Drug                June 2016 API cost/kg (USD)   Target price per 12-week treatment   Current global lowest price per 12-week treatment   Current US price per 12-week treatment
  ------------------- ----------------------------- ------------------------------------ --------------------------------------------------- ----------------------------------------
  Sofosbuvir (SOF)    \$1094                        \$62                                 \$324                                               \$49,860--84,000
  Daclatasvir         \$998                         \$14                                 \$153                                               \$50,653--63,000
  Ledipasvir (LDV)    \$2441                        \$34                                 unknown                                             unknown
  SOF+LDV             N/A                           \$96                                 \$507                                               \$56,700--94,500
  Velpatasvir (VEL)   \$8900--11,700                \$119--154                           unknown                                             unknown
  SOF+VEL             N/A                           \$181--216                           unknown                                             \$74,760

![Proportion of samples resistant, partially resistant and susceptible to the licenced DAAs as predicted by geno2pheno(HCV).](JIAS-19-21487290-g001){#F0009_21487290}

###### 

Odds ratios from fitting a logistic regression model

                   n = 1626     n = 6562     All switches (n = 8188)                                                                  
  ---------------- ------------ ------------ ---------------------------------------------------------- --------- ------------------- -------
  Per additional                             1.07 (1.03--1.12)                                          \<0.001   1.01 (0.93--1.10)   0.82
  0--1             566 (35%)    2745 (42%)   1.00                                                                 1.0                 
  2--3             560 (34%)    2541 (39%)   1.07 (0.94--1.21)                                          0.31      1.23 (0.96--1.69)   0.09
  \>3              500 (31%)    1276 (19%)   1.90 (1.65--2.18)                                          \<0.001   1.72 (1.10--2.68)   0.02
                                             **Only switches due to treatment failure (n = 755)**                                     
  Per additional   204          551          1.07 (1.03--1.12)                                          \<0.001   0.95 (0.87--1.04)   0.27
  None             1422 (87%)   6011 (92%)   1.00                                                                 1.0                 
  1 ARV            59 (4%)      141 (2%)     1.77 (1.30--2.41)                                          \<0.001   0.94 (0.53--1.66)   0.82
  2--3 ARV         75 (5%)      228 (3%)     1.39 (1.06--1.82)                                          0.02      0.79 (0.47--1.33)   0.38
  \>3 ARV          70 (4%)      182 (3%)     1.62 (1.23--2.16)                                          \<0.001   0.81 (0.46--1.45)   0.49
                                             **Only switches due to toxicity/intolerance (n = 1471)**                                 
  Per additional   391          1080         1.10 (1.06--1.13)                                          \<0.001   1.01 (0.95--1.08)   0.80
  None             1235 (76%)   5482 (84%)   1.00                                                                 1.0                 
  1 ARV            91 (6%)      213 (3%)     1.90 (1.47--2.44)                                          \<0.001   1.28 (0.78--2.08)   0.33
  2--3 ARV         165 (10%)    550 (8%)     1.33 (1.11--1.60)                                          0.002     1.38 (0.99--1.93)   0.06
  \>3 ARV          135 (8%)     317 (5%)     1.89 (1.53--2.33)                                          \<0.001   0.98 (0.62--1.57)   0.96
                                             **Only switches due to simplification (n = 1292)**                                       
  Per additional                             0.89 (0.84--0.93)                                          \<0.001   0.86 (0.80--0.94)   0.001
  None             1474 (90%)   5422 (83%)   1.0                                                                  1.0                 
  1 ARV            9 (0.5%)     126 (2%)     0.26 (0.13--0.52)                                          \<0.001   0.21 (0.07--0.59)   0.003
  2--3 ARV         84 (5%)      728 (11%)    0.42 (0.34--0.54)                                          \<0.001   0.74 (0.49--1.12)   0.16
  \>3 ARV          59 (4%)      286 (4%)     0.76 (0.57--1.01)                                          0.06      0.48 (0.27--0.82)   0.007

Adjusted for age, CD4+, HIV RNA, mode of HIV transmission, gender, nationality, smoking, alcohol consumption, calendar year, follow-up duration and previous use of individual drugs.

![Maximum and relative change in antibody titre (%) by clinical outcome category.](JIAS-19-21487292-g001){#F0010_21487292}

###### 

HCV RNA undetectability rates for generic DAAs

                           SOF/LDV        SOF/DCV
  ------------------------ -------------- --------------
  Treatment naïve (%)      123/237 (52)   130/208 (63)
  Cirrhosis (%)            52/237 (23)    79/208 (39\]
  Genotype 1 (%)           215/237 (91)   80/208 (39)
  **HCV RNA \<25 IU/mL**                  
  Week 12/EOT (%)          180/182 (99)   171/173 (99)
  SVR4 (%)                 104/112 (93)   85/96 (89)

![Molecular clock analysis of the 193 sequences from the Group 1 maximum likelihood phylogenetic tree. Produced using a Bayesian Markov Chain Monte Carlo (MCMC) approach. Branches are coloured by location; AT -- Austria, CN -- China, DE -- Germany, ES -- Spain, FR -- France, GB -- United Kingdom, IT -- Italy, NL -- Netherlands, PT -- Portugal, US -- United States of America. The MSM and IDU clusters identified from this analysis are labelled on the figure. The sequences obtained from a Dutch MSM who also reports injecting drug use is indicated by a red arrow.](JIAS-19-21487296-g001){#F0034_21487296}

###### 

Summary baseline and outcome data for patients treated with SOF/LDV, SOF/DCV or SOF/RBV

  HCV RNA              SOF/LDV (N = 22)   SOF/DCV (N = 15)   SOF/RBV (N = 25)
  -------------------- ------------------ ------------------ ------------------
  \% cirrhosis         33% (6/18)         33% (4/12)         32% (7/22)
  \% genotype 1        91% (20/22)        14% (2/14)         56% (14/25)
  \% genotype 2        --                 7% (1/14)          --
  \% genotype 3        4.5% (1/22)        79% (11/14)        28% (7/25)
  \% genotype 4        --                 --                 8% (2/25)
  \% genotype 6        4.5% (1/22)        --                 --
  \% genotype 2,6      --                 --                 4% (1/25)
  \% genotype 3,4      --                 --                 4% (1/25)
  HCV RNA \<25 IU/mL                                         
   RVR                 86% (6/7)          100% (5/5)         75% (3/4)
   Week 12/EOT         100% (12/12)       100% (8/8)         100% (13/13)
   SVR                 100% (9/9)         100% (4/4)         100% (10/10)

SOF, sofosbuvir; LDV, ledipasvir; DCV, daclatasvir; RBV, ribavirin; RVR, rapid virological response; SVR, sustained virologic response; EOT, end of treatment.

###### 

Multivariable conditional logistic regression models for ALT elevation

                                Elevated ALT N = 687 (%)   No elevated ALT N = 1374 (%)   Total N = 2061 (%)   Unadjusted OR (95% CI); p    [a](#TF0001_21487301){ref-type="table-fn"}Adjusted OR (95% CI); p
  ----------------------------- -------------------------- ------------------------------ -------------------- ---------------------------- -------------------------------------------------------------------
  HCV status (time-dependent)                                                                                                               
   HCV negative                 418 (60.8)                 971 (70.7)                     1389 (67.4)          1.00                         1.00
   HCV positive                 269 (39.2)                 403 (29.3)                     672 (32.6)           2.89 (2.10--3.97); \<0.001   2.95 (2.09--4.16); \<0.001
  ART status (time-dependent)                                                                                                               
   ART naïve                    144 (21.0)                 389 (28.3)                     533 (25.9)           1.00                         1.00
   On ART                       543 (79.0)                 985 (71.7)                     1528 (74.1)          1.82 (1.39--2.37); \<0.001   1.87 (1.38--2.52); \<0.001

Besides HCV status and ART use, the model was further adjusted for age, CD4 cell count, HIV RNA viral load, mode of HIV transmission, gender, nationality, alcohol use, smoking status and calendar year of enrolment.

![Treatment uptake and efficacy over the 3 periods.](JIAS-19-21487302-g001){#F0011_21487302}

###### 

Baseline characteristics and outcome in patients coinfected with HIV and HCV genotype 4 treated with all-oral direct-acting antivirals for HCV

                                  LDV/SOF            OBV/PTV/r         SMV/SOF             DCV/SOF
  ------------------------------- ------------------ ----------------- ------------------- -------------------
  Age, median (IQR)               51 (47--54)        51 (46--53)       52 (47--54)         50 (48--53)
  Male, n (%)                     146 (76.8)         24 (72.7)         8 (80.0)            6 (60.0)
  Cart, n (%)                     183 (96.3)         30 (90.9)         8 (80.0)            8 (80.0)
  Log HCV RNA, median (IQR)       6.3 (5.9--6.7)     6.0 (5.8--6.6)    6.3 (6.0--6.6)      6.0 (5.5--6.5)
  Cirrhosis, n (%)                76 (40.0)          8 (24.2)          9 (90.0)            9 (90.0)
  Liver stiffness, median (IQR)   11.0 (8.1--18.6)   9.5 (8.4--12.3)   48.0 (25.7--66.4)   31.2 (20.9--48.0)
  HCV-naïve, n (%)                108 (56.8)         11 (33.3)         4 (40.0)            6 (60.0)
  Outcomes                                                                                 
   SVR12, n (%)                   177 (93.2)         32 (97.0)         5 (50.0)            6 (60.0)
   % SVR, 95% CI                  88.6--96.3         84.2--99.9        18.7--81.3          26.2--87.8
   Relapse, n (%)                 10 (5.3)           1 (3.0)           5 (50.0)            2 (20.0)
   Discontinuation, n (%)         3 (1.5)            0                 0                   2 (20.0)

SOF, sofosbuvir; LDV, ledipasvir; DCV, daclatasvir; SVR, sustained virologic response; OBV, ombitasvir; PTV/r, paritaprevir/ritonavir; SMV, simeprevir.

###### 

Baseline characteristics

  ----------------------------------------------------------------------------- ---------------------------------------
  Age, mean (SD)                                                                50.9 (5.5)
  Gender: male/female, n (%)                                                    93 (71.5)/37 (28.5)
  Risk group: PWID/heterosexual/MSM, n (%)                                      113 (86.9)/13 (10.0)/4 (3.1)
  CDC (93) classification system\'s C stage, n (%)                              48 (36.9)
  Basal HCV RNA, medIAn (UI/mL) (IQR)                                           2,047,181.5 (3,879,143.0)
  Prior INF-based therapy: none/failure/relapse/intolerance, n (%)              79 (60.8)/35 (26.9)/8 (6.2)/8 (6.2)
  Liver fibrosis assessed by transient elastography: F0--1, F2, F3, F4, n (%)   1 (0.8)/54 (41.5)/14 (10.8)/61 (46.9)
  ----------------------------------------------------------------------------- ---------------------------------------

MSM, men who have sex with men; PWID, people who inject drugs.

###### 

Means of the values in mg/dL with standard deviation

          Pre-treatment   On-treatment   After-treatment   p[\*](#TF0001_21487309){ref-type="table-fn"}   p[†](#TF0002_21487309){ref-type="table-fn"}   p[‡](#TF0003_21487309){ref-type="table-fn"}
  ------- --------------- -------------- ----------------- ---------------------------------------------- --------------------------------------------- ---------------------------------------------
  TG      156.4 (79.7)    142.7 (68.1)   161.5 (85.2)      0.073                                          1.000                                         0.011
  TC      176.0 (37.9)    199.5 (55.0)   196.1 (51.9)      \<0.001                                        \<0.001                                       1.000
  HDL-c   49.3 (20.5)     52.0 (23.4)    49.9 (18.4)       0.100                                          1.000                                         0.751
  LDL-c   97.6 (37.1)     121.1 (46.8)   114.2 (44.7)      \<0.001                                        \<0.001                                       0.107

Statistical significance p-value established in 0.05. Bonferroni correction has been done.

compares values pre-therapy versus on-treatment

compares pre-therapy versus after-treatment

compares on-treatment versus after-treatment.

TG, triglycerides; TC, total cholesterol; HDL-c, HDL cholesterol; LDL-c, LDL cholesterol.

###### 

Patients' characteristics and treatment outcomes categorized by subtypes, treatment duration and use of ribavirin

                                G1a          G1a          G1a          G1a       G1b          G1b          G1b
  ----------------------------- ------------ ------------ ------------ --------- ------------ ------------ ------------
  Age years, median             51           51           50           51        50           52           54
  Male, %                       82.2         78.4         87.9         100       77.2         68.2         64.3
  cART, %                       97.5         98.0         93.4         100       100          90.9         92.9
  Log HCV RNA, median           6.4          6.3          6.3          6.7       6.4          6.0          6.5
  Cirrhosis, %                  25.4         90.2         90.9         66.7      45.6         100          92.9
  Liver stiffness kPa, median   10.0         18.3         20.0         24.0      11.8         20.6         19.8
  HCV-naïve, %                  67.0         54.9         36.4         0         50.9         10.9         64.3
  Outcomes                                                                                                 
   SVR12, n (%)                 183 (92.9)   50 (98.0)    30 (90.9)    3 (100)   56 (98.2)    20 (90.9)    13 (92.9)
   % SVR, 95% CI                88.4--96.1   89.6--99.9   75.7--98.1   --        90.6--99.9   70.8--98.9   66.1--99.8
   Relapse, n (%)               7 (3.5)      0            2 (6.1)      0         0            1 (4.5)      0
   Breakthrough, n (%)          0            0            0            0         0            0            0
   D/C due to AEs, n (%)        1 (0.5)      0            0            0         0            0            0
   D/C other reasons, n (%)     6 (3.0)      1 (2.0)      1 (3.0)      0         1 (1.8)      1 (4.5)      1 (7.1)

RBV, ribavirin; SVR, sustained virologic response; D/C, discontinuation; AEs, adverse events.

![Number of HCV treatments (naïve, re-treatment) during the years (from 2000 to 2015), and percentage of HCV-RNA negative patients amongt the HCVAb positive population during the same period.](JIAS-19-21487315-g001){#F0012_21487315}

###### 

Clinical and laboratory baseline features of the 167 enrolled patients

                                                     Tot patients (N=167)            A (65--74 years, N=99)          B (≥75 years, N=68)
  -------------------------------------------------- ------------------------------- ------------------------------- --------------------------------
  Genotype, n° (%)                                                                                                   
  1a                                                 2 (1.2)                         0 (0.0)                         2 (2.9)
   1b                                                95 (56.9)                       45 (45.5)                       50 (73.5)
   2                                                 37 (22.2)                       23 (23.2)                       14 (20.6)
   3                                                 1 (0.6)                         1 (1.0)                         0 (0.0)
   4                                                 6 (3.6)                         5 (5.1)                         1 (1.5)
   Cirrhosis, n° (%)                                 112 (67.1)                      62 (62.6)                       50 (73.5)
   Previous failure of anti HCV therapy, n° (%)      87 (52.1)                       57 (57.6)                       30 (44.1)
   HCV RNA IU/mL, median (range)                     1.296.000 (4.501--27.590.025)   1.302.000 (4.501--17.140.000)   1.150.000 (13.000--27.590.025)
   ALT UI/L, median (range)                          72 (18--434)                    77 (18--368)                    63 (15--434)
   Total bilirubin mg/dL, median (range)             0.8 (0.2--2.9)                  0.8 (0.2--2.9)                  0.8 (0.4--2.9)
   Serum creatine mg/dL, median (range)              0.83 (0.40--1.66)               0.81 (0.46--1.30)               0.88 (0.40--1.66)
   Platelets (×10^9^/L), median (range)              136 (38--347)                   154 (50--347)                   123 (38--342)
   Body mass index, median (range)                   25.9 (17.8--38.8)               25.3 (19.3--38.8)               26.5 (17.8--31.2)
   Patients with at least 1 comorbidity, n° (%)      138 (82.6)                      81 (81.8)                       57 (83.8)
   Hypertension, n° (%)                              101 (60.5)                      60 (60.6)                       41 (60.3)
   Diabetes, n° (%)                                  38 (22.8)                       24 (24.2)                       14 (20.6)
   Oesophageal varices/portal hypertension, n° (%)   16 (9.6)                        5 (5.1)                         11 (16.2)
  Other comorbidities, n° (%)                                                                                        
   Thyreopathies                                     13 (7.8)                        14 (14.1)                       9 (13.2)
   Dyslipidemia                                      18 (10.8)                       16 (16.1)                       2 (2.9)
   Psychiatric disorders                             16 (9.6)                        10 (10.1)                       6 (8.8)
   Neoplasms                                         10 (6.0)                        6 (6.1)                         4 (5.9)
   Cardiopathies                                     24 (14.4)                       12 (12.1)                       12 (17.6)
   Prostatic hypertrophy                             19 (11.4)                       8 (8.1)                         11 (16.2)
   Others                                            32 (19.2)                       18 (18.2)                       14 (20.6)
   Pill burden of comedications, median (range)      3 (0--14)                       3 (0--14)                       3 (0--13)

###### 

Safety profile of the 134 patients who reached the end of treatment

                                                                                                                                                                      Tot pts, N:134   A (65--74 years), N:78   B (≥75 years), N:56
  ------------------------------------------------------------ ------------------------------------------------------------------------------------------------------ ---------------- ------------------------ ---------------------
  Tot pts with any AE, n° (%)                                                                                                                                         93 (69.4)        56 (71.8)                37 (66.1)
                                                               Tot pts with ≥2 AEs                                                                                    32 (23.9)        21 (26.9)                11 (19.6)
                                                               Tot pts with serious AE (WHO grade 3/4)                                                                7 (5.2)          2 (2.6)                  5 (8.9)
                                                               Tot pts with serious AE leading to therapy discontinuation[a](#TF0001_21487316){ref-type="table-fn"}   6 (4.5)          2 (2.6)                  4 (7.1)
                                                               Deaths before EOT                                                                                      1 (0.7)          0 (0.0)                  1 (1.8)
  AEs according to sex                                                                                                                                                                                          
                                                               Male sex                                                                                               43/65 (66.2)     26/36 (72.2)             17/29 (58.6)
                                                               Female sex                                                                                             50/69 (72.5)     30/42 (71.4)             20/27 (74.1)
  AEs according to comorbidities                                                                                                                                                                                
                                                               Pts without comorbidities                                                                              19/29 (65.5)     12/17 (70.6)             7/12 (58.3)
                                                               Pts any comorbidity                                                                                    74/105 (70.5)    44/61 (72.1)             30/44 (68.2)
                                                               Pts with ≥2 comorbidities                                                                              52/72 (72.2)     32/41 (78.0)             20/31 (64.5)
                                                               Pts with cirrhosis                                                                                     65/93 (69.9)     36/51 (70.6)             29/42 (69.0)
                                                               Pts with obesity (BMI ≥30)                                                                             15/21 (71.4)     12/18 (66.7)             3/3 (100.0)
  AEs according to comedications                                                                                                                                                                                
                                                               Pts with no comedications                                                                              20/33 (60.6)     15/22 (68.2)             5/11 (45.5)
                                                               Pts with pill burden between 1 and 3                                                                   29/43 (67.4)     17/25 (68.0)             12/18 (66.7)
                                                               Pts with pill burden ≥4                                                                                44/57 (77.2)     24/30 (80.0)             20/27 (74.1)
  Pts with changes in comedications due to drug interactions                                                                                                          19/27 (70.4)     9/14 (64.3)              10/13 (76.9)
  AEs according to type of DAA therapy                                                                                                                                                                          
                                                               with RBV                                                                                               65/89 (73.0)     41/54 (75.9)             24/35 (68.6)
                                                               without RBV                                                                                            28/45 (62.2)     15/24 (62.5)             13/21 (61.9)
  of which:                                                                                                                                                                                                     
                                                               SMV based ± RBV                                                                                        18/25 (72.0)     14/17 (82.4)             4/8 (50.0)
                                                               SOF based + RBV                                                                                        21/29 (72.4)     13/17 (76.5)             8/12 (66.7)
                                                               LDV based ± RBV                                                                                        19/25 (76.0)     10/13 (76.9)             9/12 (75.0)
                                                               DAC based + RBV                                                                                        1/1 (100.0)      1/1 (100.0)              0/0 (0.0)
                                                               3ABT/2ABT based ± RBV                                                                                  34/54 (63.0)     18/30 (60.0)             16/24 (66.7)

3ABT/2ABT, paritaprevir, ombitasvir/ritonavir ± dasabuvir; AE, adverse event; DAA, direct antiviral agents; DAC, daclatasvir; LDV, ledipasvir; RBV, ribavirin; SMV, simeprevir; SOF, sofosbuvir; EOT, end of treatment.

discontinuations were due to: skin reaction (one patient), cardiological adverse events (AEs) (one patient), diarrhoea (one patient), oesophageal varices bleeding (one patient) and severe anaemia (two patients).

###### 

Characteristics of the treated patients and treatment schedule

  Opera/San Vittore/Bollate correctional houses      Patients, N (%)
  -------------------------------------------------- -----------------
  Treated inmates, N                                 25
  Age, years, median (range)                         50 (45--56)
  History of drug addiction, N (%)                   15 (60)
  Co-infection with HIV, N (%)                       4 (16)
  HCV genotype, N (%)                                
  1a+1b                                              12 (48)
  3                                                  11 (44)
  4                                                  2 (8)
  CTP classification for cirrhotic patients, N (%)   
   A5                                                14 (56)
   A6                                                3 (12)
   B7                                                4 (16)
   MELD, median (range)                              8.5 (7--10)
  METAVIR fibrosis score, N (%)                      
   F4                                                21 (84)
   F3                                                3 (12)
   F2                                                1 (4)
  Fibrosis 4 score, N (%)                            
    \< 1.45                                          1 (4)
   1.45--3.25                                        5 (20)
    \> 3.25                                          19 (76)
   HCC, N (%)                                        1 (4)
  Previous HCV treatment history, N (%)              
   No                                                20 (80)
   Yes                                               5 (20)
  Current HCV treatment duration, N (%)              
   12 weeks                                          11 (44)
   24 weeks                                          14 (56)
  HCV treatment schedule, N (%)                      
   SOF+RBV                                           6 (24)
   SOF+DCV                                           1 (4)
   SOF+LDV                                           2 (8)
   SOF+P/R                                           1 (4)
   SOF+SIM+RBV                                       4 (16)
   SOF+LDV+RBV                                       5 (20)
   SOF+DCV+RBV                                       4 (16)
   3D+RBV                                            1 (4)
   2D+RBV                                            1 (4)
   EOTR, N (%)                                       21 (87)
   SVR12, N (%)                                      10 (83)
   Relapse, N (%)                                    2 (8)

2D, ombitasvir+paritaprevir/ritonavir; 3D, ombitasvir+paritaprevir+dasabuvir/ritonavir; DCV, daclatasvir; LDV, ledipasvir; P/R, peg-interferon plus ribavirin; RBV, ribavirin; SIM, simeprevir; SOF, sofosbuvir, EOTR, end-of-treatment response; HCC, hepatocellular carcinoma; CTP, child-turcotte-pugh.

###### 

Baseline characteristics and outcome in patients coinfected with HIV and HCV genotype 1 treated with dasabuvir and ombitasvir/paritaprevir/ritonavir+ribavirin

                                Genotype 1a   Genotype 1a   Genotype 1a   Genotype 1a   Genotype 1a   Genotype 1b   Genotype 1b   Genotype 1b   Genotype 1b
  ----------------------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- -------------
  Age, years, median            51            47            50            51            50            50            50            49            50
  Male, %                       66.7          100           76.2          92.3          81.9          67.6          0             72.7          68.3
  cART, %                       100           100           100           100           100           100           100           100           100
  Log HCV RNA, median           6.2           5.5           6.5           6.6           6.5           6.5           5.2           6.1           6.3
  Cirrhosis, %                  66.7          100           4.8           96.2          41.7          13.5          100           86.4          41.7
  Liver stiffness kPa, median   14.4          64.0          8.6           18.0          10.4          9.3           17.5          20.4          11.2
  HCV naïve, %                  66.7          100           52.4          65.4          58.3          67.6          0             45.4          58.3
  Outcomes                                                                                                                                      
   SVR12, n (%)                 3 (100)       0             40 (95.2)     24 (92.3)     67 (93.1)     34 (91.9)     1 (100)       21 (95.4)     56 (96.3)
   % SVR, 95% CI                --            --            83.8--99.4    74.9--99.1    84.5--99.7    78.1--98.3    --            77.2--99.9    83.8--98.2
   Relapse, n (%)               0             1 (100)       1 (2.4)       0             2 (2.8)       1 (2.7)       0             1 (4.5)       2 (3.3)
   Breakthrough, n (%)          0             0             0             0             0             1 (2.7)       0             0             1 (1.7)
   D/C due to AEs, n (%)        0             0             0             1 (3.8)       1 (1.4)       1 (2.7)       0             0             1 (1.7)
   D/C other reasons, n (%)     0             0             1 (2.4)       1 (3.8)       2 (2.8)       0             0             0             0

RBV, ribavirin; SVR, sustained virologic response; D/C, discontinuation; AEs, adverse events.

###### 

SVR stratified by treatment regimens and degree of fibrosis

                          SOF/LDV±RBV (N=60)   OMB/PTV/r+RBV (N=20)   SOF+SMV±RBV (N=14)                                  SOF+DCV±RBV (N=7)   Overall (N=102)[a](#TF0001_21487319){ref-type="table-fn"}
  ----------------------- -------------------- ---------------------- --------------------------------------------------- ------------------- -----------------------------------------------------------
  All degrees             56/60 (93)           20/20 (100)            13/14 (93)                                          5/7 (71)            95/102 (93)
  Fibrosis 3              14/14 (100)          9/9 (100)              3/3 (100)                                           1/2 (50)            27/28 (96)
  Cirrhosis               26/30 (87)           6/6 (100)              7/8 (87)                                            2/3 (67)            41/47 (87)
   Cirrhosis LS\<21 kPa   15/15 (100)          2/2 (100)              0/1[b](#TF0002_21487319){ref-type="table-fn"} (0)   2/2 (100)           19/20 (95)
   Cirrhosis LS≥21 kPa    11/15 (73)           4/4 (100)              6/6 (100)                                           0/1 (0)             21/26 (81)

LDV, ledipasvir; RBV, ribavirin; SMV, simeprevir; SOF, sofosbuvir; OMB, ombitasvir; PTV/r, paritaprevir/ritonavir; LS, liver stiffness.

One patient was treated with SOF+RBV and achieved SVR

one patient (not included) had a diagnostic of cirrhosis by clinical criteria and achieved SVR.

###### 

Patients' characteristics and treatment outcomes

                                LDV/SOF 8 weeks (N=58)           LDV/SOF 12 weeks (N=134)         P
  ----------------------------- -------------------------------- -------------------------------- -------
  Baseline variables            G1a=40, G1b=12, non-subtyped=6   G1a=95, G1b=36, non-subtyped=3   
  Age, years, median            49 (45--53)                      51 (47--54)                      0.030
  Male, %                       43 (74.1)                        105 (78.4)                       0.520
  cART, %                       55 (94.8)                        132 (98.5)                       0.140
  Log HCV RNA, median           6.1 (5.7--6.6)                   6.4 (6.0--6.8)                   0.004
  Liver stiffness kPa, median   7.7 (7.2--9.0)                   8.8 (7.7--10.3)                  0.002
  Outcomes                                                                                        
   SVR12, n (%)                 52 (89.7)                        122 (91.0)                       0.760
   % SVR12, 95% CI              78.8--96.1                       84.9--95.3                       
   Relapse, n (%)               4 (6.9)                          7 (5.2)                          0.650
   Breakthrough, n (%)          0                                0                                --
   D/C due to AEs, n (%)        0                                1 (0.7)                          0.510
   D/C other reasons, n (%)     2 (3.4)                          4 (3.0)                          0.870

SOF, sofosbuvir; LDV, ledipasvir; SVR, sustained virologic response; D/C, discontinuation; AEs, adverse events.

###### 

Baseline characteristics of patients with triple versus mono/dual ATR

                                                  All              Triple Therapy      Mono-Dual therapy   
  ----------------------------------------------- ---------------- ------------------- ------------------- ------
  Male gender                                     450 (75.4)       300 (76.3)          109 (73.2)          0.2
  Age                                             51 (48--54.2)    50.5 (47.4--54.3)   52 (49.3--54.3)     0.03
  Genotype                                                                                                 0.1
  1a                                              240 (44.1)       167 (46.9)          47 (35.1)           
  1b                                              90 (16.5)        56 (15.7)           30 (22.4)           
  3                                               78 (14.3)        48 (13.4)           23 (17.2)           
  4                                               133 (24.4)       84 (23.5)           33 (24.6)           
  RNA-HCV                                         6.2 (5.8--6.6)   6.2 (5.8--6.6)      6.3 (5.9--6.7)      0.1
  Liver Stiffness (kPa)                                                                                    0.6
  \<7                                             62 (10.4)        43 (11)             12 (8.1)            
  7.1--9.5                                        181 (30.4)       118 (30.2)          42 (28.2)           
  9.6--14                                         124 (20.8)       77 (19.7)           35 (23.5)           
  \>14                                            228 (38.3)       153 (39.1)          60 (40.3)           
  Previous HCV treatment                          248 (41.5)       174 (44.3)          54 (36.2)           0.09
  HCV treatment                                                                                            0.2
  Sofosbuvir/Ledipasvir                           410 (68.8)       261 (66.4)          105 (70.5)          
  Ombitasvir/Paritaprevir/r +/- DasabuvirAbbvie   87 (14.6)        64 (16.3)           21 (14.1)           
  Sofosbuvir/Daclatasvir                          76 (12.7)        48 (12.3)           21 (14.1)           
  Ribavirin                                       168 (28.2)       38 (25.5)           121 (30.8)          0.2
  Treatment duration                                                                                       0.1
  8 weeks                                         22 (3.7)         10 (2.5)            9 (6)               
  12 weeks                                        367 (61.6)       240 (61.1)          92 (61.7)           
  24 weeks                                        207 (34.7)       143 (36.4)          48 (32.2)           
  Baseline HIV-RNA \<50 copies/mL                 554 (94.5)       367 (94.6)          146 (98)            0.08
  Baseline CD4 cell count                         593 (399--832)   582 (379--829)      613 (433--895)      0.3

###### 

Type of DAAs therapy, effectiveness data and safety profile of the 350 patients

                                                      Total   HCV    HIV-HCV                      
  --------------------------------------------------- ------- ------ --------- ------ ---- ------ -------
  Type of therapy                                                                                 
   SOF+RBV                                            78      22.3   66        22.4   12   21.8   0.93
   SOF+SIM±RBV                                        56      16.0   39        13.2   17   30.9   0.001
   SOF+LDV±RBV                                        56      16.0   46        15.6   10   18.2   0.63
   SOF+DCV±RBV                                        25      7.1    21        7.1    4    7.3    0.96
   OMB+PTV/R+DAS±RBV                                  129     36.9   118       40.0   11   20.0   0.005
   OMB+PTV/R +RBV                                     6       1.7    5         1.7    1    1.8    0.94
   Use of ribavirin                                   234     66.8   204       69.2   30   54.5   0.03
  Effectiveness                                                                                   
   Patients with EOT                                  339     96.8   285       96.6   54   98.1   0.54
   Drop-out                                           11      3.1    10        3.3    1    1.8    0.54
   Patients with at least 3 m of follow-up post EOT   224     49.8   184       62.3   40   72.7   0.14
   SVR12                                              207     92.4   171       92.9   36   90     0.52
  Most common side effects                                                                        
   Headache                                           30      8.6    26        8.8    4    7.3    0.71
   Insomnia                                           13      3.7    11        3.7    2    3.6    0.97
   Fatigue                                            44      12.6   34        11.5   10   18.2   0.17
   Dizziness                                          14      4.0    12        4.1    2    3.6    0.88
   Mood disorders                                     13      3.7    11        3.7    2    3.6    0.97
   Gastrointestinal disorders                         22      6.3    20        6.8    2    3.6    0.38
   Jaundice                                           8       2.3    4         1.4    4    7.3    0.007
   Rash, pruritus or photosensitivity                 59      16.9   53        18.0   6    10.9   0.19
  Haematological abnormalities                                                                    
   Anaemia                                            46      13.1   40        13.6   6    10.9   0.59
   Haemoglobin \<10 g/dl                              29      8.3    23        7.8    6    10.9   0.44
   Haemoglobin \<8 g/dl                               5       1.4    5         1.7    0    0.0    0.33
   Blood transfusion                                  5       1.4    5         1.7    0    0.0    0.33
   Reduction RBV                                      27      7.7    26        8.8    1    1.8    0.07
   EPO use                                            17      4.9    14        4.7    3    5.5    0.82
  At least two adverse events                         73      20.9   68        23.1   5    9.1    0.02
  Severe adverse events                               9       2.6    8         2.7    1    1.8    0.7
  Gastrointestinal haemorrhage                        5       1.4    4         1.4    1    1.8    0.79
  Severe anaemia                                      1       0.3    1         0.3    0    0.0    0.66
  Encephalopathy                                      2       0.6    2         0.7    0    0.0    0.54
  Ascites                                             1       0.3    1         0.3    0    0.0    0.66

Results are presented as frequencies (%) for qualitative variables. DAS, dasabuvir; DCV, daclatasvir; EOT, end of treatment; LDV, ledipasvir; OMB, ombitasvir; PTV/r, paritaprevir/r; RBV, ribavirin; SIM, simeprevir; SOF, sofosbuvir; SVR, sustained virological response.

p\<0.05.

###### 

Baseline characteristics

  Baseline demographics              Total n=181   Died on treatment n=5
  ---------------------------------- ------------- -----------------------
  Median age (range), years          52 (36--73)   52.6 (44--57)
  Male, n (%)                        149 (82%)     5 (100%)
  History of decompensation, n (%)   14 (8%)       3 (60%)
  MELD score (range)                               
   0--9, n (%)                       94 (57%)      2 (40%)
   10--15, n (%)                     60 (37%)      2 (40%)
   16--21, n (%)                     9 (5%)        0 (0%)
   21+, n (%)                        1 (1%)        1 (20%)
  HCV genotype                                     
   1a, n (%)                         73 (41%)      2 (40%)
   1b, n (%)                         37 (20%)      1 (20%)
   1 (nosubtype), n (%)              51 (39%)      2 (40%)
   2, n (%)                          1 (0.6%)      0 (0%)
   3, n (%)                          37 (20.4%)    2 (40%)
   4, n (%)                          33 (18%)      0 (0%)
  Treatment experienced                            
   Dual therapy, n (%)               21 (11.6%)    1 (20%)
   PI/PR, n (%)                      105 (58%)     4 (80%)
  Child-Pugh score                                 
   A, n (%)                          124 (68.5%)   1 (20%)
   B, n (%)                          43 (25.3%)    3 (60%)
   C, n (%)                          3 (1.7%)      1 (20%)
   Median baseline HCV RNA IU/mL     6.18 MUI      1.5 MUI
  Treatment duration (weeks)                       
   12                                93 (51.4%)    0 (0%)
   24                                82 (45%)      0 (0%)
   48                                1 (0.6%)      0 (0%)
   Others                            5 (3%)        5 (100%)
   RBV use, n (%)                    61 (34%)      2 (40%)

###### 

Cases of multicentric and fatal HCC

           HCV              FBS (kPa)   Compensated cirrhosis   Previous Tx              DAAs                       AFP     Clinical presentation                                  Exitus
  -------- ---------------- ----------- ----------------------- ------------------------ -------------------------- ------- ------------------------------------------------------ ---------------------------------
  Case 1   GT 3a ILB28 CT   36          Yes                     PI/PR (1)                04/22/2015 LDV/SOF + RBV   6,48    Multicentric HCC. Portal vein thrombosis and ascites   27 days after admission/4 m DAA
  Case 2   GT 1b ILB28 CT   45          Yes                     PI/PR (2) Dual therapy   01/27/15 SOF/DCV           63751   Multicentric HCC. Portal vein thrombosis and ascites   6 days after admission/4 m DAA

###### 

Demographic, clinical and virological characteristics of patients at baseline and DAAs regimens

  Demographic characteristics                                                                                                 Total number of 49 patients
  ---------------------------------------------------------- ---------------------------------------------------------------- -----------------------------
  Male gender                                                                                                                 35 (72%)
  Age (years)                                                                                                                 52 (range 26--64)
  HIV/HCV risk factor                                                                                                         
                                                             PWIDs                                                            39 (80%)
                                                             Transfusion                                                      2 (5%)
                                                             MSM                                                              2 (5%)
                                                             Vertical transmission                                            1 (2%)
                                                             Unknown                                                          4 (8%)
  HIV characteristics                                                                                                         
   CDC stage                                                                                                                  
                                                             A                                                                9 (19%)
                                                             B                                                                17 (35%)
                                                             C                                                                23 (46%)
   Under antiretroviral treatment                                                                                             49 (100%)
   HIV RNA \<20 copies/mL                                                                                                     46 (93%)
   CD4 count (mean, cells/µL)                                                                                                 607 (±103)
   Change of antiretroviral treatment before start of DAAs                                                                    29 (60%)
   Antiretroviral regimens during DAAs                                                                                        
                                                             Raltegravir based                                                28 (58%)
                                                             PI based                                                         11 (21%)
                                                             Tenofovir/emtricitabine/rilpivirine                              7 (14%)
                                                             Dolutegravir based                                               3 (7%)
  HCV characteristics                                                                                                         
   HCV treatment-experienced                                                                                                  24 (49%)
   Liver fibrosis (FibroScan)                                                                                                 
                                                             F0--F1                                                           0 (0%)
                                                             F2                                                               10 (21%)
                                                             F3                                                               10 (21%)
                                                             F4                                                               29 (58%)
   HCV genotype                                                                                                               
                                                             GT1a                                                             15 (30%)
                                                             GT1b                                                             9 (19%)
                                                             GT1                                                              1 (2%)
                                                             GT2                                                              1 (2%)
                                                             GT3                                                              9 (19%)
                                                             GT4                                                              14 (28%)
   HCV RNA (mean, UI/mL)                                                                                                      234,1817 (±754,312)
   DAA regimens                                                                                                               
                                                             Ombitasvir/paritaprevir/ritonavir + dasabuvir (3D) + ribavirin   21 (42%)
                                                             Ledipasvir/sofosbuvir (±ribavirin)                               15 (30%)
                                                             Daclatasvir + sofosbuvir + ribavirin                             9 (19%)
                                                             Ombitasvir/paritaprevir/ritonavir (2D) + ribavirin               3 (7%)
                                                             Sofosbuvir + ribavirin                                           1 (2%)
   Use of ribavirin in DAA regimens                                                                                           41 (84%)
   Duration of DAA therapy                                                                                                    
                                                             12 weeks                                                         22 (44%)
                                                             24 weeks                                                         27 (56%)

###### 

CD4 cell count evolution during HCV treatment with DAAs

                           Mean baseline CD4 cell count (mm^3^)   Mean end of treatment CD4 cell count (mm^3^)   p
  ------------------------ -------------------------------------- ---------------------------------------------- -------
  Total (n=87)             629                                    646                                            0.408
  ≤350 CD4/mm^3^ (n=13)    253                                    285                                            0.196
  \>350 CD4/mm^3^ (n=74)   695                                    710                                            0.547

###### 

CD4 cell count evolution at the end of follow-up

                             Mean baseline CD4 cell count (mm^3^)   Mean end of follow-up CD4 cell count (mm^3^)   p
  -------------------------- -------------------------------------- ---------------------------------------------- --------
  Total (n = 126)            597                                    638                                            0.408
  ≤350 CD4/mm^3^ (n = 27)    242                                    290                                            \<0.05
  \>350 CD4/mm^3^ (n = 99)   694                                    732                                            0.063

###### 

Logistic regression odds ratios for having anti-HCV positive test at baseline screening

                                               Univariate          Multivariate                       
  -------------------------------------------- ------------------- -------------- ------------------- --------
  Female gender                                0.44 (0.28--0.69)   0.0004         0.63 (0.34--1.18)   0.148
  AST \> ULL                                   9.18 (4.85--17.4)   \<0.0001       5.15 (2.22--11.9)   0.0001
  ALT \> ULL                                   8.62 (4.52--16.4)   \<0.0001       3.01 (1.25--7.28)   0.014
  Age of first visit per each 10 years older   1.19 (1.01--1.42)   0.039          1.36 (1.08--1.71)   0.009
  Year 2011--2013 versus 2008--2010            0.93 (0.46--1.90)   0.131          0.56 (0.19--1.65)   0.068
  Year of test 2014--2016 versus 2008--2010    1.98 (1.04--3.76)   0.002          1.31 (0.49--3.49)   0.092
  HBsAg positive versus negative               3.17 (0.74--13.5)   0.173          --                  --
  HBsAg unknown versus negative                1.31 (0.75--2.29)   0.497          --                  --

All with p \< 0.01 in univariate included in final model. HIV test not included due to low number of events.

###### 

HIV regimens

  HIV regimen                                              Number (%) patients
  -------------------------------------------------------- ---------------------
  Integrase inhibitor                                      72 (39)
  Protease inhibitor (PI)                                  55 (30)
  Non-nucleoside reverse transcriptase inhibitor (NNRTI)   39 (21)
  Complex regimens                                         15 (8)
  Not on treatment                                         2 (1)

###### 

HCV regimens

  HCV regimen                        Number (%) of patients
  ---------------------------------- ------------------------
  Harvoni±ribavirin                  102 (56)
  Abbvie 3D±ribavirin                32 (17)
  Sofosbuvir/pegIFN/ribavirin        27 (15)
  Sofosbuvir/daclatasvir±ribavirin   9 (5)
  Abbvie 2D±ribavirin                8 (4)
  Other                              5 (3)

###### 

ARV changes

  ARV change                                           Number (%) of patients
  ---------------------------------------------------- ------------------------
  Omit ritonavir on Abbvie 2D/3D                       12 (7)
  NNRTI to unboosted integrase                         10 (5)
  PI to unboosted integrase                            2 (1)
  Boosted integrase converted to unboosted integrase   1 (1)
  PI changed                                           1 (1)
  Other                                                3 (2)

![Dolutegravir plasma trough concentrations clustered according to the companion antiretroviral.\
Boxplots and whiskers represent the 5th, 25th, 50th, 75th and 95th percentiles, respectively. \*\*p \< 0.001 versus other groups. Dashed lines depict the protein-adjusted 90% inhibitory concentration for wild-type and resistant viruses (64 and 640 ng/mL, respectively).](JIAS-19-21487341-g001){#F0013_21487341}

###### 

Summary of AVA PK parameters and statistical comparisons

  AVA PK Parameter       E/C/F/TAF + AVA (test) N = 16 mean (% CV)   AVA (reference) N = 16 mean (% CV)   GMR (90% CI) test/reference
  ---------------------- ------------------------------------------- ------------------------------------ -----------------------------
  AUC~inf~ (ng\*h/mL)    38.4 (32)                                   14.6 (27)                            260 (231--293)
  AUC~last~ (ng\*h/mL)   34.9 (33)                                   12.0 (30)                            291 (263--322)
  C~max~ (ng/mL)         3.0 (51)                                    1.3 (56)                             232 (191--282)

![Distribution of elvitegravir (right panel), tenofovir (middle panel) and cobicistat (left panel) trough concentrations in 65 HIV-infected patients given Stribild as maintenance antiretroviral therapy.](JIAS-19-21487347-g001){#F0014_21487347}

###### 

DRV, COBI, FTC and TAF pharmacokinetic parameters and statistical analysis

  Parameter, mean (SD)[a](#TF0001_21487348){ref-type="table-fn"}   DCFTAF fasted (test) n=24   DCFTAF fed (high-fat breakfast) (reference) n=24          LS means ratio,%   90% CI,%
  ---------------------------------------------------------------- --------------------------- --------------------------------------------------------- ------------------ ----------------
  DRV                                                                                                                                                                       
   C~max~, ng/mL[b](#TF0002_21487348){ref-type="table-fn"}         4089 (1846)                 6629 (1543)                                               54.99              46.73--64.71
   T~max~, hours[b](#TF0002_21487348){ref-type="table-fn"}         3.00 (1.00--8.02)           5.00 (1.50--8.00)                                         ND                 ND
   AUC~last~, ng.h/mL[b](#TF0002_21487348){ref-type="table-fn"}    67,504 (35,642)             93,541 (39,730)                                           65.65              56.76--75.92
   AUC~inf~, ng.h/mL[c](#TF0003_21487348){ref-type="table-fn"}     72,147 (36,009)             94,686 (40,882)                                           70.25              59.49--82.95
   t1/2term, hours[c](#TF0003_21487348){ref-type="table-fn"}       7.0 (2.3)                   7.8 (3.5)                                                 ND                 ND
  COBI                                                                                                                                                                      
   C~max~, ng/mL[b](#TF0002_21487348){ref-type="table-fn"}         704 (368)                   711 (164)                                                 76.96              55.70--106.33
   tmax, hours[b](#TF0002_21487348){ref-type="table-fn"}           3.00 (1.00--6.00)           5.00 (2.00--6.10)                                         ND                 ND
   AUC~last~, ng.h/mL[b](#TF0002_21487348){ref-type="table-fn"}    5771 (3206)                 6168 (2260)                                               70.90              51.13--98.30
   AUC~inf~, ng.h/mL[d](#TF0004_21487348){ref-type="table-fn"}     6136 (3064)                 6258 (2268)                                               84.39              68.52--103.95
   t1/2term, hours[d](#TF0004_21487348){ref-type="table-fn"}       4.1 (0.9)                   3.9 (0.6)                                                 ND                 ND
  FTC                                                                                                                                                                       
   C~max~, ng/mL                                                   2247 (573)                  1785 (486)                                                125.99             112.85--140.65
   t~max~, hours                                                   1.00 (0.50--2.00)           2.00 (0.75--5.00)                                         ND                 ND
   AUC~last~, ng.h/mL                                              11,593 (2573)               11,499 (2055)                                             100.12             96.29--104.10
   AUC~inf~, ng.h/mL[e](#TF0005_21487348){ref-type="table-fn"}     12,286 (2729)               10,029 (1079)[g](#TF0007_21487348){ref-type="table-fn"}   ND                 ND
   t1/2term, hours[e](#TF0005_21487348){ref-type="table-fn"}       10.8 (1.2)                  10.7 (1.2)[g](#TF0007_21487348){ref-type="table-fn"}      ND                 ND
  TAF                                                                                                                                                                       
   C~max~, ng/mL                                                   180 (90.6)                  107 (65.2)                                                182.29             140.50--236.50
   t~max~, hours                                                   0.50 (0.25--0.75)           0.88 (0.25--5.00)                                         ND                 ND
   AUC~last~, ng.h/mL                                              106 (44.7)                  117 (51.5)                                                89.54              81.20--98.72
   AUC~inf~, ng.h/mL[f](#TF0006_21487348){ref-type="table-fn"}     109 (47.7)                  125 (57.3)                                                80.38              73.04--88.45
   t1/2term, hours[f](#TF0006_21487348){ref-type="table-fn"}       0.3 (0.2)                   0.5 (0.1)                                                 ND                 ND

Except t~max~=median (range)

n=23 for test and n=24 for reference

n=20 for test and reference

n=22 for test and n=24 for reference

n=16 for test and n=7 for reference

n=21 for test and n=16 for reference

Accurate determination not possible for more than 50% of participants; interpret with caution.

###### 

Patient characteristics and data attended from thiol-omics analysis

  Variable                   Healthy volunteers[a](#TF0001_21487351){ref-type="table-fn"}   Naïve           NVP           EFV           p
  -------------------------- -------------------------------------------------------------- --------------- ------------- ------------- ---------------------------------------------------
  N                          63                                                             22              30            83            --
  Age (years)                NA                                                             41.6±9.9        47.9±10.1     43.30±11.1    ns
  CD4 cell count (cell/µL)   NA                                                             478.6±192.2     600.2±300.5   641.7±239.0   0.025[b](#TF0002_21487351){ref-type="table-fn"}
  Viral load (copies/mL)     --                                                             43,096±55,670   BQL           BQL           --
  Total Hcys (µM)            11.3±4.4                                                       10.5±3.7        11.4±3.6      12.6±4.9      ns
  HcysSSP (µM)               9.3±3.6                                                        8.2±3.4         9.9±3.4       10.5±4.5      0.039[c](#TF0003_21487351){ref-type="table-fn"}
  Total Cys (µM)             237.1±36.6                                                     215.7±38.7      223.9±35.0    193.3±38.4    \<0.001[b](#TF0002_21487351){ref-type="table-fn"}
  CysSSP (µM)                156.8±28.4                                                     166.9±29.2      180.6±31.6    145.9±36.3    \<0.001[b](#TF0002_21487351){ref-type="table-fn"}
  Total GSH (µM)             5.8±1.8                                                        2.4±1.2         1.7±0.5       3.9±1.9       \<0.001[c](#TF0003_21487351){ref-type="table-fn"}
  GSSP (µM)                  2.3±1.2                                                        1.5±0.8         0.9±0.4       2.7±1.5       \<0.001[c](#TF0003_21487351){ref-type="table-fn"}
  Total CysGly (µM)          19.7±3.9                                                       24.6±5.6        27.4±5.9      32.9±6.3      \<0.001[b](#TF0002_21487351){ref-type="table-fn"}
  CysGlySSP (µM)             11.9±3.0                                                       17.8±4.9        21.4±5.0      24.7±5.0      \<0.001[b](#TF0002_21487351){ref-type="table-fn"}

Data are presented as mean±SD. BQL, below quantification limit; NA, not available; ns, not significant.

Data from Rossi et al., 2009 \[[@CIT0004_21487351]\]

one-way ANOVA

Kruskal--Wallis test.

###### 

Frequency of adverse events between amlodipine users and non-users

                           All-grade AEs occurring in \>10% of participants   Drug-specific grade 2--4 treatment-emergent AEs   Treatment-emergent AEs leading to premature DC
  ------------------------ -------------------------------------------------- ------------------------------------------------- ------------------------------------------------
  Amlodipine (n=153)       49%                                                14% (22)                                          5.2% (8)
  No amlodipine (n=4514)   47%                                                5.3% (237)                                        2.3% (105)
  p                        NS                                                 \<0.001                                           0.031

![Median C~trough~ plasma concentration of atazanavir, darunavir, efavirenz, rilpivirine, etravirine and raltegravir before and during SOF-based treatment.](JIAS-19-21487353-g001){#F0015_21487353}

###### 

Medication errors detected during the study

  Type of errors (%)    Description                                                                                                                              Example of drugs affected (ratio)
  --------------------- ---------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------
  Wrong dose (34)       It was prescribed to be taken one tablet instead of two. Or it was prescribed to be taken 300 mg/24h in patients with CrCl \<50 mL/min   LPV/r (4/14) or 3TC (3/14)
  Wrong schedule (29)   It was prescribed to be taken once daily instead of twice daily, or vice versa                                                           ETR (5/12); RAL (2/12)
  Omission (22)         The rest had partial omission of treatment                                                                                               All treatment (4/9)
  Wrong drug (15)       It was prescribed TDF + FTC                                                                                                              ABC + 3TC (4/6)

3TC, lamivudine; ABC, abacavir; CrCl, creatinine clearance; ETR, etravirine; FTC, emtricitabine; LPV, lopinavir; r, ritonavir; RAL, raltegravir; TDF, tenofovir.

![Distribution of different genotypes at rs1751034 of ABCC4 in patients with or without KTD. \*χ square.](JIAS-19-21487355-g001){#F0016_21487355}

![What topics do patients discuss with their HIV doctors?](JIAS-19-21487358-g001){#F0017_21487358}

![Activities during ETW (N = 194).](JIAS-19-21487362-g001){#F0018_21487362}

###### 

Organizations carrying out testing activities during ETW (N=194)

                         HIV testing   HIV & HBV testing   HIV & HCV testing   HBV & HCV testing   HIV, HBV & HCV testing
  ---------------------- ------------- ------------------- ------------------- ------------------- ------------------------
  Organizations, N (%)   158 (81)      37 (19)             59 (30)             36 (19)             35 (18)

###### 

Lifetime Markov model results for the cost per quality adjusted life years (QALY) for 1- and 3-year delay in starting cART

                                                                                                                        Without transmission                               Low risk                                     Medium risk                                  High risk                       
  ------------------------------------ -------------------------------------------------------------- ----------------- ---------------------- -------------- ------------ ---------------- -------------- ------------ ---------------- -------------- ------------ ---------------- -------------- ------------
  Number of sexual partners per year                                                                                    --                                                 3                                            10                                           50                              
  Number of monthly sex acts                                                                                            --                                                 10                                           20                                           20                              
  Condom use per acts pct                                                                                               --                                                 90%                                          50%                                          0%                              
  Delay treatment                      Category                                                                         Immediate cART         Delayed cART   Difference   Immediate cART   Delayed cART   Difference   Immediate cART   Delayed cART   Difference   Immediate cART   Delayed cART   Difference
  1 year                               Sexual HIV transmission                                        Infected person   0.00                   0.00           0.00         0.01             0.28           −0.27        0.03             0.61           −0.59        0.09             2.07           −1.99
                                       Total treatment costs                                          PLN               516,333                473,560        42,773       516,333          473,560        42,773       516,333          473,560        42,773       516,333          473,560        42,773
                                       Cost of treatment new infections                               PLN               0                      0              0            5,895            125,975        −120,080     12,646           277,067        −264,421     42,181           939,075        −896,894
                                       Total costs (total treatment costs + cost of new infections)   PLN               516,333                473,560        42,773       522,228          599,536        −77,307      528,979          750,627        −221,648     558,515          1,412,636      −854,121
                                       QALY                                                           QALY              11.29                  11.15          0.14         11.29            11.15          0.14         11.29            11.15          0.14         11.29            11.15          0.14
                                       QALY lost                                                      QALY              0.00                   0.00           0.00         0.02             0.52           −0.50        0.04             1.13           −1.09        0.15             3.84           −3.70
                                       QALY (adj)                                                     QALY              11.29                  11.15          0.14         11.27            10.64          0.63         11.25            10.02          1.23         11.14            7.31           3.83
                                       ICUR                                                           PLN per QALY                                            313,484                                      dominates                                    dominates                                    dominates
  3 year                               Sexual HIV transmission                                        infected person   0.00                   0.00           0.00         0.04             0.82           −0.78        0.08             1.80           −1.73        0.25             6.11           −5.86
                                       Total treatment costs                                          PLN               516,333                369,129        147,204      516,3333         369,129        147,204      516,333          369,129        147,204      516,333          369,129        147,204
                                       Cost of treatment new infections                               PLN               0                      0              0            5,947            262,526        −246,580     34,208           577,394        −543,186     114,103          1,956,986      −1,842,882
                                       Total costs (total treatment costs + cost of new infections)   PLN               516,333                369,129        147,204      532,280          631,656        −99,376      550,541          946,523        −395,982     630,437          2,326,115      −1,695,678
                                       QALY                                                           QALY              11.29                  10.35          0.94         11.29            10.35          0.94         11.29            10.35          0.94         11.29            10.35          0.94
                                       QALY lost                                                      QALY              0.00                   0.00           0.00         0.06             2.02           −1.96        0.12             4.43           −4.31        0.41             15.03          −14.62
                                       QALY (adj)                                                     QALY              11.29                  10.35          0.94         11.23            8.33           2.90         11.17            5.91           5.25         10.88            −4.68          15.56
                                       ICUR                                                           PLN per QALY                                            156,335                                      dominates                                    dominates                                    dominates

*Dominates = cheaper and more effective*.

![HTC coverage after first (weekday) and second visit (weekend). Individuals with missing data on HIV status were excluded (n=157).](JIAS-19-21487369-g001){#F0019_21487369}

###### 

Proportion of individuals encountered at home, HTC uptake and HTC coverage stratified by age and gender. Individuals with missing data on age, gender were excluded (n=170)

                            Total   n (%)         Odds ratio (95% CI)   p
  ------------------------- ------- ------------- --------------------- ---------
  **Encountered at home**                                               
   Women ≥15 years          8115    7211 (88.9)   1                     
   Men ≥15 years            5209    3668 (70.4)   0.30 (0.27--0.33)     \<0.001
   Children \<15 years      4393    3534 (80.5)   0.52 (0.47--0.57)     \<0.001
  **HTC uptake**                                                        
   Women ≥15 years          7211    6204 (86.0)   1                     
   Men ≥15 years            3668    3116 (85.0)   0.92 (0.82--1.03)     0.13
   Children \<15 years      3534    3048 (86.3)   1.02 (0.91--1.14)     0.77
  **HTC coverage**                                                      
   Women ≥15 years          8115    6204 (76.5)   1                     
   Men ≥15 years            5209    3116 (59.8)   0.46 (0.43--0.49)     \<0.001
   Children \<15 years      4393    3048 (69.4)   0.70 (0.64--0.76)     \<0.001

![Continuum of care for mononucleosis-like illness.](JIAS-19-21487371-g001){#F0020_21487371}

![Progression of all HIV-infected patients included in the analysis (N = 9,229) from status at enrolment (late presentation *vs*. non-late presentation) to early (non-LI) versus late antiretroviral therapy initiation (LI) among late presenters, and ART initiation (non-NI) versus no ART initiation (NI) among late presenters and total deaths by treatment group.](JIAS-19-21487375-g001){#F0021_21487375}

![Attributable risk of death (left) and population attributable fraction (right) of death due to late presentation (CD4 \< 200 or AIDS) over time (and 95% confidence intervals).](JIAS-19-21487375-g002){#F0022_21487375}

![Estimated survival probabilities and 95% confidence intervals for patients entering care in not advanced stages of disease (non-LP) and starting ART before progression to AIDS in comparison to those who started after advancing to late stages of disease.](JIAS-19-21487375-g003){#F0001_21487375}

![Distribution of the type of MOs in our study population.](JIAS-19-21487376-g001){#F0023_21487376}

###### 

Patient demographic characteristics and mode of HIV acquisition

                                       Number of patients (%) without MOs   Number of patients (%) with MOs
  ------------------------------------ ------------------------------------ ---------------------------------
  **Age (years)**                                                           
  18--29                               23 (41)                              33 (59)
  30--49                               59 (53)                              53 (47)
  \>50                                 25 (76)                              8 (24)
  **Sex**                                                                   
  Female                               41 (54)                              34 (46)
  Male                                 66 (52)                              60 (48)
  **Geographical origin**                                                   
  Europe, North America, Australasia   58 (55)                              48 (45)
  Sub-Saharan Africa                   32 (48)                              34 (52)
  Other                                17 (59)                              12 (41)
  **Mode of HIV acquisition**                                               
  Heterosexual                         67 (59)                              47 (41)
  Men who have sex with men (MSM)      29 (43)                              39 (57)
  Injecting drug users (IVDU)          3 (33)                               6 (67)
  Other                                8 (80)                               2 (20)
  **Time since previous HIV test**                                          
  None                                 72 (61)                              47 (39)
  ≤1 year                              12 (43)                              16 (57)
  \>1 year ago                         23 (43)                              31 (57)

###### 

Demographics and baseline characteristics of individuals diagnosed with HIV in various settings

                                Outreach         GUM               GP              Home testing    Secondary care   Total
  ----------------------------- ---------------- ----------------- --------------- --------------- ---------------- ---------------
  Median age (years)            35 (27--47)      28 (22--50)       36 (25--73)     31 (26--46)     45 (20--64)      35 (20--73)
  MSM:HSM                       5:1              17:0              9:2             3:0             11:0             45:3
  Female                        0                0                 3               0               0                3
  Median CD4 count (cells/mL)   490 (275--659)   386 (234--1166)   385 (40--885)   114 (68--659)   81 (6--570)      326 (6--1166)
  CD4 count \<350 (n)           2                8                 7               3               8                28 (55%)
  CD4 count \<200 (n)           0                0                 2               3               8                13 (25%)
  Survival at 1 year            100%             100%              100%            100%            63%              92%
  Number/percentage             6 (12%)          17 (33%)          14 (27%)        3 (6%)          11 (22%)         51 (100%)

###### 

Clinical characteristics of newly diagnosed HIV patients: temporal trend analysis

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Clinical characteristics                                   Total          2006--2007 (n = 226)   2008--2009 (n = 239)   2010--2011 (n = 182)   2012--2013 (n = 179)   2014--2015 (n = 146)   p
  ---------------------------------------------------------- -------------- ---------------------- ---------------------- ---------------------- ---------------------- ---------------------- ---------
  Gender                                                                                                                                                                                       

  Male                                                       715 (73.6%)    164 (72.6%)            158 (66.1%)            138 (75.8%)            133 (74.3%)            122 (83.6%)            0.005

  Female                                                     257 (26.4%)    62 (27.4%)             81 (33.9%)             44 (24.2%)             46 (25.7%)             24 (16.4%)             

  Age (mean±SD)                                              40.78 (13.4)   40.90 (13.3)           42.48 (14.3)           40.74 (13.9)           39.56 (12.3)           39.19 (12.6)           0.101

  Risk for HIV acquisition (MSM, heterosexual, IDU, other)   284 (29.2%)\   41 (18.1%)\            51 (21.3%)\            53 (29.1%)\            76 (42.5%)\            63 (43.2%)\            \<0.001
                                                             603 (62%)\     146 (64.6%)\           173 (72.4%)\           118 (64.8%)\           95 (53.1%)\            71 (48.6%)\            
                                                             70 (7.2%)\     39 (17.3)\             9 (3.8%)\              11 (6.0%)\             7 (3.9%)\              4 (2.7%)\              
                                                             15 (1.5%)      0                      6 (2.5%)               0                      1 (0.6%)               8 (5.5%)               

  Site of referral                                           374 (38.5%)    88 (38.9%)             89 (37.2%)             72 (39.6%)             65 (36.3%)             60 (41.1%)             \<0.001

  ID ward/ER/other\                                          344 (35.4%)\   72 (31.9%)\            87 (36.4%)\            74 (40.7%)\            65 (36.3)\             46 (31.5%)\            
  Ambulatory\                                                90 (9.3%)\     41 (18.1%)\            27 (11.3%)\            13 (7.1%)\             5 (2.8%)\              4 (2.7%)\              
  Serodiscordant couple/drug centre/jails\                   110 (11.3%)\   13 (5.8%)\             24 (10%)\              19 (10.4%)\            34 (19%)\              20 (13.7%)\            
  Voluntary testing\                                         39 (4.0%)\     5 (2.2%)\              12 (5%)\               4 (2.2%)\              9 (5%)\                9 (6.2%)\              
  Blood donation/pregnancy\                                  15 (1.5%)      7 (3.1%)               0                      0                      1 (0.6%)               7 (4.8%)               
  Unknown                                                                                                                                                                                      

  CD4 cell count (mean±SD)                                   322 (252.0)    342.33 (305.1)         306.82 (269.8)         308.33 (225.2)         306.10 (199.7)         355.18 (258.5)         0.208

  CD4 cell count categorized\                                567 (58.3%)\   132 (58.4%)\           150 (62.8%)\           102 (56%)\             109 (60.9%)\           74 (50.7%)\            0.177
  \<350\                                                     405 (41.7%)    94 (41.6%)             89 (37.2%)             80 (44%)               70 (39.1%)             72 (49.3%)             
  \>350                                                                                                                                                                                        

  Clinical stageAIDSNon-AIDS                                 406 (41.8%)\   100 (44.2%)\           118 (49.4%)\           72 (39.6%)\            64 (35.8%)\            52 (35.2%)\            0.021
                                                             566 (58.2%)    126 (55.8%)            121 (50.6%)            110 (60.4%)            115 (64.2%)            94 (64.4%)             
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

![CD4 count (a), immune recovery (b) and plasma TSLP (c) before cART and during 24 months of follow-up. Mann--Whitney was used to compare PHI group with the chronic groups. Significant differences are marked: ^a^PHI versus late presenters \[s1\]with advanced disease; ^b^PHI versus late presenters without advanced disease; ^c^PHI versus early presenters.](JIAS-19-21487380-g001){#F0024_21487380}

###### 

Proportion of CD4+ T cell subsets in HIV-infected individuals with either primary HIV infection or chronic HIV infection according to CD4+ T cell count before initiation of cART

                                                      PHI, N = 14                                                                                                                                 LP-AD \<200 cells/µL, N = 20                          LP-nonAD 200-350 cells/µL, N = 24                     EP \>350 cells/µL, N = 42
  --------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------- -----------------------------------------------------
  Gender, males/females (% males)                     13/1 (92.9)                                                                                                                                 18/2 (90.0)                                           21/3 (87.5)                                           39/3 (92.9)
  Age, years, median (IQR)                            47 (12)                                                                                                                                     42 (16)                                               38 (16)                                               44.5 (12)
  Time since diagnosis, days, median (IQR)            2 (3)                                                                                                                                       3 (9)                                                 18 (269)                                              24 (983)
  CD4+ nadir, cells/µL, median (IQR)                  540 (335)                                                                                                                                   45 (113)                                              290 (95)                                              480 (170)
  CD4+ at baseline, cells/µL, median (IQR)            550 (327)                                                                                                                                   55 (110)                                              290 (97)                                              510 (172)
  CD4+ at 24 months of cART, cells/µL, median (IQR)   680 (240)[a](#TF0001_21487380){ref-type="table-fn"}                                                                                         269 (160)[a](#TF0001_21487380){ref-type="table-fn"}   695 (290)                                             820 (317)
  RTE at baseline, %, median (IQR)                    14 (11)                                                                                                                                     11 (16)                                               20 (15)                                               18 (14)
  RTE at 24 months of cART, %, median (IQR)           18 (9)[b](#TF0002_21487380){ref-type="table-fn"}                                                                                            17 (10)                                               28 (11)[b](#TF0002_21487380){ref-type="table-fn"}     17 (16)
  Naive at baseline, %, median (IQR)                  43 (20)[a](#TF0001_21487380){ref-type="table-fn"}                                                                                           23 (30)[a](#TF0001_21487380){ref-type="table-fn"}     40 (26)                                               44 (21)
  Naive at 24 months of cART, %, median (IQR)         36 (12)[b](#TF0002_21487380){ref-type="table-fn"}                                                                                           30 (16)                                               55 (16)[b](#TF0002_21487380){ref-type="table-fn"}     37 (15)
  EM at baseline, %, median (IQR)                     12 (7)                                                                                                                                      17 (14)                                               16 (12)                                               12 (6)
  EM at 24 months of cART, %, median (IQR)            9 (4)[a](#TF0001_21487380){ref-type="table-fn"}                                                                                             15 (6)[a](#TF0001_21487380){ref-type="table-fn"}      6 (7)                                                 7 (5)
  CM at baseline, %, median (IQR)                     26 (6)                                                                                                                                      20 (22)                                               24 (10)                                               24 (10)
  CM at 24 months of cART, %, median (IQR)            24 (14)                                                                                                                                     30 (23)                                               24 (8)                                                32 (16)
  LD at baseline, %, median (IQR)                     5 (4)[b](#TF0002_21487380){ref-type="table-fn"}                                                                                             3 (12)                                                1 (2)[b](#TF0002_21487380){ref-type="table-fn"}       5 (8)
  LD at 24 months of cART, %, median (IQR)            9 (16)[a](#TF0001_21487380){ref-type="table-fn"},[b](#TF0002_21487380){ref-type="table-fn"}                                                 1 (1)[a](#TF0001_21487380){ref-type="table-fn"}       3 (2)[b](#TF0002_21487380){ref-type="table-fn"}       9 (13)
  TSLP at baseline, pg/mL, median (IQR)               2.8 (2.3)[a](#TF0001_21487380){ref-type="table-fn"},[b](#TF0002_21487380){ref-type="table-fn"},[c](#TF0003_21487380){ref-type="table-fn"}   1.7 (0.8)[a](#TF0001_21487380){ref-type="table-fn"}   2.1 (1.4)[b](#TF0002_21487380){ref-type="table-fn"}   1.9 (0.7)[c](#TF0003_21487380){ref-type="table-fn"}
  TSLP at 24 months of cART, pg/mL, median (IQR)      3.9 (2.8)[a](#TF0001_21487380){ref-type="table-fn"},[c](#TF0003_21487380){ref-type="table-fn"}                                              1.3 (1.4)[a](#TF0001_21487380){ref-type="table-fn"}   2.4 (2.9)                                             2.1 (1.0)[c](#TF0003_21487380){ref-type="table-fn"}

Abbreviations: LP-AD, late presenters with advanced disease; LP-nonAD, late presenters without advanced disease; EP, early presenters; PHI, primary HIV infection. Comparing the four HIV groups by using Kruskal--Wallis test. If significant (\<0.05) then Mann--Whitney was used to compare PHI group with the other chronic groups. Only significant differences are marked

PHI versus LP-AD

PHI versus LP-nonAD

PHI versus EP.

![Cerebrospinal fluid (CSF) neurofilament light protein (NFL) and neopterin concentration by the presence of an asymptomatic CSF viral escape (CVE).](JIAS-19-21487381-g001){#F0025_21487381}

![a) Correlation between activated CD8+HLA-DR+CD38+ T-lymphocytes and CD4 recovery after 1 year of ART (Spearman r: 0.5; p=0.005). b) Kaplan-Meier analysis with endpoint=viral load \<50 copies/mL over a period of 150 days (log-rank test p=0.03).](JIAS-19-21487383-g001){#F0026_21487383}

![Type and frequency of most prevalent resistance-associated mutations observed. **NNRTI, non-nucleoside/nucleotide reverse transcriptase inhibitors; NRTI, nucleoside/nucleotide reverse transcriptase inhibitors; PI, protease inhibitors; TAM, thymidine analogue mutation**](JIAS-19-21487387-g001){#F0027_21487387}

![Transmission dynamics of resistant strains with E138A for subtypes A and B. (b) Transmission dynamics of resistant strains with K103N for subtypes A and B.](JIAS-19-21487389-g001){#F0028_21487389}

###### 

Observed pre-treatment drug resistance mutations

  Drug class and mutations        Total N = 152 (%)
  ------------------------------- -------------------
  Any NRTI mutation               5 (3.3)
  K65R                            1 (0.7)
  M184V                           2 (1.3)
  Other (M41L, T215I)             2 (1.3)
  Any NNRTI mutation              8 (5.3)
  K101E                           3 (2.0)
  Y181C                           2 (1.3)
  K103N                           2 (1.3)
  Other (M230L, G190A/S, Y188L)   4 (2.6)

![Phylodynamic characteristics of the major sub-outbreaks with resistant mutations in Southern Greece.](JIAS-19-21487395-g001){#F0029_21487395}

![Patterns of emergent resistance-associated mutations after initiation of three different non-nucleoside reverse-transcriptase inhibitor-containing regimens.](JIAS-19-21487400-g001){#F0030_21487400}

![Drug resistance mutations in pregnancy.](JIAS-19-21487402-g001){#F0031_21487402}

![Phylogenetic tree with CRF19_cpx reference sequences, and subtree containing the clustering of our 49 patients obtained by maximum likelihood. Only support values ≥70% are shown.](JIAS-19-21487407-g001){#F0032_21487407}
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